



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 35/12, C07H 17/00, C07K 1/00, 14/00, 16/00, C12N 1/00, 5/00, 15/00, C12Q 1/00, 1/68, G01N 33/53</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/18822</b> <b>(43) International Publication Date:</b> 29 May 1997 (29.05.97)
<b>(21) International Application Number:</b> PCT/US96/18675 <b>(22) International Filing Date:</b> 22 November 1996 (22.11.96)  <b>(30) Priority Data:</b> 08/561,963 22 November 1995 (22.11.95) US  <b>(71) Applicant:</b> YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06520 (US).  <b>(72) Inventors:</b> ARTANAVIS-TSAKONAS, Spyridon; 192 Ridge-wood Avenue, Hamden, CT 06517 (US). MATSUNO, Kenji; 3rd floor, 789 Orange Street, New Haven, CT 06510 (US).  <b>(74) Agent:</b> ANTILER, Adriane, M.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		<b>(81) Designated States:</b> AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> VERTEBRATE DELTEX PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES, AND RELATED METHODS AND COMPOSITIONS  <b>(57) Abstract</b>  The present invention relates to nucleotide sequences of vertebrate deltex genes, and amino acid sequences of the encoded vertebrate Deltex proteins. The invention further relates to fragments and other derivatives, and analogs, of vertebrate Deltex proteins, as well as antibodies thereto. Nucleic acids encoding such fragments or derivatives are also within the scope of the invention. Production of the foregoing proteins and derivatives, e.g., by recombinant methods is provided. In a specific embodiment, the invention relates to human deltex nucleic acids and proteins. The present invention also relates to therapeutic and diagnostic methods and compositions based on vertebrate Deltex proteins, nucleic acids, and antibodies. The invention also provides methods of inactivating Notch function in a cell, methods of identifying a compound that inhibits or reduces the binding of a vertebrate Deltex protein to a Notch protein, and methods of expanding non-terminally differentiated cells.		

\* (Referred to in PCT Gazette No. 44/1997, Section II)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**VERTEBRATE DELTEX PROTEINS, NUCLEIC ACIDS, AND  
ANTIBODIES, AND RELATED METHODS AND COMPOSITIONS**

**1. INTRODUCTION**

5           The present invention relates to vertebrate *deltex* genes and their encoded protein products, as well as derivatives and analogs thereof. The invention further relates to production of vertebrate Deltex proteins, derivatives and antibodies. Related therapeutic compositions and methods of therapy and diagnosis are also provided.

10

**2. BACKGROUND OF THE INVENTION**

          In *Drosophila melanogaster*, the so called "Notch group" of genes has been implicated in events crucial for the correct developmental choices of a wide variety of precursor cells (for review, see Fortini and Artavanis-Tsakonas, 1993, Cell 75:1245-1247;  
15 Artavanis-Tsakonas and Simpson, 1991, Trends Genet. 7:403-408). The accumulated genetic and molecular studies suggest that these genes encode elements of a cell communication mechanism which includes cell surface, cytoplasmic, and nuclear components.

20           Very little is known about the mechanisms underlying cell fate choices in higher organisms such as vertebrates; a knowledge of such mechanisms could provide insights into pathologies associated with abnormal differentiation events. Thus, a need exists in the art to obtain and characterize the human members of the "Notch group" of genes, including *deltex*, since these genes appear to play crucial roles in the determination of  
25 cell fate.

          Numerous developmental genetic studies in recent years have shown that the *Notch* locus plays a central role in regulative events influencing cell fate decisions in *Drosophila* in a very broad spectrum of developing tissues (reviewed in Artavanis-Tsakonas  
30 and Simpson, 1991, Trends Genet. 7:403-408; and in Artavanis-Tsakonas et al., 1991, Ann. Rev. Cell Biol. 7:427-452). This pleiotropy of *Notch* function is revealed by mutations affecting all stages of development and a variety of tissues (*e.g.*, Welshons, 1965, Science 150:1122-1229; Welshons, 1971, Genetics 68:259-268; Shellenbarger and Mohler, 1978,  
35 Dev Biol. 62:432-446). A dramatic illustration of *Notch* function is seen in the development of the embryonic nervous system, whereby loss of function mutations cause the misrouting of epithelial precursor cells into a neural developmental pathway and result in what has been

termed a 'neurogenic' phenotype (Poulson, 1937, Proc. Natl. Acad. Sci. USA, 23:133-137; Lehman et al., 1983, Roux's Arch. Dev. Biol. 192:62-74).

In attempts to understand the molecular contexts by which the Notch protein communicates signals from the cell surface to the nucleus to effect changes in cell fate, 5 genetic means have been used to identify loci that interact phenotypically with various *Notch* alleles. These genetic studies led to the definition of a small group of interacting loci, which has been operationally termed the 'Notch group' (Artavanis-Tsakonas and Simpson, 1991, Trends Genet. 7:403-408). The other members of the *Notch* group are *deltex* (Xu and 10 Artavanis-Tsakonas, 1991, Genetics 126:665-677), *Enhancer of (split)* [*E(spl)*] (Knust et al., 1987, EMBO J. 6:4113-4123; Hartley et al., 1988, Cell 55:785-795; Preiss et al., 1988, EMBO J. 7:3917-3927; Klambt et al., 1989, EMBO J. 8:203-210), and *mastermind* (*mam*) (Smoller et al., 1990, Genes Dev. 4:1688-1700). *mastermind*, *Hairless* (*H*), the *Enhancer of (split)*, and *Suppressor of Hairless* (*Su(H)*) encode nuclear proteins (Smoller et al., 1990, 15 Genes Dev. 4:1688-1700; Bang et al., 1992 Genes Dev. 6:1752-1769; Maier et al., 1992, Mech Dev. 38:143-156; Delidakis et al., 1991, Genetics 129:803-823; Schrons et al., 1992, Genetics 132:481-503; Furukawa et al., 1991, J. Biol Chem. 266:23334-23340; Furukawa et al, 1992, Cell 69:1191-1197; Schweisguth et al., 1992, Cell 69:, 1199-1212). *deltex* 20 mutations suppress the pupal lethality conferred by certain heteroallelic combinations of the *Abruptex* class of *Notch* alleles (Xu et al., 1990, Genes Dev. 4:464-475). From this same genetic screen, the genes *Delta* and *mastermind* were also identified, both of which belong to the same 'neurogenic' class of genes as *Notch* because of the similar mutant phenotypes 25 they produce. Moreover, subsequent analysis has shown that alleles of *deltex* exhibit genetic interactions with those of *Delta*, *mastermind*, *Hairless*, and *Su(H)*, a further suggestion of functional links among these loci (Xu and Artavanis-Tsakonas, 1990, Genetics 126:665-677).

The manner by which *Notch* is thought to influence determinative events is 30 indirect, that is, not through the direct specification of cellular fates. Instead, recent experimental studies (Coffman et al, 1993, Cell 73:659-671; Fortini et al, Nature, in press) indicate that *Notch* activity delays differentiation, and in this manner renders precursor cells competent to receive and/or interpret any number of specific developmental cues (Cagan and 35 Ready, 1989, Genes Dev. 3:1099-1112). In loss of function mutants, this inhibition is lost and cells assume default pathways of differentiation. For example, during the development

of the *Drosophila* nervous system, cells that normally would become epidermis instead adopt a neural fate in the absence of *Notch* function. However, a salient feature of *Notch* activity is its pleiotropy. *Notch* is required for the proper specification of many other cell types, including those of the compound eye (Cagan and Ready, 1989, Genes Dev. 3:1099-1112),  
5 ovary (Ruohola et al., 1991, Cell 66:433-449; Xu et al., 1992, Development 115:913-922), and mesoderm (Corbin et al., 1991, Cell 67:311-323). Similarly, the widespread expression patterns exhibited by vertebrate *Notch* cognates suggest also a broad-based functional role in these species (Coffman et al., 1993, Cell 73:659-671; Coffman et al., 1990, Science  
10 249:1438-1441; Weinmaster et al., 1991, Development 113:199-205; Weinmaster et al., 1992, Development 116:931-941; Kopan and Weintraub, 1993, J. Cell Biol. 121:631-641; Franco del Amo et al., 1992, Development 115:737-744; Ellisen et al., 1991, Cell 66:649-661; Stifani et al., 1992, Nature Genetics 2:119-127).

*Notch* homologs have been isolated from a variety of vertebrate species and  
15 have been shown to be remarkably similar to their *Drosophila* counterpart in terms of structure, expression pattern and ligand binding properties (Rebay et al., 1991, Cell 67:687-699; Coffman et al., 1990, Science 249:1438-1441; Ellisen et al., 1991, Cell 66:649-661; Weinmaster et al., 1991, Development 113:199-205). Two human *Notch*  
20 homologs have been isolated (PCT Publication No. WO 92/19737 dated November 12, 1992), termed hN and TAN-1. A human *Notch* (*TAN-1*) malfunction has been associated with a lymphatic cancer (Ellisen et al., 1991, Cell 66:649-661).

*Notch* encodes a large, structurally-complex transmembrane protein,  
25 consistent with an involvement in cell-cell communication (Wharton et al., 1985, Cell 43:567-581; Kidd et al., 1986, Mol. Cell. Biol. 6:3094-3108). *Notch* has an extracellular domain containing 36 tandem EGF-like repeats and 3 *Notch/lin12* repeats. The intracellular domain bears several common structural motifs including 6 *cdc10/SWI6/ankyrin* repeats ("ANK" repeats) Lux et al., 1990, Nature 344:36-42; Breeden and Nasmyth, 1987, Nature  
30 329:651-654; Michaely and Bennett, 1992, Trends Cell Biol. 2:127-129; Blank et al., 1992, Trends Biochem. Sci. 17:135-140; Bennett, 1992, J. Biol. Chem. 267:8703-8706), a polyglutamine stretch known as 'opa', and a PEST motif (Stifani et al., 1992, Nature Genetics 2:119-127). The remarkable degree to which these motifs have been conserved in  
35 homologs isolated from mice (Weinmaster et al., 1991, Development 113:199-205; Weinmaster et al., 1992, Development 116:931-941; Kopan and Weintraub, 1993, J. Cell

Biol. 121:631-641), rats (Kopan and Weintraub, 1993, J. Cell Biol. 121:631-641; Franco del Amo et al., 1993, Genomics 15:259-264), humans (Ellisen et al., 1991, Cell 66:649-661; Stifani et al., 1992, Nature Genetics 2:119-127; PCT Publication No. WO 92/19737 dated November 12, 1992), and *Xenopus* (Coffman et al., 1993, Cell 73:659-671; Coffman et al., 1990, Science 249:1438-1441) implies that they will have a common biochemical mode of action. In particular, ANK repeats, which constitute the most conserved region (~70% amino acid identity) between Notch and its vertebrate counterparts (Stifani et al., 1992, Nature Genetics 2:119-127), are thought to mediate protein-protein interactions among diverse groups of proteins, including those involved in signal transduction processes and cytoskeletal interactions (Lux et al., 1990, Nature 344:36-42; Breeden and Nasmyth, 1987, Nature 329:651-654; Michaely and Bennett, 1992, Trends Cell Biol. 2:127-129; Blank et al., 1992, Trends Biochem. Sci. 17:135-140; Bennett, 1992, J. Biol. Chem. 267:8703-8706). Indeed, Rebay et al. (1993, Cell 74:319-329) have recently demonstrated that the ANK repeats are crucial for Notch-mediated signaling events. Both EGF-like repeats and ankyrin motifs are found in a variety of proteins known to interact with other protein molecules. Indeed, evidence has shown a direct interaction between Notch and the products of the *Delta* and *Serrate* loci, which also encode transmembrane proteins containing EGF-like repeats (Fehon et al., 1990, Cell 61:523-534; Rebay et al., 1991, Cell 67:687-699).

In *Drosophila*, it has been demonstrated that dominant 'activated' phenotypes result from *in vivo* overexpression of a Notch protein lacking most extracellular, ligand-binding sequences, while 'dominant-negative' phenotypes result from overexpression of a protein lacking most intracellular sequences (Rebay et al., 1993, Cell 74:319-329).

In *Drosophila*, Deltex has been demonstrated to play a critical role in development and other physiological processes, in particular, in the signaling pathway of Notch which is involved in cell fate (differentiation) determination. We have demonstrated through expression studies conducted in cultured *Drosophila* cells, in yeast, and in the imaginal wing disc that *Drosophila* Deltex mediates the intracellular portion of the signal transduction cascade involved in Notch function (Diederich et al., 1994, Development 120:473-481). These studies show that *Drosophila* Deltex is localized within the cytoplasm, that it is a protein of unique sequence, that it displays homotypic interactions, and that it directly physically interacts with the *Drosophila* Notch intracellular ANK repeats.

Additionally, we have demonstrated that *Drosophila* Deltex directly interacts with the ANK repeats of human Notch.

The ANK repeat motif is shared by many proteins and has been implicated in protein-protein interactions (Lux et al., 1990, Nature 344:36-42, Thompson et al., 1991, Science 253:762-768, reviewed in Bennett, 1992, J. Biol. Chem. 267:8703-8706, Blank et al., 1992, Trends Biochem. Sci. 17:135-140, Rebay et al., 1993, Cell 74:319-329). Moreover, an *in vivo* functional analysis of various truncated forms of Notch has implicated these ANK repeats in downstream signaling events and that dominant 'activated' phenotypes result from *in vivo* overexpression of a Notch protein lacking most extracellular, ligand binding sequences, while 'dominant negative' phenotypes result from overexpression of a protein lacking most intracellular sequences (Rebay et al., 1993, Cell, 74:319-329). Furthermore, *deltex* displays genetic interactions with Notch and Delta, both transmembrane proteins, and with mastermind, a nuclear localized protein (Smoller et al., 1990, Genes Dev. 4:1688-1700). This makes *deltex* the first identified cytoplasmic component of the Notch group of interacting loci.

We have also subsequently demonstrated that a fragment mostly composed of the ankyrin repeats of the Notch protein mediate molecular interactions between Notch and the Su(H) protein (Fortini et al., 1994, Cell 79:273-282). The *Drosophila* *Su(H)* gene encodes a protein of 594 amino acids and binds to the promoters of several viral and cellular genes and interacts directly with a viral transactivator protein termed Epstein-Barr virus nuclear antigen 2 (EBNA2), which enables a virus to subvert the normal program of B cell differentiation (Schweisguth, F., et al, 1992, Cell 69: 1199; Furukawa T., et al., 1991, J. Biol. Chem. 266:23334). Genetic and molecular studies suggest that Deltex and Delta may act in concert to multimerize Notch proteins and to interfere with the cytoplasmic retention of Su(H) by Notch, thus activating the Notch signaling pathway (Diederich, J., et al., 1994, Development 120:473; Fortini, M., et al., 1994, Cell, 79:273; Matsuno, K., et al., unpublished, Artavanis-Tsakonas et al., 1995, Science, 268:225-232). This pathway is believed to control nuclear events in order to influence the progression of uncommitted cells to a more differentiated state. Three loci encoding putative nuclear proteins *Hairless*, *Enhancer of split*, and *mastermind*, have been implicated in these nuclear events.

35

Despite the cloning of a *Drosophila deltex* gene (See PCT Publication WO 95/19770 published July 27, 1995), no vertebrate *deltex* gene had been obtained prior to the present invention.

5 Citation of a reference herein shall not be construed as an admission that such reference is prior art to the present invention.

### 3. SUMMARY OF THE INVENTION

The present invention relates to nucleotide sequences of vertebrate *deltex* genes, and amino acid sequences of the encoded vertebrate Deltex proteins. The invention further relates to fragments and other derivatives, and analogs, of vertebrate Deltex proteins, as well as antibodies thereto. Nucleic acids encoding such fragments or derivatives are also within the scope of the invention. Production of the foregoing proteins and derivatives, e.g., by recombinant methods, is provided.

15 In a specific embodiment, the invention relates to human *deltex* nucleic acids and proteins.

In another specific embodiment, the invention relates to mammalian *deltex* nucleic acids and proteins.

20 In specific embodiments, the invention relates to vertebrate Deltex protein derivatives and analogs of the invention which are functionally active, or which comprise one or more domains of a vertebrate Deltex protein, including but not limited to the SH3-binding domains, ring-H2-Zinc fingers, domains which mediate binding to Notch or to a Notch derivative containing Notch cdc10/SW16/ankyrin ("ANK") repeats, or any combination of the foregoing.

The present invention also relates to therapeutic and diagnostic methods and compositions based on vertebrate Deltex proteins and nucleic acids. The invention provides for treatment of disorders of cell fate or differentiation by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics") include: vertebrate Deltex proteins and analogs and derivatives (including fragments) thereof; antibodies thereto; nucleic acids encoding the vertebrate Deltex proteins, analogs, or derivatives; and vertebrate *deltex* antisense nucleic acids. In a preferred embodiment, a Therapeutic of the invention is administered to treat a cancerous condition, or to prevent progression from a pre-neoplastic or non-malignant state into a neoplastic or a malignant



state. In other specific embodiments, a Therapeutic of the invention is administered to treat a nervous system disorder or to promote tissue regeneration and repair.

In one embodiment, Therapeutics which antagonize, or inhibit, vertebrate Notch and/or Deltex function (hereinafter "Antagonist Therapeutics") are administered for therapeutic effect. In another embodiment, Therapeutics which promote vertebrate Notch and/or Deltex function (hereinafter "Agonist Therapeutics") are administered for therapeutic effect.

Disorders of cell fate, in particular hyperproliferative (*e.g.*, cancer) or hypoproliferative disorders, involving aberrant or undesirable levels of expression or activity or localization of vertebrate Notch and/or Deltex protein can be diagnosed by detecting such levels, as described more fully *infra*.

In a preferred aspect, a Therapeutic of the invention is a protein consisting of at least a fragment (termed herein "adhesive fragment") of vertebrate Deltex which mediates binding to a Notch protein or a fragment thereof.

The invention also provides methods of inactivating Notch function in a cell, methods of identifying a compound that inhibits or reduces the binding of a vertebrate Deltex protein to a Notch protein, and methods of expanding non-terminally differentiated cells.

#### 4. DESCRIPTION OF THE FIGURES

**Figure 1A-F.** Nucleotide sequence (SEQ ID NO:1) and deduced amino acid sequence (SEQ ID NO:2) of *Drosophila deltex* cDNA.

**Figure 2A-C.** Composite nucleotide sequence (SEQ ID NO:11) derived from the cDNA (nucleotide 1 to 2547), and deduced amino acid sequence (SEQ ID NO:12) of the human *deltex* locus. The predicted amino acid sequence is depicted below the DNA sequence. The symbol: \* designates the start of T05200 and \$ the end of T05200. Core H and C residues in Ring-H2-zinc finger are shown by underlining. PCR primers hdx-1 to 4 (SEQ ID NO:26), (SEQ ID NO:27), (SEQ ID NO:28), and (SEQ ID NO:29), respectively, are indicated in bold. X and N represent amino acid residues and nucleotides, respectively, not yet determined.

**Figure 3.** Aligned amino acid sequences of human Deltex

(SEQ ID NO:12) and *Drosophila* Deltex (SEQ ID NO:2) proteins. Those positions at which residues are identical are shaded. Sites in which amino acids are chemically similar are boxed.

5                   **Figure 4A-B.** Amino acid sequence of *Drosophila* Deltex (SEQ ID NO:2) and designated fragments implicated in protein-protein interactions. Fragments A-D (SEQ ID NOS:13-16, respectively) are shown.

**Figure 5.** Schematic diagram of Deltex fragments mediating Deltex-Deltex interactions.

10                   **Figure 6.** Schematic diagram of the Deltex and Notch fragments mediating Deltex-Notch interactions.

## 5. DETAILED DESCRIPTION OF THE INVENTION

15                   The present invention relates to nucleotide sequences of vertebrate *deltex* genes, and amino acid sequences of their encoded Deltex proteins. The invention further relates to fragments and other derivatives, and analogs, of vertebrate Deltex proteins. Nucleic acids encoding such fragments or derivatives are also within the scope of the invention. Production of the foregoing proteins and derivatives, *e.g.*, by recombinant  
20 methods, is provided.

In a specific embodiment, the invention relates to a human *deltex* gene and protein.

25                   In a another specific embodiment, the invention relates to a mammalian *deltex* gene and protein.

The invention also relates to vertebrate Deltex protein derivatives and analogs of the invention which are functionally active, *i.e.*, they are capable of displaying one or more known functional activities associated with a full-length (wild-type) vertebrate Deltex protein. Such functional activities include but are not limited to antigenicity [ability to bind  
30 (or compete with a vertebrate Deltex protein for binding) to an anti-vertebrate Deltex protein antibody], immunogenicity (ability to generate antibody which binds to a vertebrate Deltex protein), ability to bind (or compete with a vertebrate Deltex protein for binding) to Notch or a second Deltex protein or other proteins or fragments thereof, ability to bind (or  
35 compete with a vertebrate Deltex protein for binding) to a receptor or ligand for a vertebrate Deltex protein.

The invention further relates to fragments (and derivatives and analogs thereof) of a vertebrate Deltex protein which comprise one or more domains of a vertebrate Deltex protein (see *infra*), including but not limited to the SH3-binding domains, ring-H2-zinc fingers, domains which mediate binding to Notch (or a derivative thereof containing the Notch ANK repeats) or to a second Deltex molecule or fragment thereof, or any combination of the foregoing.

Antibodies to vertebrate Deltex proteins, their derivatives and analogs, are additionally provided.

Our prior attempts to clone human, zebrafish, and *Xenopus deltex* using *Drosophila deltex* as a probe were unsuccessful. In contrast to such prior failures, the present invention is based on the successful cloning of human *deltex*. As described by way of example below, we have used an innovative methodology to clone the transcription unit corresponding to human *deltex*. As described therein (see Section 6), our results show a significant structural conservation of Deltex in humans, indicative of functional conservation. Moreover, we demonstrate that human Deltex displays direct molecular interaction with both human and *Drosophila* Notch intracellular ANK repeats (see Section 7). Knowledge of the sequence of human *deltex* allows the identification of regions strongly conserved between *Drosophila* and human *deltex*, and provides a method for readily isolating other vertebrate *deltex* genes by use of such strongly conserved regions (see Sections 5.6 and 8 *infra*).

The vertebrate *deltex* nucleic acid and amino acid sequences and antibodies thereto of the invention can be used for the detection and quantitation of vertebrate *deltex* mRNA and protein, to study expression thereof, to produce vertebrate Deltex proteins, fragments and other derivatives, and analogs thereof, in the study, assay, and manipulation of differentiation and other physiological processes, and are of therapeutic and diagnostic use, as described *infra*. The agonists and antagonists of Deltex function can be used to alter the ability of a cell to differentiate. The vertebrate *deltex* nucleic acids and antibodies can also be used to clone vertebrate *deltex* homologs of other species, as described *infra*. Such vertebrate *deltex* homologs are expected to exhibit significant homology to each other, and encode proteins which exhibit the ability to bind to a Notch protein.

The present invention also relates to therapeutic and diagnostic methods and compositions based on vertebrate Deltex proteins and nucleic acids. The invention provides

for treatment of disorders of cell fate or differentiation by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics") include: vertebrate Deltex proteins and analogs and derivatives (including fragments) thereof; antibodies thereto; nucleic acids encoding the vertebrate Deltex proteins, analogs, or derivatives; and vertebrate *deltex* antisense nucleic acids. In a preferred embodiment, a Therapeutic of the invention is administered to treat a cancerous condition, or to prevent progression from a pre-neoplastic or non-malignant state into a neoplastic or a malignant state. In other specific embodiments, a Therapeutic of the invention is administered to treat a nervous system disorder or to promote tissue regeneration and repair.

In one embodiment, Therapeutics which antagonize, or inhibit, Notch and/or vertebrate Deltex function (hereinafter "Antagonist Therapeutics") are administered for therapeutic effect. In another embodiment, Therapeutics which promote Notch and/or vertebrate Deltex function (hereinafter "Agonist Therapeutics") are administered for therapeutic effect.

Disorders of cell fate, in particular hyperproliferative (*e.g.*, cancer) or hypoproliferative disorders, involving aberrant or undesirable levels of expression or activity or localization of Notch and/or vertebrate Deltex protein can be diagnosed by detecting such levels, as described more fully *infra*.

In a preferred aspect, a Therapeutic of the invention is a protein consisting of at least a fragment (termed herein "adhesive fragment") of vertebrate Deltex that mediates binding to a Notch protein, a second Deltex protein, or a fragment of Notch or Deltex.

The invention is illustrated by way of examples *infra* which disclose, *inter alia*, the cloning and sequencing of human *deltex*, and the identification of regions of human Deltex which are predicted to bind to the ANK repeats of Notch, or which are predicted to bind to regions of human Deltex.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections set forth below.

### **5.1. ISOLATION OF THE VERTEBRATE *DELTEX* NUCLEIC ACIDS**

The invention relates to the nucleotide sequences of vertebrate *deltex* nucleic acids. In specific embodiments, human *deltex* nucleic acids comprise the cDNA sequence shown in Figure 2A-C (SEQ ID NO:11), or the coding region thereof (nucleotide numbers

504-2363), or nucleic acids encoding a human Deltex protein (*e.g.*, having the sequence of SEQ ID NO:12). The invention provides nucleic acids consisting of at least 8 nucleotides (*i.e.*, a hybridizable portion) of a vertebrate *deltex* sequence; in other embodiments, the nucleic acids consist of at least 25 (continuous) nucleotides, 50 nucleotides, 100 nucleotides, 150 nucleotides, or 200 nucleotides of a vertebrate *deltex* sequence, or a full-length vertebrate *deltex* coding sequence. The invention also relates to nucleic acids hybridizable to or complementary to the foregoing sequences. In specific aspects, nucleic acids are provided which comprise a sequence complementary to at least 10, 25, 50, 100, or 200 nucleotides or the entire coding region of a vertebrate *deltex* gene. In a specific embodiment, the sequence is naturally occurring.

In other specific embodiments, the invention provides nucleic acids comprising at least 110, 150, or 200 continuous nucleotides of the sequence of SEQ ID NO:11. In other embodiments, the invention provides a nucleic acid comprising the first 25, 50, 100, 150, 200, or 230 amino acids of SEQ ID NO:12.

In a specific embodiment, vertebrate *deltex* nucleic acids comprise those nucleic acids which are substantially homologous to the nucleic acids encoding the amino terminal 180 amino acids (encoded, *e.g.*, by nucleotide numbers 504-1044 of SEQ ID:11) of human *deltex*, or fragments thereof. In one embodiment, the vertebrate *deltex* nucleic acid has at least 50% identity over the corresponding nucleotide sequence of an identically sized human *deltex*. In another embodiment this identity is greater than 55%. In a preferred embodiment, the nucleotide sequence identity of the vertebrate *deltex* is greater than 60%. In a more preferred embodiment this identity is greater than 65%. In a most preferred embodiment, the nucleotide sequence identity of the vertebrate *deltex* is greater than 70% over that of the corresponding nucleotide sequence of identically sized human *deltex*.

In another specific embodiment, vertebrate *deltex* nucleic acids comprise those nucleic acids which are substantially homologous to the nucleic acids encoding the central region amino acids of human *deltex* (*e.g.*, nucleotide numbers 1045-1821 of SEQ ID NO:11) or fragments thereof. In one embodiment, the nucleic acids encoding the central amino acids of the vertebrate Deltex protein has at least 50% nucleotide sequence identity with the corresponding human *deltex* sequence of identical size. In another embodiment this identity is greater than 55%. In a preferred embodiment, this nucleotide sequence identity is

greater than 60%. In a more preferred embodiment this identity is greater than 65%. In a most preferred embodiment, the homology of the nucleic acids encoding the central region amino acids of the vertebrate *deltex* has a nucleotide sequence identity that is greater than 65% over that of the corresponding nucleotide sequence of identically sized human *deltex*.

5 In another specific embodiment, vertebrate *deltex* nucleic acids comprise those nucleic acids which are substantially homologous to the nucleic acids encoding the 180 carboxy terminal amino acids of human *deltex* (nucleotide numbers 1822-2366), or fragments thereof. In one embodiment, the nucleic acids encoding the carboxy terminal  
10 region of the vertebrate *Deltex* protein has at least 50% nucleotide sequence identity over the corresponding human *deltex* sequence of identical size. In another embodiment this identity is greater than 55%. In a preferred embodiment, this identity is greater than 60%. In a more preferred embodiment this identity is greater than 65%. In a most preferred  
15 embodiment, the identity of the nucleotides encoding the amino terminal amino acids of the vertebrate *deltex* is greater than 70% over that of the corresponding nucleotide sequence of identically sized human *deltex*.

In a specific embodiment, a nucleic acid which is hybridizable to a vertebrate *deltex* nucleic acid (*e.g.*, having sequence SEQ ID NO:11), or to a nucleic acid encoding a  
20 vertebrate *deltex* derivative, under conditions of low stringency is provided. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792): Filters containing DNA are pretreated for 6 h at 40°C in a solution containing 35%  
25 formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10<sup>6</sup> cpm  
30 <sup>32</sup>P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed  
35 to film. Other conditions of low stringency which may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations).

In another specific embodiment, a nucleic acid which is hybridizable to a vertebrate *deltex* nucleic acid under conditions of high stringency is provided. By way of example and not limitation, procedures using such conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 5 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Washing of filters is done at 10 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art.

Nucleic acids encoding derivatives (*e.g.*, fragments) of vertebrate Deltex proteins (see Section 5.6), and vertebrate *deltex* antisense nucleic acids (see Section 5.11) 15 are additionally provided. As is readily apparent, as used herein, a "nucleic acid encoding a fragment or portion of a vertebrate Deltex protein" shall be construed as referring to a nucleic acid encoding only the recited fragment or portion of the vertebrate Deltex protein and not the other contiguous portions of the vertebrate Deltex protein as a continuous 20 sequence.

Specific embodiments for the cloning of a vertebrate *deltex* gene, *e.g.*, a human *deltex* gene, presented as a particular example but not by way of limitation, follows:

For expression cloning (a technique commonly known in the art), an expression library is obtained or is constructed by methods known in the art. For example, 25 mRNA (*e.g.*, human) is isolated, cDNA is made and ligated into an expression vector (*e.g.*, a bacteriophage derivative) such that it is capable of being expressed by the host cell into which it is then introduced. Various screening assays can then be used to select for the expressed vertebrate Deltex product. In a preferred aspect, anti-human Deltex antibodies 30 can be used to select the recombinant host cell expressing a cloned vertebrate *deltex* gene.

In a specific embodiment, PCR is used to amplify the desired vertebrate *deltex* sequence in a genomic or cDNA library, prior to selection (see, by way of example Section 8, *infra*). Oligonucleotide primers representing known vertebrate *deltex* sequences, 35 preferably regions known to be conserved between *Drosophila* and human, can be used as primers in PCR. The synthetic oligonucleotides may be utilized as primers to amplify by

PCR sequences from a source (RNA or DNA), preferably a cDNA library, of potential interest. PCR can be carried out, *e.g.*, by use of a Perkin-Elmer Cetus thermal cycler and Taq polymerase (Gene Amp™). The DNA being amplified can include human mRNA or cDNA or genomic DNA. One can choose to synthesize several different degenerate  
5 primers, for use in the PCR reactions. It is also possible to vary the stringency of hybridization conditions used in priming the PCR reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the known vertebrate *deltex* nucleotide sequence and the nucleic acid homolog being isolated. For cross species hybridization, low  
10 stringency conditions are preferred (see *supra*). For same species hybridization, moderately stringent or highly stringent conditions are preferred (see *supra*). After successful amplification of a segment of a vertebrate *deltex* gene homolog, that segment may be molecularly cloned and sequenced, and utilized as a probe to isolate a complete cDNA or  
15 genomic clone. This, in turn, will permit the determination of the gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis, as described *infra*. In a preferred aspect, human genes encoding *Deltex* proteins may be identified in this fashion. Alternatively to selection by hybridization, the PCR-amplified DNA can be inserted into an expression vector for expression cloning as  
20 described above.

In the event that it is desired to isolate a vertebrate *deltex* gene by cross-species hybridization (either by direct hybridization to a vertebrate *deltex* probe representing all or a part of a vertebrate *deltex* gene of a different species, or by PCR using  
25 oligonucleotide primers derived from the sequence of a vertebrate *deltex* gene of a different species), the desired vertebrate *deltex* gene can be isolated as set forth in Example 8, by screening with a probe, or priming for PCR with an oligonucleotide, containing *deltex* sequences encoding regions highly conserved between human and *Drosophila*. For example, the human *Deltex* amino acid stretches 414-419 (SEQ ID NO:30), 475-480 (SEQ  
30 ID NO:31), 504-511 (SEQ ID NO: 32), 531-539 (SEQ ID NO:33) and 557-564 (SEQ ID NO:34) are conserved in *Drosophila* *Deltex* amino acid stretches 549-555 (SEQ ID NO:35), 603-608 (SEQ ID NO:36), 632-639 (SEQ ID NO:37), 659-667 (SEQ ID NO:38) and 685-692 (SEQ ID NO:39), respectively. In a preferred embodiment, a pair of oligonucleotides  
35 comprising sequences separated by a length in the range from 50-500 nucleotides is used as primers in PCR. The invention envisions the use of nucleic acids encoding conserved



regions of the Deltex protein in combination to isolate the Deltex encoding nucleic acids of other organisms, by use in PCR to amplify the desired sequence or less preferably, without PCR, as a probe in selection by virtue of direct colony hybridization (*e.g.*, Grunstein, M. and Hogness, D., 1975, Proc. Natl. Acad. Sci. U.S.A. 72, 3961).

5 In the event that it is desired to isolate a *deltex* gene by cross-species hybridization (either by direct hybridization to a *deltex* probe representing all or a part of a *deltex* gene of an evolutionarily distant, different species, or by PCR using oligonucleotide primers derived from the sequence of a *deltex* gene of a different, evolutionarily distant  
10 species), the desired *deltex* gene can be isolated by a more gradual method of evolutionary walking via first isolating a *deltex* gene from a more closely related species, identifying the portions of *deltex* which are conserved cross-species, and then screening with a probe or priming for PCR with a nucleic acid containing the conserved sequence. This method,  
15 while more cumbersome, is straightforward and can be readily carried out by routine methods. For example, if it is desired to proceed further down the evolutionary tree, one may first isolate a murine *deltex* gene using nucleic acids encoding human Deltex as a probe. A conserved portion of the murine *deltex* sequence is then used to screen or amplify  
20 *deltex* in an avian library; a conserved portion of the avian clone is used to screen an amphibian library, a conserved portion of the amphibian clone is used to screen a fish library, etc. If desired, the species to be selected in the next round of screening can be selected from among various species by hybridizing the *deltex* probe to a Southern blot containing genomic DNA from each species, and selecting a species to which hybridization  
25 occurs.

The above-methods are not meant to limit the following general description of methods by which clones of vertebrate *deltex* may be obtained.

30 Any eukaryotic cell can potentially serve as the nucleic acid source for the molecular cloning of the vertebrate *deltex* gene. The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.*, a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired human cell (see, for example Sambrook et al., 1989, Molecular  
35 Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 2d. Ed., Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL

Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

5

In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired gene may be accomplished in a number of ways. For example, if an amount of a portion of a vertebrate *deltex* (of any species) gene or its specific RNA, or a fragment thereof *e.g.*, the adhesive domain, is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, Science 196, 180; Grunstein, M. And Hogness, D., 1975, Proc. Natl. Acad. Sci. U.S.A. 72, 3961). Those DNA fragments with substantial homology to the probe will hybridize. For cross species hybridization, low stringency conditions are preferred (see *supra*). For same species hybridization, moderately stringent conditions are preferred (see *supra*). It is also possible to identify the appropriate fragment by restriction enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection can be carried out on the basis of the properties of the gene. Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, *e.g.*, has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, binding to Notch, or antigenic properties as known for vertebrate Deltex. If an antibody to vertebrate Deltex is available, the vertebrate Deltex protein may be identified by binding of labeled antibody to the putatively vertebrate Deltex synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure.

The vertebrate *deltex* gene can also be identified by mRNA selection by nucleic acid hybridization followed by *in vitro* translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified vertebrate *deltex* DNA of another species (*e.g.*, human).  
5 Immunoprecipitation analysis or functional assays (*e.g.*, ability to bind Notch) of the *in vitro* translation products of the isolated products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to  
10 immobilized antibodies specifically directed against vertebrate Deltex protein. A radiolabelled vertebrate *deltex* cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabelled mRNA or cDNA may then be used as a probe to identify the vertebrate *deltex* DNA fragments from among other genomic DNA  
15 fragments.

Alternatives to isolating the vertebrate *deltex* genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the vertebrate *deltex* gene. For example, RNA for cDNA cloning of the vertebrate *deltex* gene can be isolated from cells which express  
20 vertebrate Deltex. Other methods are possible and within the scope of the invention.

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector  
25 system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as PBR322, pUC, or Bluescript (Stratagene) plasmid derivatives. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to  
30 fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease  
35 recognition sequences. In an alternative method, the cleaved vector and vertebrate *deltex* gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced

into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

5 In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionization, can be done before insertion into the cloning vector.

10 In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated vertebrate *deltex* gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

15 The vertebrate *deltex* sequences provided by the instant invention include those nucleotide sequences encoding substantially the same amino acid sequences as found in native vertebrate Deltex protein, and those encoded amino acid sequences with functionally equivalent amino acids, all as described in Section 5.6 *infra* for vertebrate Deltex derivatives.

20

## 5.2. EXPRESSION OF VERTEBRATE *DELTEX* NUCLEIC ACIDS

The nucleic acid coding for a vertebrate Deltex protein or a functionally active fragment or other derivative thereof can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native vertebrate *deltex* gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to vertebrate cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

35 In a specific embodiment, a molecule comprising a portion of a vertebrate *deltex* gene which

encodes a protein that binds to Notch or to a molecule comprising the Notch ANK repeats is expressed. In another embodiment, a molecule comprising a portion of a vertebrate *deltex* gene which encodes a protein that binds to a fragment of a Deltex protein is expressed. In other specific embodiments, mammalian *deltex* gene is expressed, or a sequence encoding a functionally active portion of mammalian Deltex. In other specific embodiments, the human *deltex* gene is expressed, or a sequence encoding a functionally active portion of human Deltex. In a specific embodiment, a chimeric protein comprising a Notch-binding domain of a vertebrate Deltex protein is expressed. In other specific embodiments, a full-length vertebrate *deltex* cDNA is expressed, or a sequence encoding a functionally active portion of a vertebrate Deltex protein. In yet another embodiment, a fragment of a vertebrate Deltex protein comprising a domain of the protein, or other derivative, or analog of a vertebrate Deltex protein is expressed.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of a nucleic acid sequence encoding a vertebrate Deltex protein or peptide fragment may be regulated by a second nucleic acid sequence so that the vertebrate Deltex protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a vertebrate Deltex protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control vertebrate *deltex* gene expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the  $\beta$ -lactamase (Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), *tac* (DeBoer et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25),  $\lambda P_L$ , or *trc* promoters; see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; plant expression vectors comprising the nopaline synthetase promoter region or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., 1981, Nucl.

Acids Res. 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310:115-120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

Expression vectors containing vertebrate *deltex* gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted vertebrate *deltex* gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation

phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the vertebrate *deltex* gene is inserted within the marker gene sequence of the vector, recombinants containing the vertebrate *deltex* insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the vertebrate *deltex* gene product in *in vitro* assay systems, *e.g.*, binding to Notch, binding with antibody.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (*e.g.*, lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered vertebrate Deltex protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (*e.g.*, phosphorylation, cleavage) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.

In other specific embodiments, the vertebrate Deltex protein, fragment, analog, or derivative may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, *e.g.*, by use of a peptide synthesizer.

Both cDNA and genomic sequences can be cloned and expressed.

In other embodiments, a vertebrate *deltex* cDNA sequence may be chromosomally integrated and expressed. Homologous recombination procedures known in the art may be used.

5

### **5.3. IDENTIFICATION AND PURIFICATION OF THE VERTEBRATE *DELTEX* GENE PRODUCTS**

In particular aspects, the invention provides amino acid sequences of vertebrate Deltex, preferably human Deltex, and fragments and derivatives thereof which  
10 comprise an antigenic determinant (*i.e.*, can be recognized by an antibody) or which are functionally active, as well as nucleic acid sequences encoding the foregoing. "Functionally active" material as used herein refers to that material displaying one or more known functional activities associated with the full-length (wild-type) vertebrate Deltex protein  
15 product, *e.g.*, binding to Notch or a portion thereof, binding to another Deltex molecule or portion thereof, binding to any other Deltex ligand, antigenicity (binding to an anti-vertebrate Deltex antibody), immunogenicity (generating anti-Deltex antibody), Notch intracellular signal transduction, etc.

20 In specific embodiments, the invention provides fragments of a vertebrate Deltex protein consisting of at least 6 amino acids, 10 amino acids, 50 amino acids, or of at least 75 amino acids. In other embodiments, the proteins comprise, or alternatively, consist essentially of; one or more of the SH3-binding domains (*e.g.*, SEQ ID NOS: 17-21 of Table III); one or more ring-H2-zinc finger domains (*e.g.*, SEQ ID NO:25), or a portion which  
25 binds to Notch (*e.g.*, comprising the first approximately 230 amino acids of vertebrate Deltex), or any combination of the foregoing, of a vertebrate Deltex protein. Fragments, or proteins comprising fragments, lacking some or all of the foregoing regions of vertebrate Deltex are also provided. Molecules comprising more than one copy of the foregoing  
30 regions are also provided. Nucleic acids encoding the foregoing are provided.

Once a recombinant which expresses a vertebrate *deltex* gene sequence is identified, the gene product can be analyzed. This is achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis, immunoassay, etc. Chemically  
35 synthesized proteins, derivatives, and analogs can be similarly analyzed.



Once a vertebrate Deltex protein is identified, it may be isolated and purified by standard methods including chromatography (*e.g.*, ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.7).

Alternatively, the amino acid sequence of a vertebrate Deltex protein can be deduced from the nucleotide sequence of the chimeric gene contained in the recombinant. Once the amino acid sequence is thus known, the protein can be synthesized by standard chemical methods known in the art (*e.g.*, see Hunkapiller et al., 1984, Nature 310:105-111).

By way of example, the deduced amino acid sequence (SEQ ID NO:12) of a human Deltex protein is presented in Figure 2A-C.

#### 5.4. STRUCTURE OF THE VERTEBRATE DELTEX GENES AND PROTEINS

The structure of the vertebrate *deltex* genes and proteins can be analyzed by various methods known in the art.

##### 5.4.1. GENETIC ANALYSIS

The cloned DNA or cDNA corresponding to the vertebrate *deltex* gene can be analyzed by methods including but not limited to Southern hybridization (Southern, 1975, J. Mol. Biol. 98:503-517), Northern hybridization (see *e.g.*, Freeman et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:4094-4098), restriction endonuclease mapping (Maniatis, 1982, Molecular Cloning, A Laboratory, Cold Spring Harbor, New York), and DNA sequence analysis. Polymerase chain reaction (PCR; U.S. Patent Nos. 4,683,202, 4,683,195 and 4,889,818; Gyllenstein et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7652-7656; Ochman et al., 1988, Genetics 120:621-623; Loh et al., 1989, Science 243:217-220) followed by Southern hybridization with a vertebrate *deltex*-specific probe can allow the detection of the vertebrate *deltex* genes in DNA from various cell types. In one embodiment, Southern hybridization can be used to determine the genetic linkage of vertebrate *deltex*. Northern hybridization analysis can be used to determine the expression of the vertebrate *deltex* genes. Various cell types, at various states of development or activity can be tested for vertebrate *deltex* gene expression. The stringency of the hybridization conditions for both Southern

and Northern hybridization can be manipulated to ensure detection of nucleic acids with the desired degree of relatedness to the specific vertebrate *deltex* probe used.

5 Restriction endonuclease mapping can be used to roughly determine the genetic structure of the vertebrate *deltex* gene. Restriction maps derived by restriction endonuclease cleavage can be confirmed by DNA sequence analysis. Alternatively, restriction maps can be deduced, once the nucleotide sequence is known.

DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 10 65:499-560), the Sanger dideoxy method (Sanger et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699; Sequenase, U.S. Biochemical Corp.), or Taq polymerase, or use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA). The cDNA 15 sequence of a human *deltex* gene is shown in Figure 2A-C (SEQ ID NO:11) and is described in Section 6, *infra*.

#### 5.4.2. PROTEIN ANALYSIS

The amino acid sequence of a vertebrate Deltex protein can be derived by 20 deduction from the DNA sequence, or alternatively, by direct sequencing of the protein, e.g., with an automated amino acid sequencer. The amino acid sequence of a representative vertebrate Deltex protein comprises the sequence substantially as depicted in Figure 2A-C (SEQ ID NO:12), and detailed in Section 6, *infra*.

25 The vertebrate Deltex protein sequence can be further characterized by a hydrophilicity analysis (Hopp and Woods, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824). A hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of a vertebrate Deltex protein and the corresponding regions of the gene sequence which encode such regions. Hydrophilic regions are predicted to be immunogenic.

30 Secondary, structural analysis (Chou and Fasman, 1974, Biochemistry 13:222) can also be done, to identify regions of a vertebrate Deltex protein that assume specific secondary structures.

35 Manipulation, translation, and secondary structure prediction, as well as open reading frame prediction and plotting, can also be accomplished using computer software programs available in the art.

Other methods of structural analysis can also be employed. These include but are not limited to X-ray crystallography (Engstrom, 1974, Biochem. Exp. Biol. 11:7-13) and computer modeling (Fletterick and Zoller (eds.), 1986, Computer Graphics and Molecular Modeling, in Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York).

#### 5.5. GENERATION OF ANTIBODIES TO VERTEBRATE DELTEX PROTEINS AND DERIVATIVES THEREOF

According to the invention, a vertebrate Deltex protein, its fragments or other derivatives, or analogs thereof, may be used as an immunogen to generate antibodies which recognize such an immunogen. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. In a preferred embodiment, antibodies which specifically bind to vertebrate Deltex proteins are produced. In a more preferred embodiment, an antibody which binds to a vertebrate Deltex protein (*e.g.*, mammalian, preferably human) but does not bind to (full length) *Drosophila* Deltex protein, is produced. In a preferred embodiment, such an antibody is produced by using as immunogen, regions least conserved between *Drosophila melanogaster* and the vertebrate Deltex protein.

In another embodiment, antibodies to a particular domain of a vertebrate Deltex protein are produced. In a specific embodiment, an antibody is produced which binds to a fragment of vertebrate Deltex which binds to Notch; in another embodiment, an antibody binds to a molecule comprising the first 230 amino-terminal amino acids of vertebrate Deltex. In another embodiment the antibody binds to an amino-terminal fragment of vertebrate Deltex containing not more than the first 200 amino acids of vertebrate Deltex. In yet another embodiment, an antibody binds to a fragment of vertebrate Deltex which binds to a second Deltex molecule.

Various procedures known in the art may be used for the production of polyclonal antibodies to a vertebrate Deltex protein or derivative or analog. In a particular embodiment, rabbit polyclonal antibodies to an epitope of the vertebrate Deltex protein having a sequence depicted in Figure 2A-C or a subsequence thereof, can be obtained. For the production of antibody, various host animals can be immunized by injection with a native vertebrate Deltex protein, or a synthetic version, or derivative (*e.g.*, fragment) thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used

to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum.

In a preferred embodiment, polyclonal or monoclonal antibodies are produced by use of a hydrophilic portion of a vertebrate Deltex peptide (e.g., identified by the procedure of Hopp and Woods (1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824)).

For preparation of monoclonal antibodies directed toward a vertebrate Deltex protein sequence or analog thereof, any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) can be used. In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals (PCT Publication No. WO 89/12690 dated December 28, 1989). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus *in vitro* (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96), or by other methods known in the art. In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851-6855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for a vertebrate Deltex protein together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Non-human antibodies can be humanized by the method of Winter (see U.S. Patent No. 5,225,539).

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce vertebrate Deltex protein-specific single chain antibodies. An additional embodiment of the invention utilizes

the techniques described for the construction of Fab expression libraries (Huse et al., 1989, Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for vertebrate Deltex proteins, derivatives, or analogs.

5 Antibody fragments and other derivatives which contain the idiotype (binding domain) of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')<sub>2</sub> fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')<sub>2</sub> fragment, and the Fab fragments which can be  
10 generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g. ELISA (enzyme-linked immunosorbent assay). For example, to select antibodies which recognize a specific domain of a vertebrate  
15 Deltex protein, one may assay generated hybridomas for a product which binds to a vertebrate Deltex fragment containing such domain. For selection of an antibody specific to human Deltex protein(s), one can select on the basis of positive binding to a human Deltex protein and a lack of binding to *Drosophila* Deltex protein.

In a specific embodiment, antibodies specific to a phosphorylated epitope of  
20 vertebrate Deltex are produced.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the protein sequences of the invention e.g., for imaging these proteins, measuring levels thereof in appropriate physiological samples, etc. Antibodies to  
25 vertebrate Deltex (since it normally colocalizes with Notch) can be used to determine the intracellular distribution of Notch and/or vertebrate Deltex, in diagnostic methods such as described *infra*. The antibodies also have use in immunoassays. In another embodiment of the invention (see *infra*), anti-vertebrate Deltex antibodies and fragments thereof containing the binding domain are Therapeutics.

30

#### 5.6. VERTEBRATE DELTEX PROTEINS, DERIVATIVES AND ANALOGS

The invention further provides vertebrate Deltex proteins, and derivatives (including but not limited to fragments) and analogs of vertebrate Deltex proteins. Nucleic  
35 acids encoding vertebrate Deltex protein derivatives and protein analogs are also provided. In one embodiment, the vertebrate Deltex proteins are encoded by the vertebrate *deltex*

nucleic acids described in Section 5.1 *supra*. In particular aspects, the proteins, derivatives, or analogs are of mouse or rat; agricultural stock such as cow, sheep, horse, goat, pig and the like; pets such as cats, dogs; or other domesticated mammals, or primate Deltex proteins.

5

The production and use of derivatives and analogs related to vertebrate Deltex are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, *i.e.*, capable of exhibiting one or more functional activities associated with a full-length, wild-type vertebrate Deltex protein.

10

In particular, vertebrate Deltex derivatives can be made by altering vertebrate *deltex* sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a vertebrate *deltex* gene may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of vertebrate *deltex* genes which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. Likewise, the vertebrate Deltex derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a vertebrate Deltex protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

15

20

25

30

In a specific embodiment of the invention, proteins consisting of or comprising a fragment of a vertebrate Deltex protein consisting of at least 10 (continuous) amino acids of the vertebrate Deltex protein is provided. In other embodiments, the

35

fragment consists of at least 20 or 50 amino acids of the vertebrate Deltex protein. In specific embodiments, such fragments are not larger than 35, 100 or 200 amino acids. Derivatives or analogs of vertebrate Deltex include but are not limited to those peptides which are substantially homologous to human Deltex or fragments thereof.

5 In a specific embodiment, derivatives or analogs of vertebrate Deltex include those peptides which are substantially homologous to the amino terminal 180 amino acids (1-180) of human Deltex. In one embodiment, the amino terminal region of the vertebrate Deltex protein has at least 30% identity over the amino terminal amino acid sequence of  
10 identically sized human Deltex. In another embodiment this identity is greater than 35%. In a preferred embodiment, the amino terminal amino acid identity of the vertebrate Deltex is greater than 45%. In a more preferred embodiment this identity is greater than 55%. In a most preferred embodiment, the homology of the amino terminal amino acids of the  
15 vertebrate Deltex is greater than 65% over the corresponding human Deltex amino terminal amino acid sequence of identical size.

In another specific embodiment, derivatives or analogs of vertebrate Deltex include those peptides which are substantially homologous to the central region (amino acids 181-441) of human Deltex, or fragments thereof. In one embodiment, the central region of  
20 the vertebrate Deltex protein has at least 30% identity with the corresponding human Deltex sequence of identical size. In another embodiment this identity is greater than 35%. In a preferred embodiment, the amino acid identity of the central region of vertebrate Deltex and human Deltex is greater than 45%. In a more preferred embodiment this identity is greater  
25 than 55%. In a most preferred embodiment, the homology of the central amino acids of the vertebrate Deltex to corresponding human Deltex amino acids of identical size is greater than 65%.

Additionally, derivatives or analogs of vertebrate Deltex include but are not limited to those peptides which are substantially homologous to the carboxy terminal amino  
30 acids of human Deltex or fragments thereof. In one embodiment, the carboxy terminal region of the vertebrate Deltex protein (the carboxy terminal 180 amino acids) has at least 45% identity over the amino acid sequence of identical size. In another embodiment this identity is greater than 50%. In a preferred embodiment, the amino terminal amino acid  
35 identity of the vertebrate Deltex is greater than 55%. In a more preferred embodiment this identity is greater than 60%. In a most preferred embodiment, the homology of the amino terminal amino acids of the vertebrate Deltex is greater than 65%.

In another preferred embodiment, derivatives or analogs of vertebrate Deltex comprise regions conserved between *Drosophila* and human Deltex (see Section 8).

5 The vertebrate Deltex protein derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned vertebrate *deltex* gene sequence can be modified by any of numerous strategies known in the art (Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York). The sequence can be cleaved at appropriate  
10 sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of a vertebrate Deltex protein, care should be taken to ensure that the modified gene remains within the same translational reading frame as the vertebrate *deltex* gene, uninterrupted by  
15 translational stop signals, in the gene region where the desired vertebrate Deltex activity is encoded.

Additionally, the vertebrate Deltex-encoding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction  
20 endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, J. Biol. Chem 253:6551), use of TAB® linkers (Pharmacia), etc.

25 Manipulations of the vertebrate *deltex* sequence may also be made at the protein level. Included within the scope of the invention are vertebrate Deltex protein fragments or other derivatives or analogs which are differentially modified during or after translation, *e.g.*, by acetylation, phosphorylation, carboxylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or  
30 other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>, acetylation, formylation, oxidation, reduction, etc.

35 In a preferred aspect, phosphorylation or, alternatively, dephosphorylation is carried out, which can be to various extents, on the purified vertebrate Deltex protein or



derivative thereof. The phosphorylation state of the molecule may be important to its role in intracellular signal transduction of Notch function. Phosphorylation can be carried out by reaction with an appropriate kinase (*e.g.*, possibly cdc2 or CK II). Dephosphorylation can be carried out by reaction with an appropriate phosphatase.

5 In addition, analogs and derivatives of vertebrate Deltex proteins can be chemically synthesized. For example, a peptide corresponding to a portion of a vertebrate Deltex protein which comprises the desired domain, or which mediates the desired activity *in vitro*, can be synthesized by use of a peptide synthesizer. Furthermore, if desired,  
10 nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the vertebrate Deltex protein sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, designer amino acids such as  $\beta$ -  
15 methyl amino acids, C $\alpha$ -methyl amino acids, and N $\alpha$ -methyl amino acids.

In a specific embodiment, the vertebrate Deltex derivative is a chimeric, or fusion, protein comprising a vertebrate Deltex protein or fragment thereof (preferably consisting of at least a domain or motif of the vertebrate Deltex protein, or at least 10 amino  
20 acids of the vertebrate Deltex protein) joined at its amino or carboxy-terminus via a peptide bond to an amino acid sequence of a different protein. In one embodiment, such a chimeric protein is produced by recombinant expression of a nucleic acid encoding the protein (comprising a vertebrate Deltex-coding sequence joined in-frame to a coding sequence for a different protein). Such a chimeric product can be made by ligating the appropriate nucleic  
25 acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, *e.g.*, by use of a peptide synthesizer. A specific embodiment  
30 relates to a chimeric protein comprising a fragment of a vertebrate Deltex protein which comprises a domain or motif of the vertebrate Deltex protein, *e.g.*, a portion which binds to a Notch protein or to a second Deltex protein, an SH-3 binding domain, a ring-H2-zinc finger domain, etc. In a particular embodiment, a chimeric nucleic acid can be constructed,  
35 encoding a fusion protein consisting of a vertebrate Deltex Notch-binding fragment joined to a non-Deltex protein. As another example, and not by way of limitation, a recombinant

molecule can be constructed according to the invention, comprising coding portions of both a vertebrate *deltex* gene and another gene which is a member of the "Notch group."

Another specific embodiment relates to a chimeric protein comprising a fragment of a vertebrate Deltex protein of at least six amino acids. Particular examples of the construction and expression of fusion proteins comprising human Deltex or various Notch fragments, are described in Section 7.

Other specific embodiments of derivatives and analogs are described in the subsection below and examples sections *infra*.

#### **5.6.1. DERIVATIVES OF VERTEBRATE DELTEX CONTAINING ONE OR MORE DOMAINS OF THE PROTEIN**

In a specific embodiment, the invention provides vertebrate Deltex derivatives and analogs, in particular vertebrate Deltex fragments and derivatives of such fragments, that comprise or consist of one or more domains of the vertebrate Deltex protein, including but not limited to a region which binds to a Notch protein (or a molecule comprising the ANK repeats thereof), a region which binds to a second Deltex protein or portion thereof, an SH3-binding domain, or a ring-H2-zinc finger domain. In specific embodiments, the vertebrate Deltex derivative may lack all or a portion of one or more of the foregoing domains.

In specific embodiments directed to the domains of the human Deltex protein, the aforesaid domains consist of approximately the following amino-acid sequences (see Section 6.1.1 *infra*):

SH3 binding domains: SEQ ID NOS: 17-21

Ring-H2-zinc finger domain: SEQ ID NO:25

Other binding fragments, *e.g.*, smaller than those set forth above, can be identified by routine methods, *e.g.*, by construction of nucleic acids encoding such fragments and assays for binding (*e.g.*, via the interaction trap method described in Section 7 *infra*).

In a specific embodiment, relating to a vertebrate Deltex protein of a species other than human, fragments comprising specific domains of vertebrate Deltex are those comprising domains in the respective vertebrate Deltex protein most homologous to the specific domain of the human Deltex protein.

We have demonstrated that *Drosophila* Deltex binds to human Notch-1 and 2, suggesting evolutionary conservation of biochemical activity between human and *Drosophila* Deltex. We have also demonstrated that human Deltex binds to human Notch-1 and 2, and that human Deltex binds to *Drosophila* Notch. Using the interaction trap system (described *infra*) as our assay we systematically examined, by deletion analysis, the domains of Notch and Deltex which are responsible for protein-protein interactions. Both Deltex-Deltex as well as Deltex-Notch interactions were detected. Deletion constructs encoding various fragments (described below) of *Drosophila* Deltex, *Drosophila* Notch and human Notch were expressed as fusion constructs (LexA or ACT fusions), and assayed.

The sequences of fragments A-D (SEQ ID NOS:13-16, respectively) of *Drosophila* Deltex which were expressed are shown in Fig. 4A-B.

Figure 5 summarizes the Deltex-Deltex interactions we have detected. Fragment A interacts with Fragment A (homotypic interactions). Fragment B interacts with Fragment B (homotypic interactions). Fragment C interacts with Fragment C (homotypic interactions). In addition, we detected interactions between fragments C and B. However, we can only detect the fragment C-B interaction if fragment C is tested as the "bait" (*i.e.*, as the LexA fusion). If Fragment B is the bait, this interaction is not detected. All the other aforesaid interactions occur irrespective of which fragment is used as the bait. Fragment A consists of amino acids 1-303. Fragment B consists of amino acids 306-486. Fragment C consists of amino acids 514-737.

The heterotypic interaction between Notch and Deltex is occurred between the ANK repeat region of Notch and fragment D of Deltex (which is part of fragment A and includes amino acids 1-204). *Drosophila* Notch ANK repeats as well as the ANK repeats of both human Notch proteins (encoded by TAN-1 and hN) were tested in this interaction assay and showed positive binding to fragment D. The following fragments containing the ANK repeat region were used: *Drosophila* Notch amino acids: 1889-2076 (numbering per Wharton et al., 1985, Cell 43:567-581); Human Notch TAN-1 amino acids: 1826-2146; Human Notch hN amino acids: 1772-2093. All displayed interactions with fragment D. Figure 6 summarizes schematically this interaction.

In specific embodiments, vertebrate Deltex regions are provided that are most homologous to *Drosophila* fragment A (SEQ ID NO:13), fragment B (SEQ ID NO:14), fragment C (SEQ ID NO:15), and fragment D (SEQ ID NO:16), shown in Figure 4A-B.

Binding interactions between fragments are indicated by arrows in Figures 5 and 6. Such regions homologous to A-D are predicted also to display the binding interactions shown in Figures 5 and 6. Thus, amino acids 1-237, 238-391, 392-620, and 1-175 of SEQ ID NO:12 correspond to *Drosophila* fragments A-D, respectively. Molecules comprising one or more of the foregoing regions are provided. Accordingly, by way of example, a molecule comprising amino acid numbers 1-237 of SEQ ID NO:12 is predicted to bind the Notch ankyrin repeats.

Also provided are inhibitors (e.g., peptide inhibitors) of the foregoing protein interactions with Notch or with a second Deltex protein.

The ability to bind to a Notch protein or a Deltex protein (or derivative thereof) can be demonstrated by *in vitro* assays such as the interaction trap technique (Section 7, *infra*).

The nucleic acid sequences encoding Notch or vertebrate Deltex proteins or fragments thereof, for use in such assays, can be isolated from porcine, bovine, equine, feline, canine, as well as primate sources and any other mammals in which homologs of known genes can be identified. For example, the Notch protein or portion thereof comprising the ANK repeats which can be expressed and assayed for binding to Deltex or a Deltex derivative can be derived from any of the Notch homologs: human hN, human TAN-1, *Xenopus*, and *Drosophila*.

Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as the aforesaid domains may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of the vertebrate *deltex* genes which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. Likewise, the vertebrate Deltex proteins, fragments or derivatives thereof, of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of the domains including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence ("conservative" changes).

The derivatives, analogs, and peptides of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level.

Additionally, the nucleic acid sequence can be mutated *in vitro* or *in vivo*; and manipulations of the sequence may also be made at the protein level.

In addition, analogs and peptides can be chemically synthesized.

5

#### **5.7. IN VITRO ASSAYS OF VERTEBRATE DELTEX PROTEINS, DERIVATIVES AND ANALOGS**

The functional activity of vertebrate Deltex proteins, derivatives and analogs, can be assayed *in vitro* by various methods.

10

For example, in one embodiment, where one is assaying for the ability to bind or compete with wild-type vertebrate Deltex for binding to anti-vertebrate Deltex antibody, various immunoassays known in the art can be used, including but not limited to competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labelled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

25

In another embodiment, where one is assaying for the ability to mediate binding to Notch or portion thereof (*e.g.*, Notch ankyrin repeats) to a second Deltex protein or portion thereof, one can carry out assays such as that described *infra* in Section 7.

30

Other methods will be known to the skilled artisan and are within the scope of the invention.

In another embodiment, a method of identifying a molecule that inhibits or reduces the binding of a vertebrate Deltex protein to a Notch protein is provided. In this manner, agonists and antagonists of Deltex can be identified. Such a method comprises the steps of contacting a Notch protein and a vertebrate Delta protein such that binding between the Notch protein and the Deltex protein can occur, in the presence of one or more

35

molecules which are desired to be tested for the ability to inhibit or reduce binding between the Notch protein and the Deltex protein, and identifying the molecules that inhibit or reduce the binding of the Deltex protein to the Notch protein. Any of various binding assays known in the art can be used to carry out such a method, including but not limited to yeast interaction trap assays, cell culture *in vitro* aggregation assays, and soluble binding assays using purified Notch and Deltex proteins. A specific embodiment is as follows: Cultured cells are cotransfected with plasmid expression constructs that place *Notch* and *deltex* under distinct inducible promoters. Notch expression in these cells is first induced to ensure proper cell surface localization; Deltex expression is then induced. These cells are then aggregated with cells expressing Delta, to produce mutual capping of Notch and Delta at the point of mutual contact (see Singer J., 1992, Science, 255:1671-1677; Fehon et al., 1990, Cell, 61:523-534; Heitzler, et al., 1991, Cell, 64:1083-1092). Under these conditions, Deltex colocalizes with the capped Notch by virtue of its binding to Notch. The cells are then incubated in the presence of one or more molecules (preferably, purified molecules) which are desired to be tested for the ability to inhibit binding between Notch and Deltex. Molecules which inhibit or reduce the binding of Deltex to Notch will result in an increased localization of Deltex throughout the cell cytoplasm. This increased localization can be determined according to methods known in the art (*e.g.*, immunofluorescent staining with antibody to Deltex). The method can also be carried out using derivatives of Notch and Deltex that mediate binding to Deltex and to Notch, respectively.

#### 5.8. THERAPEUTIC USES

The invention provides for treatment of disorders of cell fate or differentiation by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics") include: vertebrate Deltex proteins and analogs and derivatives (including fragments) thereof (*e.g.*, as described hereinabove); antibodies thereto (as described hereinabove); nucleic acids encoding the vertebrate Deltex proteins, analogs, or derivatives (*e.g.*, as described hereinabove); and vertebrate *deltex* antisense nucleic acids. As stated *supra*, the Antagonist Therapeutics of the invention are those Therapeutics which antagonize, or inhibit, a vertebrate Deltex function and/or Notch function. Such Antagonist Therapeutics are most preferably identified by use of known convenient *in vitro* assays, *e.g.*, based on their ability to inhibit binding of vertebrate Deltex

to another protein (*e.g.*, a Notch protein), or inhibit any known Notch or vertebrate Deltex function as preferably assayed *in vitro* or in cell culture, although genetic assays (*e.g.*, in *Drosophila* or mouse) may also be employed. In a preferred embodiment, the Antagonist Therapeutic is a protein or derivative thereof comprising a functionally active fragment such as a fragment of vertebrate Deltex which mediates binding to Notch, or an antibody thereto. In other specific embodiments, such an Antagonist Therapeutic is a nucleic acid capable of expressing a molecule comprising a fragment of vertebrate Deltex which binds to Notch, or a vertebrate *deltex* antisense nucleic acid (see Section 5.11 herein). It should be noted that preferably, suitable *in vitro* or *in vivo* assays, as described *infra*, should be utilized to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue, since the developmental history of the tissue may determine whether an Antagonist or Agonist Therapeutic is desired.

In another embodiment of the invention, a nucleic acid containing a portion of a vertebrate *deltex* gene is used, as an Antagonist Therapeutic, to promote vertebrate *deltex* inactivation by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438).

The Agonist Therapeutics of the invention, as described *supra*, promote vertebrate Deltex function. Such Agonist Therapeutics include but are not limited to proteins and derivatives comprising the portions of Notch that mediate binding to vertebrate Deltex, *i.e.*, the ANK repeats, and nucleic acids encoding the foregoing (which can be administered to express their encoded products *in vivo*).

Further descriptions and sources of Therapeutics of the inventions are found in Sections 5.1 through 5.7 herein.

Molecules which retain, or alternatively inhibit, a desired vertebrate Deltex property, *e.g.*, binding to Notch, binding to an intracellular ligand, can be used therapeutically as inducers, or inhibitors, respectively, of such property and its physiological correlates. In a specific embodiment, a peptide (*e.g.*, in the range of 6-50 or 15-25 amino acids; and particularly of about 10, 15, 20 or 25 amino acids) containing the sequence of a portion of vertebrate Deltex which binds to Notch is used to antagonize Notch function. In a specific embodiment, such an Antagonist Therapeutic is used to treat or prevent human or other malignancies associated with increased Notch expression (*e.g.*, cervical cancer, colon cancer, breast cancer, squamous adenocarcinomas (see *infra*)). Derivatives or analogs of

vertebrate Deltex can be tested for the desired activity by procedures known in the art, including but not limited to the assays described in the examples *infra*. For example, molecules comprising Deltex fragments which bind to Notch ANK repeats (see Section 7), can be obtained and selected by expressing deletion mutants of human Deltex (or of a  
5 nucleotide sequence of another species and assaying for binding of the expressed product to Notch by any of several methods, such as the interaction trap system described in the Examples Sections *infra*. In one specific embodiment, peptide libraries can be screened to select a peptide with the desired activity; such screening can be carried out by assaying,  
10 *e.g.*, for binding to Notch or a molecule containing the Notch ANK repeats.

The Agonist and Antagonist Therapeutics of the invention have therapeutic utility for disorders of cell fate. The Agonist Therapeutics are administered therapeutically (including prophylactically): (1) in diseases or disorders involving an absence or decreased  
15 (relative to normal, or desired) levels of Notch or vertebrate Deltex function, for example, in patients where Notch or vertebrate Deltex protein is lacking, genetically defective, biologically inactive or underactive, or underexpressed; and (2) in diseases or disorders wherein *in vitro* (or *in vivo*) assays (see *infra*) indicate the utility of vertebrate Deltex agonist administration. The absence or decreased levels in Notch or vertebrate Deltex  
20 function can be readily detected, *e.g.*, by obtaining a patient tissue sample (*e.g.*, from biopsy tissue) and assaying it *in vitro* for protein levels, structure and/or activity of the expressed Notch or vertebrate Deltex protein. Many methods standard in the art can be thus employed, including but not limited to immunoassays to detect and/or visualize Notch or  
25 vertebrate Deltex protein (*e.g.*, Western blot, immunoprecipitation followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect Notch or vertebrate Deltex expression by detecting and/or visualizing respectively Notch or vertebrate *deltex* mRNA (*e.g.*, Northern assays, dot blots, *in situ* hybridization, etc.)

30 *In vitro* assays which can be used to determine whether administration of a specific Agonist Therapeutic or Antagonist Therapeutic is indicated, include *in vitro* cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a Therapeutic, and the effect of such Therapeutic upon the tissue  
35 sample is observed. In one embodiment, where the patient has a malignancy, a sample of cells from such malignancy is plated out or grown in culture, and the cells are then exposed



to a Therapeutic. A Therapeutic which inhibits survival or growth of the malignant cells (e.g., by promoting terminal differentiation) is selected for therapeutic use *in vivo*. Many assays standard in the art can be used to assess such survival and/or growth; for example, cell proliferation can be assayed by measuring <sup>3</sup>H-thymidine incorporation, by direct cell  
5 count, by detecting changes in transcriptional activity of known genes such as proto-oncogenes (e.g., *fos*, *myc*) or cell cycle markers; cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in morphology, etc. In a specific aspect, the malignant cell cultures are separately exposed to (1) an Agonist  
10 Therapeutic, and (2) an Antagonist Therapeutic; the result of the assay can indicate which type of Therapeutic has therapeutic efficacy.

In another embodiment, a Therapeutic is indicated for use which exhibits the desired effect, inhibition or promotion of cell growth, upon a patient cell sample from tissue  
15 having or suspected of having a hyper- or hypoproliferative disorder, respectively. Such hyper- or hypoproliferative disorders include but are not limited to those described in Sections 5.8.1 through 5.8.3 *infra*.

In another specific embodiment, a Therapeutic is indicated for use in treating nerve injury or a nervous system degenerative disorder (see Section 5.8.2) which exhibits *in*  
20 *vitro* promotion of nerve regeneration/neurite extension from nerve cells of the affected patient type.

In addition, administration of an Antagonist Therapeutic of the invention is also indicated in diseases or disorders determined or known to involve a Notch or Deltex  
25 dominant activated phenotype ("gain of function" mutations.) Administration of an Agonist Therapeutic is indicated in diseases or disorders determined or known to involve a Notch or Deltex dominant negative phenotype ("loss of function" mutations). The functions of various structural domains of the Notch protein have been investigated *in vivo*, by ectopically expressing a series of *Drosophila Notch* deletion mutants under the hsp70 heat-  
30 shock promoter, as well as eye-specific promoters (see Rebay et al., 1993, Cell 74:319-329). Two classes of dominant phenotypes were observed, one suggestive of *Notch* loss-of function mutations and the other of *Notch* gain-of-function mutations. Dominant "activated" phenotypes resulted from overexpression of a protein lacking most extracellular  
35 sequences, while dominant "negative" phenotypes resulted from overexpression of a protein lacking most intracellular sequences. The results indicated that Notch functions as a

receptor whose extracellular domain mediates ligand-binding, resulting in the transmission of developmental signals by the cytoplasmic domain. The phenotypes observed also suggested that the ANK repeat region within the intracellular domain plays an essential role in Notch mediated signal transduction events (intracellular function). We have shown that *Drosophila* Deltex binds to the Notch ANK repeat region.

In various specific embodiments, *in vitro* assays can be carried out with representative cells of cell types involved in a patient's disorder, to determine if a Therapeutic has a desired effect upon such cell types.

In another embodiment, cells of a patient tissue sample suspected of being pre-neoplastic are similarly plated out or grown *in vitro*, and exposed to a Therapeutic. The Therapeutic which results in a cell phenotype that is more normal (*i.e.*, less representative of a pre-neoplastic state, neoplastic state, malignant state, or transformed phenotype) is selected for therapeutic use. Many assays standard in the art can be used to assess whether a pre-neoplastic state, neoplastic state, or a transformed or malignant phenotype, is present. For example, characteristics associated with a transformed phenotype (a set of *in vitro* characteristics associated with a tumorigenic ability *in vivo*) include a more rounded cell morphology, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, release of proteases such as plasminogen activator, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton surface protein, etc. (see Luria et al., 1978, *General Virology*, 3d Ed., John Wiley & Sons, New York pp. 436-446).

In other specific embodiments, the *in vitro* assays described *supra* can be carried out using a cell line, rather than a cell sample derived from the specific patient to be treated, in which the cell line is derived from or displays characteristic(s) associated with the malignant, neoplastic or pre-neoplastic disorder desired to be treated or prevented, or is derived from the neural or other cell type upon which an effect is desired, according to the present invention.

In a specific embodiment, an antagonist of Notch and/or Deltex function that can be used as an Antagonist Therapeutic is a molecule comprising a Deltex protein or portion thereof that mediates binding to Notch, covalently bound to a protease or proteolytically active fragment thereof. Such protease preferably is able to cleave a Notch protein. The molecule is preferably a fusion protein (*i.e.*, the covalent bond is a peptide

bond). The Deltex protein is preferably a vertebrate protein, most preferably human. Accordingly, the invention provides a method of targeting or inactivating proteins to which Deltex binds (*e.g.*, Notch) in a cell. According to this method, the molecule comprising the Deltex protein or portion thereof and the protease sequences is produced through chemical  
5 or via molecular biological techniques. This molecule (*e.g.*, fusion protein) is introduced into the cell by techniques known in the art (*e.g.*, transfection of the cell with a nucleic acid encoding the molecule such that its expression occurs intracellularly). Inside the cell, the molecule can bind to Notch and/or other Deltex binding partners. Upon such binding, the  
10 protease portion of the molecule cleaves the protein to which the molecule is bound, thus inactivating it. For example, a fusion protein containing domain I of human Deltex and the protease thermolysin, when introduced into the cell would bind to and cleave Notch, thereby inactivating the Notch signaling pathway. Molecules which would inactivate protein  
15 function *e.g.*, by binding thereto, can be used as an alternative to proteases.

The Antagonist Therapeutics are administered therapeutically (including prophylactically): (1) in diseases or disorders involving increased (relative to normal, or desired) levels of Notch or vertebrate Deltex function, for example, where the Notch or vertebrate Deltex protein is overexpressed or overactive; and (2) in diseases or disorders  
20 wherein *in vitro* (or *in vivo*) assays indicate the utility of vertebrate Deltex antagonist administration. The increased levels of Notch or vertebrate Deltex function can be readily detected by methods such as those described above, by quantifying protein and/or RNA. *In vitro* assays with cells of patient tissue sample or the appropriate cell line or cell type, to  
25 determine therapeutic utility, can be carried out as described above.

#### 5.8.1. MALIGNANCIES

Malignant and pre-neoplastic conditions which can be tested as described  
*supra* for efficacy of intervention with Antagonist or Agonist Therapeutics, and which can  
30 be treated upon thus observing an indication of therapeutic utility, include but are not limited to those described below in Sections 5.8.1 and 5.9.1.

Malignancies and related disorders, cells of which type can be tested *in vitro* (and/or *in vivo*), and upon observing the appropriate assay result, treated according to the  
35 present invention, include but are not limited to those listed in Table 1 (for a review of such disorders, see Fishman et al., 1985, *Medicine*, 2d Ed., J.B. Lippincott Co., Philadelphia):

**TABLE 1**  
**MALIGNANCIES AND RELATED DISORDERS**

5	Leukemia
	acute leukemia
	acute lymphocytic leukemia
	acute myelocytic leukemia
	myeloblastic
	promyelocytic
10	myelomonocytic
	monocytic
	erythroleukemia
	chronic leukemia
	chronic myelocytic (granulocytic) leukemia
	chronic lymphocytic leukemia
	Polycythemia vera
15	Lymphoma
	Hodgkin's disease
	non-Hodgkin's disease
	Multiple myeloma
	Waldenström's macroglobulinemia
	Heavy chain disease
	Solid tumors
20	sarcomas and carcinomas
	fibrosarcoma
	myxosarcoma
	liposarcoma
	chondrosarcoma
	osteogenic sarcoma
	chordoma
25	angiosarcoma
	endotheliosarcoma
	lymphangiosarcoma
	lymphangioendotheliosarcoma
	synovioma
	mesothelioma
30	Ewing's tumor
	leiomyosarcoma
	rhabdomyosarcoma
	colon carcinoma
	pancreatic cancer
	breast cancer
	ovarian cancer
35	prostate cancer
	squamous cell carcinoma
	basal cell carcinoma

	adenocarcinoma
	sweat gland carcinoma
	sebaceous gland carcinoma
	papillary carcinoma
	papillary adenocarcinomas
5	cystadenocarcinoma
	medullary carcinoma
	bronchogenic carcinoma
	renal cell carcinoma
	hepatoma
	bile duct carcinoma
	choriocarcinoma
10	seminoma
	embryonal carcinoma
	Wilms' tumor
	cervical cancer
	testicular tumor
	lung carcinoma
	small cell lung carcinoma
15	bladder carcinoma
	epithelial carcinoma
	glioma
	astrocytoma
	medulloblastoma
	craniopharyngioma
20	ependymoma
	pinealoma
	hemangioblastoma
	acoustic neuroma
	oligodendroglioma
	menangioma
	melanoma
25	neuroblastoma
	retinoblastoma

30 In specific embodiments, malignancy or dysproliferative changes (such as metaplasias and dysplasias) are treated or prevented in epithelial tissues such as those in the cervix, esophagus, and lung.

Malignancies of the colon and cervix can exhibit increased expression of human Notch relative to such non-malignant tissue (see PCT Publication WO 94/07474 published April 14, 1994, incorporated by reference herein in its entirety). Thus, in specific  
 35 embodiments, malignancies of the colon or cervix are treated or prevented by administering an effective amount of an Antagonist Therapeutic of the invention. The presence of

increased Notch expression in colon, and cervical cancer suggests that many more cancerous and hyperproliferative conditions exhibit upregulated Notch. Thus, in specific embodiments, various cancers, *e.g.*, breast cancer, squamous adenocarcinoma, seminoma, melanoma, and lung cancer, as well as other hyperproliferative disorders, can be treated or prevented by administration of an Antagonist Therapeutic.

### 5.8.2. NERVOUS SYSTEM DISORDERS

- Nervous system disorders, involving cell types which can be tested as described *supra* for efficacy of intervention with Antagonist or Agonist Therapeutics, and which can be treated upon thus observing an indication of therapeutic utility, include but are not limited to nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination.
- Nervous system lesions which may be treated in a patient (including human and non-human vertebrate patients) according to the invention include but are not limited to the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems:
- (i) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries;
  - (ii) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia;
  - (iii) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue;
  - (iv) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis;
  - (v) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including

but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis;

- 5 (vi) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary  
10 degeneration of the corpus callosum), and alcoholic cerebellar degeneration;
- (vii) neurological lesions associated with systemic diseases including but not limited to diabetes (diabetic neuropathy, Bell's palsy), systemic  
15 lupus erythematosus, carcinoma, or sarcoidosis;
- (viii) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and
- (ix) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not  
20 limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

25 Therapeutics which are useful according to the invention for treatment of a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons (see also Section 5.8). For example, and not by way of limitation, Therapeutics which elicit any of the following effects may be useful according to the invention:

- 30 (i) increased survival time of neurons in culture;
- (ii) increased sprouting of neurons in culture or *in vivo*;
- (iii) increased production of a neuron-associated molecule in culture or *in vivo*, *e.g.*, choline acetyltransferase or acetylcholinesterase with  
35 respect to motor neurons; or
- (iv) decreased symptoms of neuron dysfunction *in vivo*.

Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may be measured by the method set forth in Arakawa et al. (1990, J. Neurosci. 10:3507-3515); increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, Exp. Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci. 4:17-42); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, *e.g.*, weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron disorders that may be treated according to the invention include but are not limited to disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including but not limited to progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

### 5.8.3. TISSUE REPAIR AND REGENERATION

In another embodiment of the invention, a Therapeutic of the invention is used for promotion of tissue regeneration and repair, including but not limited to treatment of benign dysproliferative disorders. Specific embodiments are directed to treatment of cirrhosis of the liver (a condition in which scarring has overtaken normal liver regeneration processes), treatment of keloid (hypertrophic scar) formation (disfiguring of the skin in which the scarring process interferes with normal renewal), psoriasis (a common skin condition characterized by excessive proliferation of the skin and delay in proper cell fate determination), and baldness (a condition in which terminally differentiated hair follicles (a tissue rich in Notch) fail to function properly).

Deltex agonists and antagonists can also be used to manipulate the differentiation state of non-terminally differentiated (*e.g.*, stem and progenitor) cells. For example, a stem cell can be exposed to such an agonist to inhibit its differentiation and



achieve expansion of the stem cell population by incubation *in vitro* under growth conditions. Such stem cells have use in transplantation for *in vivo* repopulation of their progeny cells and tissue regeneration. (For methods that can be used in the foregoing, see United States patent application Serial No. 08/537,210 filed September 29, 1995 by  
5 Artavanis-Tsakonas et al., entitled "Manipulation of Non-Terminally Differentiated Cells Using the Notch Pathway," which is incorporated by reference herein in its entirety.) For example, a method for the expansion of a precursor cell (*e.g.*, a human stem or progenitor cell) comprises contacting the cell with an amount of a vertebrate (*e.g.*, human) Deltex  
10 protein or functionally active portion thereof effective to inhibit differentiation of the cell, and exposing the cell to cell growth conditions such that the cell proliferates. In various embodiments, the precursor cell can be but is not limited to a hematopoietic precursor cell, epithelial precursor cell, kidney precursor cell, neural precursor cell, skin precursor cell, osteoblast precursor cell, chondrocyte precursor cell, liver precursor cell, and muscle cell.  
15

## 5.9. PROPHYLACTIC USES

### 5.9.1. MALIGNANCIES

The Therapeutics of the invention can be administered to prevent progression  
20 to a neoplastic or malignant state, including but not limited to those disorders listed in Table 1. Such administration is indicated where the Therapeutic is shown in assays, as described *supra*, to have utility for treatment or prevention of such disorder. Such prophylactic use is indicated in conditions known or suspected of preceding progression to neoplasia or cancer,  
25 in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, *Basic Pathology*, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-79.) Hyperplasia is a form of controlled cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. As  
30 but one example, endometrial hyperplasia often precedes endometrial cancer. Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplasia can occur in epithelial or connective tissue cells. Atypical metaplasia involves a somewhat disorderly metaplastic epithelium.  
35 Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell

uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation, and is often found in the cervix, respiratory passages, oral cavity, and gall bladder.

5 Alternatively or in addition to the presence of abnormal cell growth characterized as hyperplasia, metaplasia, or dysplasia, the presence of one or more characteristics of a transformed phenotype, or of a malignant phenotype, displayed *in vivo* or displayed *in vitro* by a cell sample from a patient, can indicate the desirability of  
10 prophylactic/therapeutic administration of a Therapeutic of the invention. As mentioned *supra*, such characteristics of a transformed phenotype include morphology changes, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, protease release, increased sugar transport, decreased serum requirement, expression of fetal  
15 antigens, disappearance of the 250,000 dalton cell surface protein, etc. (see also *id.*, at pp. 84-90 for characteristics associated with a transformed or malignant phenotype).

In a specific embodiment, leukoplakia, a benign-appearing hyperplastic or dysplastic lesion of the epithelium, or Bowen's disease, a carcinoma *in situ*, are pre-neoplastic lesions indicative of the desirability of prophylactic intervention.

20 In another embodiment, fibrocystic disease (cystic hyperplasia, mammary dysplasia, particularly adenosis (benign epithelial hyperplasia)) is indicative of the desirability of prophylactic intervention.

In other embodiments, a patient which exhibits one or more of the following  
25 predisposing factors for malignancy is treated by administration of an effective amount of a Therapeutic: a chromosomal translocation associated with a malignancy (*e.g.*, the Philadelphia chromosome for chronic myelogenous leukemia, t(14;18) for follicular lymphoma, etc.), familial polyposis or Gardner's syndrome (possible forerunners of colon cancer), benign monoclonal gammopathy (a possible forerunner of multiple myeloma), and a  
30 first degree kinship with persons having a cancer or precancerous disease showing a Mendelian (genetic) inheritance pattern (*e.g.*, familial polyposis of the colon, Gardner's syndrome, hereditary exostosis, polyendocrine adenomatosis, medullary thyroid carcinoma with amyloid production and pheochromocytoma, Peutz-Jeghers syndrome,  
35 neurofibromatosis of Von Recklinghausen, retinoblastoma, carotid body tumor, cutaneous melanocarcinoma, intraocular melanocarcinoma, xeroderma pigmentosum, ataxia

telangiectasia, Chediak-Higashi syndrome, albinism, Fanconi's aplastic anemia, and Bloom's syndrome; *see* Robbins and Angell, 1976, *Basic Pathology*, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 112-113) etc.)

5 In another specific embodiment, an Antagonist Therapeutic of the invention is administered to a human patient to prevent progression to breast, colon, or cervical cancer.

#### 5.9.2. OTHER DISORDERS

10 In other embodiments, a Therapeutic of the invention can be administered to prevent a nervous system disorder described in Section 5.8.2, or other disorder (*e.g.*, liver cirrhosis, psoriasis, keloids, baldness) described in Section 5.8.3.

#### 5.10. DEMONSTRATION OF THERAPEUTIC OR PROPHYLACTIC UTILITY

15 The Therapeutics of the invention can be tested *in vivo* for the desired therapeutic or prophylactic activity. For example, such compounds can be tested in suitable animal model systems prior to testing in humans, including but not limited to rats, mice, chicken, cows, monkeys, rabbits, etc. For *in vivo* testing, prior to administration to  
20 humans, any animal model system known in the art may be used.

#### 5.11. ANTISENSE REGULATION OF VERTEBRATE DELTEX EXPRESSION

The present invention provides the therapeutic or prophylactic use of nucleic  
25 acids of at least six nucleotides that are antisense to a gene or cDNA encoding vertebrate Deltex or a portion thereof. "Antisense" as used herein refers to a nucleic acid capable of hybridizing to a portion of a vertebrate *deltex* RNA (preferably mRNA) by virtue of some sequence complementarity. Such antisense nucleic acids have utility as Antagonist  
30 Therapeutics of the invention, and can be used in the treatment or prevention of disorders as described *supra* in Section 5.8 and its subsections.

The antisense nucleic acids of the invention can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be directly administered to a cell, or which can be produced intracellularly by  
35 transcription of exogenous, introduced sequences.

In a specific embodiment, the vertebrate *deltex* antisense nucleic acids provided by the instant invention can be used for the treatment of tumors or other disorders, the cells of which tumor type or disorder can be demonstrated (*in vitro* or *in vivo*) to express a vertebrate *deltex* gene or a *Notch* gene. Such demonstration can be by detection  
5 of RNA or of protein.

The invention further provides pharmaceutical compositions comprising an effective amount of the vertebrate *deltex* antisense nucleic acids of the invention in a pharmaceutically acceptable carrier, as described *infra* in Section 5.12. Methods for  
10 treatment and prevention of disorders (such as those described in Sections 5.8 and 5.9) comprising administering the pharmaceutical compositions of the invention are also provided.

In another embodiment, the invention is directed to methods for inhibiting the expression of a vertebrate *deltex* nucleic acid sequence in a prokaryotic or eukaryotic cell  
15 comprising providing the cell with an effective amount of a composition comprising an antisense vertebrate *deltex* nucleic acid of the invention.

Vertebrate *deltex* antisense nucleic acids and their uses are described in detail below.  
20

#### 5.11.1. VERTEBRATE DELTEX ANTISENSE NUCLEIC ACIDS

The vertebrate *deltex* antisense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging from 6 to about 50 oligonucleotides). In  
25 specific aspects, the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 200 nucleotides. The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as  
30 peptides, or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO 88/09810, published December 15, 1988) or blood-brain barrier (see, *e.g.*, PCT Publication No. WO 89/10134, published April 25,  
35 1988), hybridization-triggered cleavage agents (see, *e.g.*, Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents (see, *e.g.*, Zon, 1988, Pharm. Res. 5:539-549).

In a preferred aspect of the invention, a vertebrate *deltex* antisense oligonucleotide is provided, preferably of single-stranded DNA. In a most preferred aspect, such an oligonucleotide comprises a sequence antisense to the sequence encoding an SH3-binding domain or a Notch-binding domain of vertebrate *deltex* or zinc finger domain, most preferably, of human *deltex*. The oligonucleotide may be modified at any position on its structure with substituents generally known in the art.

The vertebrate *deltex* antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to

5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

In another embodiment, the oligonucleotide comprises at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the oligonucleotide is an  $\alpha$ -anomeric oligonucleotide. An  $\alpha$ -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641).

The oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

Oligonucleotides of the invention may be synthesized by standard methods  
5 known in the art, *e.g.*, by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore  
10 glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

In a specific embodiment, the vertebrate *deltex* antisense oligonucleotide comprises catalytic RNA, or a ribozyme (see, *e.g.*, PCT International Publication  
15 WO 90/11364, published October 4, 1990; Sarver et al., 1990, Science 247:1222-1225). In another embodiment, the oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

In an alternative embodiment, the vertebrate *deltex* antisense nucleic acid of  
20 the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector can be introduced *in vivo* such that it is taken up by a cell, within which cell the vector or a portion thereof is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the vertebrate *deltex*  
25 antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding the vertebrate *deltex*  
30 antisense RNA can be by any promoter known in the art to act in vertebrate, preferably human, cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus  
35 (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner

et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42), etc.

The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a vertebrate *deltex* gene,  
5 preferably a human *deltex* gene. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded vertebrate *deltex* antisense  
10 nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a vertebrate *deltex* RNA it may  
15 contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

#### 5.11.2. THERAPEUTIC UTILITY OF VERTEBRATE 20 DELTEX ANTISENSE NUCLEIC ACIDS

The vertebrate *deltex* antisense nucleic acids can be used to treat (or prevent) malignancies or other disorders, of a cell type which has been shown to express vertebrate *deltex* or *Notch*. In specific embodiments, the malignancy is cervical, breast, or colon cancer, or squamous adenocarcinoma. Malignant, neoplastic, and pre-neoplastic cells which  
25 can be tested for such expression include but are not limited to those described *supra* in Sections 5.8.1 and 5.9.1. In a preferred embodiment, a single-stranded DNA antisense vertebrate *deltex* oligonucleotide is used.

Malignant (particularly, tumor) cell types which express vertebrate *deltex* or  
30 *Notch* RNA can be identified by various methods known in the art. Such methods include but are not limited to hybridization with a vertebrate *deltex* or *Notch*-specific nucleic acid (e.g., by Northern hybridization, dot blot hybridization, *in situ* hybridization), observing the ability of RNA from the cell type to be translated *in vitro* into Notch or vertebrate Deltex, immunoassay, etc. In a preferred aspect, primary tumor tissue from a patient can be  
35 assayed for Notch or vertebrate Deltex expression prior to treatment, e.g., by immunocytochemistry or *in situ* hybridization.

Pharmaceutical compositions of the invention (see Section 5.12), comprising an effective amount of a vertebrate *deltex* antisense nucleic acid in a pharmaceutically acceptable carrier, can be administered to a patient having a malignancy which is of a type that expresses *Notch* or vertebrate *deltex* RNA or protein.

5 The amount of vertebrate *deltex* antisense nucleic acid which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the antisense cytotoxicity of the tumor type to be  
10 treated *in vitro*, and then in useful animal model systems prior to testing and use in humans.

In a specific embodiment, pharmaceutical compositions comprising vertebrate *deltex* antisense nucleic acids are administered via liposomes, microparticles, or microcapsules. In various embodiments of the invention, it may be useful to use such  
15 compositions to achieve sustained release of the vertebrate *deltex* antisense nucleic acids. In a specific embodiment, it may be desirable to utilize liposomes targeted via antibodies to specific identifiable tumor antigens (Leonetti et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:2448-2451; Renneisen et al., 1990, J. Biol. Chem. 265:16337-16342).

20

#### 5.12. THERAPEUTIC/PROPHYLACTIC ADMINISTRATION AND COMPOSITIONS

The invention provides methods of treatment (and prophylaxis) by administration to a subject of an effective amount of a Therapeutic of the invention. In a preferred aspect, the Therapeutic is substantially purified. The subject is preferably an  
25 animal, including but not limited to animals such as cows, pigs, chickens, etc., and is preferably a mammal, and most preferably human.

Various delivery systems are known and can be used to administer a Therapeutic of the invention, *e.g.*, encapsulation in liposomes, microparticles,  
30 microcapsules, expression by recombinant cells, receptor mediated endocytosis (see, *e.g.*, Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a Therapeutic nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal,  
35 epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (*e.g.*, oral mucosa, rectal and intestinal mucosa, etc.) and may be



administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, *e.g.*, by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.

In another embodiment, the Therapeutic can be delivered in a vesicle, in particular a liposome (*see* Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; *see generally ibid.*)

In yet another embodiment, the Therapeutic can be delivered in a controlled release system. In one embodiment, a pump may be used (*see* Langer, *supra*; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (*see* Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); *see also* Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); Howard et al., J. Neurosurg. 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, *i.e.*, the brain, thus requiring only a fraction of the

systemic dose (*see, e.g.,* Goodson, in *Medical Applications of Controlled Release, supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

5 In a specific embodiment, administration of a Therapeutic into a Notch-expressing cell is accomplished by linkage of the Therapeutic to a Delta (or other toporythmic) protein or portion thereof capable of mediating binding to Notch. Contact of a Notch-expressing cell with the linked Therapeutic results in binding of the linked  
10 Therapeutic via its Delta portion to Notch on the surface of the cell, followed by uptake of the linked Therapeutic into the Notch-expressing cell.

In a specific embodiment, the Therapeutic is delivered intracellularly (*e.g.,* by expression from a nucleic acid vector, or by linkage to a Delta protein capable of binding to Notch followed by binding and internalization, or by receptor-mediated or diffusion  
15 mechanisms).

In a specific embodiment where the Therapeutic is a nucleic acid encoding a protein Therapeutic, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression  
20 vector and administering it so that it becomes intracellular, *e.g.,* by use of a retroviral vector (*see* U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (*e.g.,* a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide  
25 which is known to enter the nucleus (*see e.g.,* Joliot et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:1864-1868), etc. Alternatively, a nucleic acid Therapeutic can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

In specific embodiments directed to treatment or prevention of particular  
30 disorders, preferably the following forms of administration are used:

<u>Disorder</u>	<u>Preferred Forms of Administration</u>
Cervical cancer	Topical
35 Gastrointestinal cancer	Oral; intravenous
Lung cancer	Inhaled; intravenous

	Leukemia	Intravenous; extracorporeal
	Metastatic carcinomas	Intravenous; oral
	Brain cancer	Targeted; intravenous; intrathecal
	Liver cirrhosis	Oral; intravenous
5	Psoriasis	Topical
	Keloids	Topical
	Baldness	Topical
	Spinal cord injury	Targeted; intravenous; intrathecal
10	Parkinson's disease	Targeted; intravenous; intrathecal
	Motor neuron disease	Targeted; intravenous; intrathecal
	Alzheimer's disease	Targeted; intravenous; intrathecal

15           The present invention also provides pharmaceutical compositions. Such  
 compositions comprise a therapeutically effective amount of a Therapeutic, and a  
 pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically  
 acceptable" means approved by a regulatory agency of the Federal or a state government or  
 listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in  
 20 animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant,  
 excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical  
 carriers can be sterile liquids, such as water and oils, including those of petroleum, animal,  
 vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the  
 25 like. Water is a preferred carrier when the pharmaceutical composition is administered  
 intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be  
 employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical  
 excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica  
 gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk,  
 30 glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can  
 also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.  
 These compositions can take the form of solutions, suspensions, emulsion, tablets, pills,  
 capsules, powders, sustained-release formulations and the like. The composition can be  
 35 formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral  
 formulation can include standard carriers such as pharmaceutical grades of mannitol,  
 lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate,

etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the Therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The  
5 formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. In another preferred embodiment, the composition is formulated in  
10 accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to mammals. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site  
15 of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the  
20 composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The Therapeutics of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed  
25 with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

The amount of the Therapeutic of the invention which will be effective in the  
30 treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, *in vitro* assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and  
35 the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for

intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

5           Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

          The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical  
10 compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

15

### 5.13. DIAGNOSTIC UTILITY

          Vertebrate Deltex proteins, analogues, derivatives, and subsequences thereof, vertebrate *deltex* nucleic acids (and sequences complementary thereto), anti-vertebrate Deltex antibodies, have uses in diagnostics. Such molecules can be used in assays, such as  
20 immunoassays, to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders affecting vertebrate Deltex expression, or monitor the treatment thereof. In particular, such an immunoassay is carried out by a method comprising contacting a sample derived from a patient with an anti-vertebrate Deltex antibody under conditions such that  
25 immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody. In a specific aspect, such binding of antibody, in tissue sections, preferably in conjunction with binding of anti-Notch can be used to detect aberrant Notch and/or vertebrate Deltex localization or aberrant levels of Notch-vertebrate Deltex colocalization in a disease state. In a specific embodiment, antibody to vertebrate  
30 Deltex can be used to assay in a patient tissue or serum sample for the presence of vertebrate Deltex where an aberrant level of vertebrate Deltex is an indication of a diseased condition. Aberrant levels of vertebrate Deltex binding ability in an endogenous Notch protein, or aberrant levels of binding ability to Notch (or other vertebrate Deltex ligand) in  
35 an endogenous vertebrate Deltex protein may be indicative of a disorder of cell fate (*e.g.*, cancer, etc.) By "aberrant levels," is meant increased or decreased levels relative to that

present, or a standard level representing that present, in an analogous sample from a subject not having the disorder.

The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.

Vertebrate *deltex* genes and related nucleic acid sequences and subsequences, including complementary sequences, and other toporythmic gene sequences, can also be used in hybridization assays. Vertebrate *deltex* nucleic acid sequences, or subsequences thereof comprising about at least 8 nucleotides, can be used as hybridization probes. Hybridization assays can be used to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with aberrant changes in vertebrate *Deltex* expression and/or activity as described *supra*. In particular, such a hybridization assay is carried out by a method comprising contacting a sample containing nucleic acid with a nucleic acid probe capable of hybridizing to vertebrate *deltex* DNA or RNA, under conditions such that hybridization can occur, and detecting or measuring any resulting hybridization.

## 6. EXAMPLE: CLONING AND CHARACTERIZATION OF HUMAN DELTEX

As described herein, we have accomplished the isolation and molecular characterization of human *deltex*. We report the cloning and sequencing of human *deltex*. Human *deltex* encodes five putative SH3 domain binding sites and a ring-H2-zinc finger in similar locations to the corresponding motifs found in *Drosophila* *Deltex*.

### 6.1. RESULTS

#### 6.1.1. MOLECULAR CLONING OF THE HUMAN DELTEX LOCUS

Human *deltex* was isolated through a combination of computer and biochemical screens. Initially, a human expressed sequence tag database was screened for homology against the amino acid sequence of *Drosophila* *Deltex*. The critical part of this search involved the assumption that stop codons in a particular reading frame of the database

are the result of sequencing mistakes. Accordingly, stop codons were ignored and the open reading frame was extended in a different frame. The predicted amino acid sequence encoded by the hypothetical open reading frames were then compared with the protein product of the *Drosophila deltex* transcription unit.

5 We previously identified the *Drosophila deltex* transcription unit by showing via germline-mediated transformation experiments that a genomic fragment containing this transcription unit is capable of complementing most *deltex* mutant defects. Moreover, this genomic fragment rescues the normally lethal genetic interaction that results when flies are  
10 doubly mutant for *deltex* and *nd*. Finally, Northern analysis indicates a maternal loading of *deltex* transcripts into the developing oocyte, a finding that is consistent with the maternal effect observed upon embryogenesis in eggs laid by homozygous mutant mothers (Xu and Artavanis-Tsakonas, 1990 Genetics 126:665-677). cDNA clones homologous to the  
15 transcription unit were isolated from an embryonic cDNA library, the complete nucleotide sequence (SEQ ID NO:1) and predicted protein product were then determined (SEQ ID NO:2).

Comparison of the amino acid sequence of *Drosophila Deltex* with that predicted for what we deduced to be hypothetical open reading frames in the database  
20 identified a sequence:gnl I dbest I 24254 T05200 with significant homology to *Drosophila Deltex*. Within T05200, five conserved stretches of amino acids were found in different reading frames, at residues 7-39 (SEQ ID NO:4), 102-149 (SEQ ID NO:6), 138-245 (SEQ ID NO:8), and 200-310 (SEQ ID NO:10) corresponding to *Drosophila Deltex* residues 545-  
25 555 (SEQ ID NO:3), 565-580 (SEQ ID NO:5), 581-616 (SEQ ID NO:7) and 602-638 (SEQ ID NO:9) respectively. These sequences are shown in Table II, identical amino acids are shown in bold.

30

35

TABLE II

	AMINO ACID NOS.	
Drosophila Deltex	602-638	VYGEKVGVPPIGSMWSIISKNLPGHEGQNTIQIVYD
T05200	200-310	IYGEKTGTQPPGKMEFHLIPHSLXFGPDTQTXRIVYD
Drosophila Deltex	565-580	LSRCQHLMHLQCLNGM
T05200	102-149	LGRCGHMYHLLCLVAM
Drosophila Deltex	581-616	IIAQQNEMNKNLFIECPVCGIVYGEKVGNGPIGSM
T05200	138-245	LVAMYSNGNKGSLQCPTCKPSMGRRRVRSRLGRWS
Drosophila Deltex	545-555	QPCPMCMEELV
T05200	7-39	EDCTICMERLV

A series of two 5' primers (hdx-1 (SEQ ID NO:26) and hdx-2 (SEQ ID NO:27)) and two 3' primers (hdx-3 (SEQ ID NO:28) and hdx-4 (SEQ ID NO:29)) were synthesized based on the DNA sequence of gnl I dbest I 24254 T05200. PCR reactions were performed using the four different primer combinations and a human fetal brain cDNA library (Invitrogen) as the template. The PCR product was sequenced and found to have the same DNA sequence as gnl I dbest I 24254 T05200.

The PCR product generated using the hdx-1 and hdx-4 primers was then labeled and used to screen another human fetal brain cDNA library. The isolate was sequenced (SEQ ID NO:11) and the predicted protein determined (SEQ ID NO:12) (Figure 2A-C). Not greater than 107 continuous nucleotides of SEQ ID NO:11 were present in T05200. Applying standard techniques, the cDNA isolate obtained using the PCR product as probe was then labeled and itself used as a probe to screen a northern blot containing poly(A)<sup>+</sup> mRNA isolated from various human tissue samples. This probe was observed to hybridize to a 5.4-kb RNA in



heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. When this probe was used to screen a zoo blot (a blot containing genomic EcoRI-digested DNA of various species, obtained from Clontech) by Southern hybridization, hybridization was observed in genomic human, monkey, rat, mice, dog, cow, and yeast DNA. Hybridization was not observed in the rabbit and chicken genomic DNA.

#### Structural analysis of the human Deltex protein:

The predicted human Deltex product has 720 amino acids and an estimated molecular mass of approximately 80 kDa. The 180 amino terminal residues of human Deltex have an approximate identity of 33% with the corresponding amino acid residues of *Drosophila* Deltex and the nucleic acids encoding these amino acids have an approximate 52% identity. The 180 carboxy terminal amino acids of human Deltex have an approximate 48% identity with the corresponding amino acid residues of *Drosophila* Deltex and the nucleic acids encoding these carboxy terminal amino acids have an approximate 49% identity.

A structural analysis of human Deltex protein revealed a conserved structure among Deltex proteins (see Figure 3). Like *Drosophila* Deltex, human Deltex has both ring-H2-zinc finger (amino acids 411-471) (SEQ ID NO:25) and putative SH3-binding domains. Noticeably absent from the human Deltex are the two opa repeats that subdivide the primary structure of the *Drosophila* Deltex into three domains. Each of the *Drosophila* Deltex domains I, II, and III, has been found using the yeast "interaction trap assay" to be capable of mediating homotypic interactions (*see infra*).

##### i) Domain I:

Domain I corresponds to the N-terminal 303 amino acids of *Drosophila* and the first 237 amino acids of human Deltex. In *Drosophila*, we have demonstrated that the region of human Deltex corresponding to the first 175 amino acids of domain I is essential and sufficient to bind the Notch ANK repeats and overexpression of this domain can rescue loss-of-function phenotypes of Deltex. Since *Drosophila* Deltex can bind to human Notch-1 and 2, conservation

of binding activity between human Deltex and *Drosophila* domain I is suggested. Furthermore, this has been demonstrated. *See infra*.

ii) Putative SH3 binding domains:

Domain II of *Drosophila* Deltex contains a putative SH3-binding site (amino acids 476-484) (Matsuno et al., 1995, Development 121(8):2633-2644). Five putative SH3-binding sites (SEQ ID NOS:17-21) are found in human Deltex (within amino acids 226-377) in a position corresponding to the SH3-binding site in domain II of *Drosophila* Deltex (Table III).

SH2 and SH3 domains are conserved protein modules so named based on their homology to the oncogene Src (Src Homology). These motifs have been implicated in mediating protein-protein interactions in a number of signal transduction pathways (reviewed in Cell 71:359-362; Science 252:668-674; Trends Cell Biol. 3:8-13; FEBS 307:55-61). Recently, a complementary motif that binds to the SH3 domain has been identified and called simply an 'SH3-binding domain' ("SH3-BD") (Science 259:1157-1161). The core binding region of SH3-BD is proline-rich and approximately ten residues in length. As shown in Table III, this motif, as defined from a mouse protein that experimentally bound an SH3 domain (SEQ ID NO:23), is shown aligned to the putative SH3-binding site in *Drosophila* Deltex (SEQ ID NO:22) and the five regions (SEQ ID NOS: 17-21) that may represent human versions of this motif. These regions are located centrally in the Deltex protein. For reference, regions of the protein encoded by the *Drosophila* Son of sevenless (SOS) protein (SEQ ID NO:24), which may also contain SH3-BD, is shown. The Son of sevenless encoded protein, a putative guanine nucleotide exchange factor (GNEF), has been shown to bind to an 'adaptor' protein (drk) containing only SH2 and SH3 modules, although the actual residues that mediate binding have not been accurately defined (Simon M., et al., 1993, Cell 73:169-177 and Olivier J., et al., 1993, Cell 73:179-191).

TABLE III

Putative SH-3 Domain Binding Sites in Deltex Proteins				SEQ ID NO:
5	Fly Deltex		RAP-VPPPLPLHPRQQ	22
	Mouse 3BP-1		RAPTMPPPLPPVPPQP	23
	Fly Son of sevenless		RA--VPPPLPPRRKER	24
10	Human Deltex			
	I	226-244	VXPAPPLSXPPXPGGPPGA	17
15	II	271-285	XSPGXPPRSPGAPGG	18
	III	311-322	SIPPGVPALPVK	19
	IV	353-365	RAPKPILHPPPVVS	20
	V	368-377	VKPVPGVPGV	21

20 There are currently only six SH3-containing proteins identified in *Drosophila*, any one of which may be a direct binding partner of Deltex, and thus an indirect partner of Notch.

The functional requirement of the Deltex domain II-III in *Drosophila* which contains the putative SH3 domain binding site and ring-H2-zinc finger has been suggested from deletion analyses, in which the deletion of these domains resulted in a significant reduction of the ability to activate the Notch signaling pathway. These results indicate that domains II and III are not redundant.

30 iii) Ring-H2-zinc finger:

Human *deltex* (nucleotides 1734-1916 of SEQ ID NO: 11) encodes a ring-H2-zinc finger (SEQ ID NO: 25), appearing as amino acids 411-471 of SEQ ID NO:12 in that part of human Deltex which corresponds to domain III of *Drosophila* Deltex. This type of zinc finger is believed to be involved in protein/protein interactions.

## 6.2. MATERIAL AND METHODS

### 6.2.1. SEQUENCE DETERMINATION AND ANALYSIS

5 The *EcoRI*-cDNA insert was subcloned directly in both orientations into Bluescript KS. Overlapping deletions were produced on the insert using the DNase I method to generate bidirectional deletions (Eberle et al., 1993, Biotechniques 14:408). The resulting deletions were analyzed using an IBI automatic sequencer.

10 DNA sequence manipulations were performed using Intelligenetic's PC-GENE software. Open reading frame prediction and plotting were performed using the University of Wisconsin program CODONPREFERENCE (Gribshov et al., 1984, Nucl. Acids Res. 12:539-549). The GenPept and SWISS-PROT databases were searched with all or part of the deduced amino acid sequence using the FASTA program (Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA, 15 85:2444-2448) available by the GenBank FASTA server through BITNET.

## 7. EXAMPLE: HUMAN DELTEX BINDS HUMAN AND DROSOPHILA NOTCH

20 We have demonstrated in *Drosophila* a specific and direct physical interaction between Deltex and Notch ANK repeats (Diederich et al., 1994, Development 120:473-481). To study protein-protein interactions between human Deltex and various cytoplasmic domains of human and *Drosophila* Notch receptors, we conducted expression studies in yeast using the so-called 'interaction trap' assay technique (Zervos et al., 1993, Cell 72:223-232). 25

In this assay, one protein segment is fused to the DNA-binding domain of the LexA protein, which in turn binds to the promoter of a *LexAop-lacZ* reporter construct without activating transcription. These constructs are referred as pEG. 30 A second foreign protein segment is fused to an acidic transcriptional activation domain that does not bind DNA on its own. These constructs are referred to as pJG. Coexpression of these two proteins in yeast cells results in the functional reconstruction of an active LexA "hybrid" transcription factor if the foreign proteins physically interact with one another. Activity of the hybrid transcription factor is monitored by transcription of the  $\beta$ -galactosidase reporter gene. 35 Expression of fusion proteins from the pJG construct is induced when yeast cells

are cultured in the galactose media but not in the glucose media. Therefore, positive interaction should be observed only in galactose media.

The constructs examined using the yeast interaction were as follows:

the pEGhDeltex construct contains the entire coding region of human Deltex;

pJGhNotch-1 encodes the ankyrin repeats region of human Notch-1 from amino acids 1826-2147; pJGhNotch-2 encodes the ankyrin repeats region of human Notch-2 from amino acids 1772-2084; pJGhNotch encodes the ankyrin repeats of *Drosophila* Notch from amino acids 1827-2259; and JGfHairless contains the entire coding region of *Drosophila* Hairless.

As presented in Table IV, significant induction of  $\beta$ -galactosidase activity was observed when yeast cells cotransfected with pEGhDeltex and pJGhNotch-1, pJGhNotch-2 or pJGfNotch, were cultured in galactose media (Table IV). These results indicate that human Deltex binds to the ankyrin repeats human Notch-1, human Notch-2 as well as that of *Drosophila* Notch. Standard deviation is presented in the parentheses.

TABLE IV

Coexpressed Constructs	Media	
	Galactose	Glucose
pEGhDeltex/pJGhNotch-1	732(35)	4(1)
pEGhDeltex/pJGhNotch-2	195(25)	11(5)
pEGhDeltex/pJGfNotch	892(184)	14(4)
pEGhDeltex/pJGHairless	61(13)	20(2)
pEGhDeltex/pJG	38(1)	21(5)
pEG/pJGhNotch-1	47(13)	13(5)
pEG/pJGhNotch-2	48(7)	19(8)
pEG/pJGfNotch	69(18)	20(5)
pEG/pJGHairless	59(4)	39(14)
pEG/pJG	60(10)	32(4)

## 8. EXAMPLE: CLONING OF VERTEBRATE DELTEX GENES

The evolution of humans and *Drosophila* diverged about 600 million years ago. As discussed *supra*, Deltex protein demonstrates a conserved structure in these two evolutionary distant species. Knowledge of the conserved regions of the protein allows one to design synthetic degenerate primers for use in hybridization and PCR reactions which enable the cloning of Deltex encoding nucleic acids in other organisms.

Five regions of high conservation between human and *Drosophila* are found in amino acid stretches of human Deltex amino acid numbers 414-419 (SEQ ID NO:30), 475-480 (SEQ ID NO:31), 504-511 (SEQ ID NO:32), 531-539 (SEQ ID NO:33) and 557-564 (SEQ ID NO:34). These sequences are conserved in *Drosophila* Deltex amino acid stretches 549-555 (SEQ ID NO:35), 603-608 (SEQ ID NO:36), 632-639 (SEQ ID NO:37), 659-667 (SEQ ID NO:38) and 685-692 (SEQ ID NO:39), respectively. Conserved amino acid stretches may be used alone or in combination to isolate the *deltex* encoding nucleic acids of other organisms.

By way of example, a murine *deltex* gene is obtained as follows: Standard techniques are utilized to synthesize a series of degenerate primers encoding amino acids 414-419 in *Drosophila* (SEQ ID NO:30) and 549-555 in human (SEQ ID NO:35) in a 5' to 3' orientation. A second series of degenerate primers corresponding to the antisense strand of the nucleic acids encoding amino acids 475-480 in *Drosophila* (SEQ ID NO:31) and 603-608 in human (SEQ ID NO:36) is also synthesized. The two series of primers are added to a mixture containing mouse embryonic cDNA as template for the PCR amplification. PCR is carried out at a range of stringencies, according to methods commonly known, to allow for varying degrees of nucleotide similarity between the known *deltex* sequences and the mouse nucleic acid homolog being isolated.

After successful PCR amplification, the segment of mouse *deltex* gene is molecularly cloned and sequenced through techniques known in the art. This segment is used as a probe to isolate a complete cDNA and genomic clone. The complete nucleotide sequence of the mouse *deltex* homolog is determined by sequence analysis.

### 9. DEPOSIT OF MICROORGANISMS

Plasmid pBS hdx containing a cDNA insert encoding a full-length human *deltex* as a EcoRI insert in Bluescript vector (Stratagene) was deposited by S. Leslie Misrock, of Pennie & Edmonds, 1155 Avenue of the Americas, New York, New York 10036 on behalf of Yale University on November 17, 1995, with the American Type Culture Collection, 1201 Parklawn Drive, Rockville, Maryland 20852, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned accession number 97341.

The present invention is not to be limited in scope by the microorganism deposited or the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated in their entireties.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Artavanis-Tsakonas, Spyridon  
Matsuno, Kenji
- (ii) TITLE OF INVENTION: VERTEBRATE DELTEX PROTEINS, NUCLEIC  
ACIDS, AND ANTIBODIES, AND RELATED METHODS AND  
COMPOSITIONS
- (iii) NUMBER OF SEQUENCES: 39
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Pennie & Edmonds
  - (B) STREET: 1155 Avenue of the Americas
  - (C) CITY: New York
  - (D) STATE: New York
  - (E) COUNTRY: U.S.A.
  - (F) ZIP: 10036-2711
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: To Be Assigned
  - (B) FILING DATE: 22-NOV-1995
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Misrock, S. Leslie
  - (B) REGISTRATION NUMBER: 18,872
  - (C) REFERENCE/DOCKET NUMBER: 7326-036
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (212) 790-9090
  - (B) TELEFAX: (212) 869-9741/8864
  - (C) TELEX: 66141 PENNIE

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 3771 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
  - (A) NAME/KEY: CDS
  - (B) LOCATION: 345..2555

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAATGCTAGA AAAACCGTTT TTACCATCAA ACGTGAATTC TTAAGCTGCG CCTAAACGAA	60
AACCGAGTGAC TAAAGAACCA GAACGAAAAC TTCGGGAAAA TGGAAGCCAG GGAAATCAG	120
GGATAACTAA CGCTGGCAGC GGGTCCACCA TTTTAAATTT CTTTGTTTAT TTTGTGCCCA	180
TCTTCGCGAG CGAGCGAGAT AGCGCGACAG CAACAGCAAG AGAGAGCGAG AGAGAGAGTG	240



AGTGAGTGAG AGCTAGTGAA GAGAGCGCAG GAGGAGTTGG ATATGGAAAT GGGCATGGAT	300
ATGGCAATGG GCTCACTCCA CGGATAACGG ATCAACTGCA AGCA ATG GCC AGC AGC Met Ala Ser Ser 1	356
GCC GGA AGT GCG GCA TCC GGA TCC GTT GTT CCC GGT GGC GGA GGT AGC Ala Gly Ser Ala Ala Ser Gly Ser Val Val Pro Gly Gly Gly Gly Ser 5 10 15 20	404
GCC GCC TCC AGT TGT GCC ACC ATG GCC CTG TCC ACC GCC GGA TCC GGT Ala Ala Ser Ser Cys Ala Thr Met Ala Leu Ser Thr Ala Gly Ser Gly 25 30 35	452
GGG CCG CCC GTG AAC CAC GCC CAC GCC GTC TGC GTG TGG GAG TTC GAG Gly Pro Pro Val Asn His Ala His Ala Val Cys Val Trp Glu Phe Glu 40 45 50	500
TCG CGC GGC AAG TGG CTG CCC TAT TCG CCG GCG GTG TCG CAG CAC TTG Ser Arg Gly Lys Trp Leu Pro Tyr Ser Pro Ala Val Ser Gln His Leu 55 60 65	548
GAA CGC GCC CAC GCC AAG AAA CTG ACG CGC GTC ATG CTG AGC GAT GCG Glu Arg Ala His Ala Lys Lys Leu Thr Arg Val Met Leu Ser Asp Ala 70 75 80	596
GAT CCC AGC CTG GAG CAG TAC TAC GTC AAC GTG CGC ACA ATG ACC CAG Asp Pro Ser Leu Glu Gln Tyr Tyr Val Asn Val Arg Thr Met Thr Gln 85 90 95 100	644
GAA TCG GAG GCG GAA ACG CGC TCC GGC CTG CTG ACC ATC GGT GTT CCG Glu Ser Glu Ala Glu Thr Arg Ser Gly Leu Leu Thr Ile Gly Val Arg 105 110 115	692
CGC ATG TTA TAC GCA CCC AGC TCG CCG GCG GGC AAG GGC ACC AAG TGG Arg Met Leu Tyr Ala Pro Ser Ser Pro Ala Gly Lys Gly Thr Lys Trp 120 125 130	740
GAG TGG TCG GGC GGC AGT GCC GAT AGC AAC AAC GAC TGG CGG CCC TAC Glu Trp Ser Gly Gly Ser Ala Asp Ser Asn Asn Asp Trp Arg Pro Tyr 135 140 145	788
AAC ATG CAC GTC CAG TGC ATC ATC GAG GAC GCC TGG GCG AGG GGC GAA Asn Met His Val Gln Cys Ile Ile Glu Asp Ala Trp Ala Arg Gly Glu 150 155 160	836
CAA ACC TTG GAC CTG TGC AAC ACC CAC ATC GGC CTG CCG TAC ACC ATT Gln Thr Leu Asp Leu Cys Asn Thr His Ile Gly Leu Pro Tyr Thr Ile 165 170 175 180	884
AAT TTT TGC AAT CTC ACC CAC GTG CGC CAA CCC AGC GGA CCC ATG CGC Asn Phe Cys Asn Leu Thr His Val Arg Gln Pro Ser Gly Pro Met Arg 185 190 195	932
AGC ATT CGG CGT ACC CAA CAG GCG CCG TAT CCC TTG GTG AAA CTA ACG Ser Ile Arg Arg Thr Gln Gln Ala Pro Tyr Pro Leu Val Lys Leu Thr 200 205 210	980
CCA CAA CAG GCC AAC CAA CTC AAG TCG AAT TCC GCC AGC GTG AGC AGC Pro Gln Gln Ala Asn Gln Leu Lys Ser Asn Ser Ala Ser Val Ser Ser 215 220 225	1028
CAG TAC AAC ACT CTA CCC AAA CTG GGC GAC ACC AAG AGC CTG CAC AGA Gln Tyr Asn Thr Leu Pro Lys Leu Gly Asp Thr Lys Ser Leu His Arg 230 235 240	1076
GTG CCC ATG ACC AGG CAA CAG-CAC CCA TTG CCC ACC AGC CAT CAA GTG Val Pro Met Thr Arg Gln Gln His Pro Leu Pro Thr Ser His Gln Val 245 250 255 260	1124

CAG Gln	CAG Gln	CAG Gln	CAG Gln	CAT His	CAG Gln	CTC Leu	CAG Gln	CAT His	CAA Gln	CAG Gln	CAG Gln	CAG Gln	CAG Gln	CAA Gln	1172
				265					270					275	
CAT His	CAT His	CAC His	CAG Gln	CAT His	CAG Gln	CAA Gln	CAA Gln	CAG Gln	CAT His	CAG Gln	CAA Gln	CAG Gln	CAG Gln	CAA Gln	1220
			280						285					290	
CAG Gln	ATG Met	CAG Gln	CAC His	CAT His	CAG Gln	ATC Ile	CAT His	CAT His	CAG Gln	ACG Thr	GCG Ala	CCC Pro	AGG Arg	AAG Lys	1268
			295						300					305	
CCC Pro	AAG Lys	AAG Lys	CAC His	AGC Ser	GAG Glu	ATC Ile	TCC Ser	ACC Thr	ACC Thr	AAT Asn	CTA Leu	CGC Arg	CAG Gln	ATA Ile	1316
	310														
AAC Asn	AAC Asn	CTA Leu	AAC Asn	ATC Ile	TTC Phe	AGC Ser	AGC Ser	AGC Ser	ACT Thr	AAG Lys	CAC His	CAA Gln	TCG Ser	AAC Asn	1364
					330										
TCG Ser	ACG Thr	GCG Ala	GCC Ala	AGT Ser	GCC Ala	AGT Ser	TCA Ser	TCC Ser	TCC Ser	TCA Ser	TCG Ser	GCC Ala	TCG Ser	CTG Leu	1412
					345										
CAT His	GCC Ala	AAC Asn	CAT His	CTG Leu	TCG Ser	CAT His	GCG Ala	CAC His	TTT Phe	TCG Ser	CAC His	GCC Ala	AAG Lys	AAC Asn	1460
				360					365					370	
CTG Leu	ACT Thr	GCC Ala	TCG Ser	ATG Met	AAC Asn	AGT Ser	CAT His	CAT His	AGT Ser	CGC Arg	TGC Cys	TCG Ser	GAG Glu	GGA Gly	1508
				375					380						
CTG Leu	CAG Gln	TCG Ser	CAA Gln	AGG Arg	AGC Ser	AGC Ser	CGG Arg	ATG Met	GGC Gly	TCG Ser	CAT His	CGC Arg	TCG Ser	AGA Arg	1556
				390					395						
CGA Arg	ACG Thr	CGG Arg	ACC Thr	TCG Ser	GAC Asp	ACG Thr	GAC Asp	ACG Thr	AAC Asn	AGT Ser	GTG Val	AAA Lys	TCG Ser	CAT His	1604
					410										
CGG Arg	AGA Arg	CCC Pro	AGT Ser	GTG Val	GAC Asp	ACC Thr	GTG Val	TCC Ser	ACT Thr	TAC Tyr	CTC Leu	AGC Ser	CAC His	GAG Glu	1652
					425										
AAG Lys	GAG Glu	AGC Ser	CTG Leu	CGC Arg	AGC Ser	AGG Arg	AAC Asn	TTT Phe	GCC Ala	ATT Ile	TCG Ser	GTC Val	AAT Asn	GAT Asp	1700
					440										
CTG Leu	GAC Asp	TGC Cys	TCG Ser	CTT Leu	GGC Gly	AGC Ser	GAT Asp	GAA Glu	GTT Val	TTT Phe	GTG Val	CCC Pro	TCC Ser	GTG Val	1748
					455										
CCA Pro	TCG Ser	TCG Ser	CTG Leu	GGC Gly	GAA Glu	AGG Arg	GCG Ala	CCG Pro	GTG Val	CCG Pro	CCG Pro	CCA Pro	TTA Leu	CCA Pro	1796
					470										
CAT His	CCG Pro	CGA Arg	CAG Gln	CAA Gln	CAG Gln	CAG Gln	CAG Gln	CAA Gln	CAA Gln	CAG Gln	CAG Gln	CAA Gln	CAG Gln	CTG Leu	1844
ATG Met	CAA Gln	CAG Gln	CAG Gln	CAA Gln	CAG Gln	GCG Ala	CAG Gln	CAG Gln	CAG Gln	CAG Gln	CAG Gln	CAA Gln	TCA Ser	ATC Ile	1892
GGT Gly	TCG Ser	ATT Ile	GTG Val	GGC Gly	GTG Val	GAC Asp	CCG Pro	GCC Ala	AGC Ser	GAT Asp	ATG Met	ATA Ile	TCG Ser	CGT Arg	1940
					520										
GTC Val	AAG Lys	GTG Val	GTG Val	GAG Glu	CCA Pro	CCG Pro	CTG Leu	TGG Trp	CCC Pro	AAT Asn	GCC Ala	CAG Gln	CCC Pro	TG1 Cys	1988

535	540	545	
ATG TGC ATG GAG GAG CTG Met Cys Met Glu Glu Leu 550	GTG CAC TCC GCC CAG Val His Ser Ala Gln 555	AAT CCG GCC ATT TCG Asn Pro Ala Ile Ser 560	2036
CTG AGT CGC TGC CAG CAT Leu Ser Arg Cys Gln His 565	CTC ATG CAT TTG CAG Leu Met His Leu Gln 570	TGC CTC AAT GGG ATG Cys Leu Asn Gly Met 575	2084
ATA ATT GCC CAG CAA AAC Ile Ile Ala Gln Asn 585	GAA ATG AAC AAG AAC Glu Met Asn Lys Asn 590	CTT TTC ATC GAG TGC Leu Phe Ile Glu Cys 595	2132
CCT GTA TGC GGC ATC GTT Pro Val Cys Gly Ile 600	TAC GGC GAG AAG GTC Tyr Gly Glu Lys Val 605	GGC AAT CAG CCC ATT Asn Gln Pro Ile 610	2180
GGC AGC ATG TCG TGG AGC Gly Ser Met Ser Trp Ser 615	ATA ATT AGC AAG AAT Ile Ile Ser Lys Asn 620	CTG CCA GGA CAC GAG Leu Pro Gly His Glu 625	2228
GGT CAG AAC ACC ATA CAG Gly Gln Asn Thr Ile Gln 630	ATT GTT TAC GAC ATT Ile Val Tyr Asp Ile 635	GCA TCG GGA CTG CAG Ala Ser Gly Leu Gln 640	2276
ACG GAG GAG CAT CCG CAT Thr Glu Glu His Pro His 645	CCA GGT CGT GCC TTC Pro Gly Arg Ala Phe 650	TTC GCC GTG GGA TTC Phe Ala Val Gly Phe 655	2324
CCG CGG ATC TGC TAC TTG Pro Arg Ile Cys Tyr Leu 665	CCG GAC TGC CCG CTG Pro Asp Cys Pro Leu 670	GGG CGA AAG GTT TTG Gly Arg Lys Val Leu 675	2372
CGC TTC CTC AAG ATT GCA Arg Phe Leu Lys Ile Ala 680	TTC GAT CGT CGG CTG Phe Asp Arg Arg Leu 685	CTT TTC TCG ATC GGA Leu Phe Ser Ile Gly 690	2420
CGA TCG GTG ACC ACC GGA Arg Ser Val Thr Thr Gly 695	CGC GAG GAT GTG GTG Arg Glu Asp Val Val 700	ATC TGG AAC AGT GTG Ile Trp Asn Ser Val 705	2468
GAT CAC AAG ACG CAG TTC Asp His Lys Thr Gln Phe 710	AAT ATG TTT CCG GAT Asn Met Phe Pro Asp 715	CCC ACC TAT TTG CAG Pro Thr Tyr Leu Gln 720	2516
CGA ACC ATG CAA CAG CTG Arg Thr Met Gln Gln Leu 725	GTG CAC CTG GGC GTG Val His Leu Gly Val 730	ACG GAT TAAGGATTAG Thr Asp 735	2565
TTCCCTGTCC CCAAGTAGAA CTACCAACCA	ACCAATCAAC CACCCACCCA	CCGAAGTCCC	2625
CTCGATCATT CTCTTCCATT CGTCGTTAAG	TTACTTTCTA CATAATCTCA	GTGTGTGTGC	2685
AATCCTCGTT TACTATGATA TATTTTTTTT	ATAGATATAT TGTAATAGCG	TTCGAGCTGC	2745
TCGAACCCCTA AAACAACAGC AAACCACAAT	TGCAATTGTA GCTTCCTTTC	CGCTCTTCCA	2805
ATTTCGTATTT GTACGCACAT ACGCAATAAG	TTGGCGTACA TCATATGTAT	TAGCTAGTTA	2865
GTTAGTTAGT TAGTTAGTTG TAGCTGTAGT	TCCCAAGAGA ATCTTGACCC	AAGACACCTA	2925
CTAGTATTAG GCATTATCCT GATTCTTGAT	TCCTGATTTC ATTCAAGCCA	AGCCAAGCCA	2985
CGCCATTTCGA GTGCAAGCTG TGCCAAAATC	GTAGCGCTCC CGTTTATAGG	ATATGTATAT	3045
TGTTGATATA GCTAGCTATA ACCATTGCCC	ATCTCTCCAT CTCTCTCGGT	TTCGAATTTG	3105
TCTCTTTCAT CAGATCCATG TGAATTTTCT	TTATATCGGA TTTATATAGG	ATTAAATAG	3165

TATTTTGAGA GAGGAAATGG AGATGGGTAA ATTCGATAGA CTTGTCTCAC TTGTCTTGGC	3225
CATTTAATCT CTTTCATTCA GCGAATTTGA TGTGATTTTA ATTTGAATTA TTCATTATTA	3285
AACGGAGCAT TTAGGAAGCA TAGTTGTAAC GCAGCCAGAT ATTCCATTAC GCATATACAT	3345
ATACATATAC ATATACATAC ATACATAAAC ATATTTTAAAC ATAGCCCCAT AGCCATACGA	3405
CATAACAATA ATTTTTTTTTC TCGAATCCCT TGCATACATT TGATGAATTG TTGCTTTCAT	3465
ATTGATATCA TCGAGCATCG AACGAACTAT CGTATACATC GCCAATATAT AGCATATATA	3525
GCATATACTA TGTAGAGATC GTACGGACAG CTAGCGGCTA CTGACCGCGC CACCATATTT	3585
GATATGATAT GATATGATTT TACTAAGTTG TATTTAGCAC TGATTAGTTA TTAAAGTTCA	3645
TTTGACGAAT ATTCCACAAC AAATTCCACA CCATTTATGT ATGCATATTA CGCATATATA	3705
ATACAGTACA TTTATATATA GTTCAAATAA AGTAACTTCA TTCATGTTCA AAAAAAAAAA	3765
AAAAAA	3771

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 737 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Ala	Ser	Ser	Ala	Gly	Ser	Ala	Ala	Ser	Gly	Ser	Val	Val	Pro	Gly	1	5	10	15
Gly	Gly	Gly	Ser	Ala	Ala	Ser	Ser	Cys	Ala	Thr	Met	Ala	Leu	Ser	Thr	20	25	30	
Ala	Gly	Ser	Gly	Gly	Pro	Pro	Val	Asn	His	Ala	His	Ala	Val	Cys	Val	35	40	45	
Trp	Glu	Phe	Glu	Ser	Arg	Gly	Lys	Trp	Leu	Pro	Tyr	Ser	Pro	Ala	Val	50	55	60	
Ser	Gln	His	Leu	Glu	Arg	Ala	His	Ala	Lys	Lys	Leu	Thr	Arg	Val	Met	65	70	75	80
Leu	Ser	Asp	Ala	Asp	Pro	Ser	Leu	Glu	Gln	Tyr	Tyr	Val	Asn	Val	Arg	85	90	95	
Thr	Met	Thr	Gln	Glu	Ser	Glu	Ala	Glu	Thr	Arg	Ser	Gly	Leu	Leu	Thr	100	105	110	
Ile	Gly	Val	Arg	Arg	Met	Leu	Tyr	Ala	Pro	Ser	Ser	Pro	Ala	Gly	Lys	115	120	125	
Gly	Thr	Lys	Trp	Glu	Trp	Ser	Gly	Gly	Ser	Ala	Asp	Ser	Asn	Asn	Asp	130	135	140	
Trp	Arg	Pro	Tyr	Asn	Met	His	Val	Gln	Cys	Ile	Ile	Glu	Asp	Ala	Trp	145	150	155	160
Ala	Arg	Gly	Glu	Gln	Thr	Leu	Asp	Leu	Cys	Asn	Thr	His	Ile	Gly	Leu	165	170	175	
Pro	Tyr	Thr	Ile	Asn	Phe	Cys	Asn	Leu	Thr	His	Val	Arg	Gln	Pro	Ser	180	185	190	

Gly Pro Met Arg Ser Ile Arg Arg Thr Gln Gln Ala Pro Tyr Pro Leu  
 195 200 205  
 Val Lys Leu Thr Pro Gln Gln Ala Asn Gln Leu Lys Ser Asn Ser Ala  
 210 215 220  
 Ser Val Ser Ser Gln Tyr Asn Thr Leu Pro Lys Leu Gly Asp Thr Lys  
 225 230 235 240  
 Ser Leu His Arg Val Pro Met Thr Arg Gln Gln His Pro Leu Pro Thr  
 245 250 255  
 Ser His Gln Val Gln Gln Gln Gln His Gln Leu Gln His Gln Gln Gln  
 260 265 270  
 Gln Gln Gln Gln His His His Gln His Gln Gln Gln His Gln Gln  
 275 280 285  
 Gln Gln Gln His Gln Met Gln His His Gln Ile His His Gln Thr Ala  
 290 295 300  
 Pro Arg Lys Pro Pro Lys Lys His Ser Glu Ile Ser Thr Thr Asn Leu  
 305 310 315 320  
 Arg Gln Ile Leu Asn Asn Leu Asn Ile Phe Ser Ser Ser Thr Lys His  
 325 330 335  
 Gln Ser Asn Met Ser Thr Ala Ala Ser Ala Ser Ser Ser Ser Ser  
 340 345 350  
 Ala Ser Leu His His Ala Asn His Leu Ser His Ala His Phe Ser His  
 355 360 365  
 Ala Lys Asn Met Leu Thr Ala Ser Met Asn Ser His His Ser Arg Cys  
 370 375 380  
 Ser Glu Gly Ser Leu Gln Ser Gln Arg Ser Ser Arg Met Gly Ser His  
 385 390 395 400  
 Arg Ser Arg Ser Arg Thr Arg Thr Ser Asp Thr Asp Thr Asn Ser Val  
 405 410 415  
 Lys Ser His Arg Arg Arg Pro Ser Val Asp Thr Val Ser Thr Tyr Leu  
 420 425 430  
 Ser His Glu Ser Lys Glu Ser Leu Arg Ser Arg Asn Phe Ala Ile Ser  
 435 440 445  
 Val Asn Asp Leu Leu Asp Cys Ser Leu Gly Ser Asp Glu Val Phe Val  
 450 455 460  
 Pro Ser Val Pro Pro Ser Ser Leu Gly Glu Arg Ala Pro Val Pro Pro  
 465 470 475 480  
 Pro Leu Pro Leu His Pro Arg Gln Gln Gln Gln Gln Gln Gln Gln  
 485 490 495  
 Gln Gln Leu Gln Met Gln Gln Gln Gln Gln Ala Gln Gln Gln Gln  
 500 505 510  
 Gln Ser Ile Ala Gly Ser Ile Val Gly Val Asp Pro Ala Ser Asp Met  
 515 520 525  
 Ile Ser Arg Phe Val Lys Val Val Glu Pro Pro Leu Trp Pro Asn Ala  
 530 535 540  
 Gln Pro Cys Pro Met Cys Met- Glu Glu Leu Val His Ser Ala Gln Asn  
 545 550 555 560  
 Pro Ala Ile Ser Leu Ser Arg Cys Gln His Leu Met His Leu Gln Cys

565								570					575			
Leu	Asn	Gly	Met	Ile	Ile	Ala	Gln	Gln	Asn	Glu	Met	Asn	Lys	Asn	Leu	
580								585					590			
Phe	Ile	Glu	Cys	Pro	Val	Cys	Gly	Ile	Val	Tyr	Gly	Glu	Lys	Val	Gly	
595								600					605			
Asn	Gln	Pro	Ile	Gly	Ser	Met	Ser	Trp	Ser	Ile	Ile	Ser	Lys	Asn	Leu	
610								615					620			
Pro	Gly	His	Glu	Gly	Gln	Asn	Thr	Ile	Gln	Ile	Val	Tyr	Asp	Ile	Ala	
625								630					635			
Ser	Gly	Leu	Gln	Thr	Glu	Glu	His	Pro	His	Pro	Gly	Arg	Ala	Phe	Phe	
640								645					650			
Ala	Val	Gly	Phe	Pro	Arg	Ile	Cys	Tyr	Leu	Pro	Asp	Cys	Pro	Leu	Gly	
655								660					665			
Arg	Lys	Val	Leu	Arg	Phe	Leu	Lys	Ile	Ala	Phe	Asp	Arg	Arg	Leu	Leu	
670								675					680			
Phe	Ser	Ile	Gly	Arg	Ser	Val	Thr	Thr	Gly	Arg	Glu	Asp	Val	Val	Ile	
685								690					695			
Trp	Asn	Ser	Val	Asp	His	Lys	Thr	Gln	Phe	Asn	Met	Phe	Pro	Asp	Pro	
700								705					710			
Thr	Tyr	Leu	Gln	Arg	Thr	Met	Gln	Gln	Leu	Val	His	Leu	Gly	Val	Thr	
715								720					725			
730								735					740			

Asp

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Gln Pro Cys Pro Met Cys Met Glu Glu Leu Val  
1 5 10

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Glu Asp Cys Thr Ile Cys Met Glu Arg Leu Val  
1 5 10

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Leu Ser Arg Cys Gln His Leu Met His Leu Gln Cys Leu Asn Gly Met  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Leu Gly Arg Cys Gly His Met Tyr His Leu Leu Cys Leu Val Ala Met  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Ile Ile Ala Gln Gln Asn Glu Met Asn Lys Asn Leu Phe Ile Glu Cys  
 1 5 10 15

Pro Val Cys Gly Ile Val Tyr Gly Glu Lys Val Gly Asn Gln Pro Ile  
 20 25 30

Gly Ser Met Ser  
 35

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 36 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Leu Val Ala Met Tyr Ser Asn Gly Asn Lys Asp Gly Ser Leu Gln Cys  
 1 5 10 15  
 Pro Thr Cys Lys Pro Ser Met Gly Arg Arg Arg Val Arg Ser Arg Leu  
 20 25 30  
 Gly Arg Trp Ser  
 35

## (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 37 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Val Tyr Gly Glu Lys Val Gly Val Gln Pro Ile Gly Ser Met Ser Trp  
 1 5 10 15  
 Ser Ile Ile Ser Lys Asn Leu Pro Gly His Glu Gly Gln Asn Thr Ile  
 20 25 30  
 Gln Ile Val Tyr Asp  
 35

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 37 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Ile Tyr Gly Glu Lys Thr Gly Thr Gln Pro Pro Gly Lys Met Glu Phe  
 1 5 10 15  
 His Leu Ile Pro His Ser Leu Xaa Phe Gly Pro Asp Thr Gln Thr Xaa  
 20 25 30  
 Arg Ile Val Tyr Asp  
 35

## (2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 2547 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: 504..2363



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCGAGAAGCC CCACTGAAGC CGGGCGCAGG GTCTGGGACG CAGTTGGGAG TGCAAAGGGC	60
TGGCTGAGAG CCGCAGGAGC AGCAGGCTGT GGCCAGGCC TCCTGGGTGA CAGGCCCTGT	120
CTGGCGGGGA ACAGGGACCA AGAGACAACA CAGAAGAGGC TGGACCTCGA ACAGGGGCGG	180
CTGCCTCACT CCCTACCTGA GCCAGCCGAG GGGGCCAAGG ACTTTAGAGC TGTTCCTCC	240
GGCATAAGAG AGACACTTGC TTTCCAGGGC AGCACCCTTT ATCGGAGAAG GCTCTACAGG	300
GAAGGGGTCT TTGCAGCCTG GATGGCCATC CCACATTCCT TTAACGGAGG TCTCTAGGCC	360
TCAGAGAGAA CCCAGAGTTA GAAAGGAGGC CAGACGGTCC TTGCTGTCCC CCTGGGGAGA	420
GAGGAAGTTG CCGCCTGCTG CCAGGCCAG GAGGAGCTGG GCCTGCAATA GTGGGGGACC	480
TGCCCCCTGA GGCAGTGGCG GCC ATG TCA CGG CCA GGC CAC GGT GGG CTG	530
Met Ser Arg Pro Gly His Gly Gly Leu	
1 5	
ATG CCT GTG AAT GGT CTG GGC TTC CCA CCG CAG AAC GTG GCC CGG GTG	578
Met Pro Val Asn Gly Leu Gly Phe Pro Pro Gln Asn Val Ala Arg Val	
10 15 20 25	
GTG GTG TGG GAG TGT CTG AAT GAG CAC AGC CGC TGG CGG CCC TAC ACG	626
Val Val Trp Glu Cys Leu Asn Glu His Ser Arg Trp Arg Pro Tyr Thr	
30 35 40	
GCC ACC GTG TGC CAC CAC ATT GAG AAC GTG CTG AAG GAG GAC GCT CGC	674
Ala Thr Val Cys His His Ile Glu Asn Val Leu Lys Glu Asp Ala Arg	
45 50 55	
GGT TCC GTG GTC CTG GGG CAG GTG GAC GCC CAG CTT GTG CCC TAC ATC	722
Gly Ser Val Val Leu Gly Gln Val Asp Ala Gln Leu Val Pro Tyr Ile	
60 65 70	
ATC GAC CTG CAG TCC ATG CAC CAG TTT CGC CAG GAC ACA GGC ACC ATG	770
Ile Asp Leu Gln Ser Met His Gln Phe Arg Gln Asp Thr Gly Thr Met	
75 80 85	
CGG CCC GTG CGG CGC AAC TTC TAC GAC CCG TCG TCG GCG CCG GGC AAG	818
Arg Pro Val Arg Arg Asn Phe Tyr Asp Pro Ser Ser Ala Pro Gly Lys	
90 95 100 105	
GGC ATC GTG TGG GAG TGG GAG AAC GAC GGC GGC GCA TGG ACG GCC TAC	866
Gly Ile Val Trp Glu Trp Glu Asn Asp Gly Gly Ala Trp Thr Ala Tyr	
110 115 120	
GAT ATG GAC ATC TGC ATC ACC ATC CAG AAC GCC TAC GAG AAG CAG CAC	914
Asp Met Asp Ile Cys Ile Thr Ile Gln Asn Ala Tyr Glu Lys Gln His	
125 130 135	
CCG TGG CTC GAC CTC TCA TCG CTA GGC TTC TGC TAC CTC ATC TAC TTC	962
Pro Trp Leu Asp Leu Ser Ser Leu Gly Phe Cys Tyr Leu Ile Tyr Phe	
140 145 150	
AAC AGC ATG TCG CAG ATG ARC CGC CAG ACG CGC CGG CGC CGC CGT CTG	1010
Asn Ser Met Ser Gln Met Xaa Arg Gln Thr Arg Arg Arg Arg Arg Leu	
155 160 165	
CGC CGC CGC CTG GAC CTC GCC TAC CCG CTC ACC GTG GGC TCC ATC CCT	1058
Arg Arg Arg Leu Asp Leu Ala Tyr Pro Leu Thr Val Gly Ser Ile Pro	
170 175 180 185	
AAG TCG CAG TCG TGG CCC GTG GGT GBC AGC TCG GGH CAG CCC TGC TCC	1106
Lys Ser Gln Ser Trp Pro Val Gly Xaa Ser Ser Gly Gln Pro Cys Ser	
190 195 200	

16M	CAG	CAG	TGC	CTG	YTG	GTC	AAC	AGC	ACG	CGC	GCC	GTC	TCC	AAC	GTC	1154
Xaa	Gln	Gln	Cys	Leu	Leu	Val	Asn	Ser	Thr	Arg	Ala	Val	Ser	Asn	Val	
			205					210					215			
ATC	CTG	GYC	TCG	CAG	CGT	CGT	AAG	GTG	MCC	CCC	GCG	CCC	CCG	CTG	TCG	1202
Ile	Leu	Xaa	Ser	Gln	Arg	Arg	Lys	Val	Xaa	Pro	Ala	Pro	Pro	Leu	Ser	
		220					225					230				
YCG	CCG	YCG	MCA	CCT	GGA	GGG	CCT	CCA	GGC	GCG	CTT	GGC	GTG	CGC	CCC	1250
Xaa	Pro	Xaa	Xaa	Pro	Gly	Gly	Pro	Pro	Gly	Ala	Leu	Gly	Val	Arg	Pro	
	235					240					245					
AGY	GTC	ACC	TTC	ACA	GGC	GNC	GNG	CTC	TGN	GAA	GTG	NNN	TTC	NAC	GGT	1298
Ser	Val	Thr	Phe	Thr	Gly	Xaa	Xaa	Leu	Xaa	Glu	Val	Xaa	Phe	Xaa	Gly	
	250				255					260					265	
CCC	GTC	GAG	CCC	GMG	YCG	TCT	CCC	GGG	GYG	CCC	CCA	CGG	AGC	CCG	GGC	1346
Pro	Val	Glu	Pro	Xaa	Xaa	Ser	Pro	Gly	Xaa	Pro	Pro	Arg	Ser	Pro	Gly	
				270					275					280		
GCC	CCC	GGC	GGA	GCG	CGC	ACC	CCG	GGG	CAG	AAC	AAC	CTC	AAC	CGG	BCC	1394
Ala	Pro	Gly	Gly	Ala	Arg	Thr	Pro	Gly	Gln	Asn	Asn	Leu	Asn	Arg	Xaa	
			285					290					295			
GGG	CCC	CAG	CGC	ACC	ACC	AGH	GTG	AGC	GCG	CGC	GCC	TCC	ATC	CCG	CCG	1442
Gly	Pro	Gln	Arg	Thr	Thr	Xaa	Val	Ser	Ala	Arg	Ala	Ser	Ile	Pro	Pro	
	300					305						310				
GGG	GTC	CCC	GCA	CTC	CCG	GTG	AAG	AAC	TTG	AAT	GGT	ACT	GGG	CCG	GTC	1490
Gly	Val	Pro	Ala	Leu	Pro	Val	Lys	Asn	Leu	Asn	Gly	Thr	Gly	Pro	Val	
	315					320					325					
CAT	CCG	GCC	CTG	GCA	GGG	ATG	ACC	GGG	ATA	CTG	CTG	TGC	GCG	GCC	GGG	1538
His	Pro	Ala	Leu	Ala	Gly	Met	Thr	Gly	Ile	Leu	Leu	Cys	Ala	Ala	Gly	
	330				335				340						345	
CTG	CCC	GTG	TGC	CTG	ACG	CGG	GCC	CCC	AAG	CCC	ATC	CTG	CAC	CCG	CCG	1586
Leu	Pro	Val	Cys	Leu	Thr	Arg	Ala	Pro	Lys	Pro	Ile	Leu	His	Pro	Pro	
				350					355					360		
CCC	GTG	AGC	AAG	AGC	GAC	GTG	AAG	CCC	GTG	CCT	GGC	GTG	CCC	GGG	GTG	1634
Pro	Val	Ser	Lys	Ser	Asp	Val	Lys	Pro	Val	Pro	Gly	Val	Pro	Gly	Val	
			365					370					375			
TGC	CGC	AAG	ACC	AAG	AAG	AAG	CAC	CTT	AAA	AAG	AGT	AAG	AAT	CCC	GAG	1682
Cys	Arg	Lys	Thr	Lys	Lys	Lys	His	Leu	Lys	Lys	Ser	Lys	Asn	Pro	Glu	
	380						385					390				
GAT	GTG	GTT	CGA	AGA	TAC	ATG	CAG	AAG	GTG	AAA	AAC	CCA	CCT	GAT	GAG	1730
Asp	Val	Val	Arg	Arg	Tyr	Met	Gln	Lys	Val	Lys	Asn	Pro	Pro	Asp	Glu	
	395					400					405					
GAC	TGC	ACC	ATC	TGC	ATG	GAG	CGA	CTG	GTC	ACA	GCA	TCA	GGC	TAC	GAG	1778
Asp	Cys	Thr	Ile	Cys	Met	Glu	Arg	Leu	Val	Thr	Ala	Ser	Gly	Tyr	Glu	
	410				415					420					425	
GGC	GTG	CTT	CGG	CAC	AAG	GGC	GTG	CGG	CCT	GAG	CTC	GTG	GGC	CGC	CTG	1826
Gly	Val	Leu	Arg	His	Lys	Gly	Val	Arg	Pro	Glu	Leu	Val	Gly	Arg	Leu	
				430				435					440			
GGC	CGC	TGT	GGC	CAC	ATG	TAC	CAC	CTG	CTG	TGC	CTC	GTG	GCC	ATG	TAC	1874
Gly	Arg	Cys	Gly	His	Met	Tyr	His	Leu	Leu	Cys	Leu	Val	Ala	Met	Tyr	
			445					450					455			
TCC	AAT	GGC	AAC	AAG	GAT	GGC	AGC	CTG	CAG	TGC	CCC	ACC	TGC	AAG	GCC	1922
Ser	Asn	Gly	Asn	Lys	Asp	Gly	Ser	Leu	Gln	Cys	Pro	Thr	Cys	Lys	Ala	
		460					465					470				
ATC	TAC	GGG	GAG	AAG	ACG	GGT	ACG	CAG	CCG	CCT	GGG	AAG	ATG	GAC	TTC	1970
Ile	Tyr	Gly	Glu	Lys	Thr	Gly	Thr	Gln	Pro	Pro	Gly	Lys	Met	Glu	Phe	

475	480	485	
CAC CTC ATC CCC CAC TCG CTG CCC GGC TTC CCT GAT ACC CAG ACC ATC His Leu Ile Pro His S r Leu Pro Gly Phe Pro Asp Thr Gln Thr Ile 490 495 500 505			2018
CGC ATC GTC TAT GAC ATC CCC ACA GGC ATC CAG GGC CCT GAG CAC CCC Arg Ile Val Tyr Asp Ile Pro Thr Gly Ile Gln Gly Pro Glu His Pro 510 515 520			2066
AAC CCC GGG AAG AAG TTC ACC GCA AGA GGA TTC CCT CGC CAC TGC TAT Asn Pro Gly Lys Lys Phe Thr Ala Arg Gly Phe Pro Arg His Cys Tyr 525 530 535			2114
CTA CCC AAC AAC GAG AAA GGC CGG AAG GTG CTG CGG CTG CTC ATC ACG Leu Pro Asn Asn Glu Lys Gly Arg Lys Val Leu Arg Leu Leu Ile Thr 540 545 550			2162
GCC TGG GAG AGA AGA CTC ATC TTC ACT ATC GGC ACG TCC AAC ACC ACG Ala Trp Glu Arg Arg Leu Ile Phe Thr Ile Gly Thr Ser Asn Thr Thr 555 560 565			2210
GGC GAG TCG GAC ACC GTG GTG TGG AAC GAG ATC CAC CAC AAG ACC GAG Gly Glu Ser Asp Thr Val Val Trp Asn Glu Ile His His Lys Thr Glu 570 575 580 585			2258
TTT GGA TCC AAC CTC ACG GGA CAC GGC TAC CCG GAC GCT AGC TAC CTA Phe Gly Ser Asn Leu Thr Gly His Gly Tyr Pro Asp Ala Ser Tyr Leu 590 595 600			2306
GAC AAC GTG CTG GCT GAG CTC ACA GSC CAG GGC GTA TCC GAG GCT GCA Asp Asn Val Leu Ala Glu Leu Thr Xaa Gln Gly Val Ser Glu Ala Ala 605 610 615			2354
GGC AAG GCT TGAGGSCCAA GGCTGCCCCAC CTTCCTCCT GSTTTGGCCC Gly Lys Ala 620			2403
TGGTCCGGCA AATGCCTCCT TCGCCAGGTG TGTCTGGTA GCCCAGGTTC AGGGCTGGGG			2463
AGGAGCCTGC GGAAGGGGCC GCAGCCATTC AGGGGACTGN CTGGNGGAAG TTGGATGAGG			2523
AGAGNTGGAT TTNAGGTTGG CCCC			2547

## (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 620 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

```

Met Ser Arg Pro Gly His Gly Gly Leu Met Pro Val Asn Gly Leu Gly
 1           5           10           15
Phe Pro Pro Gln Asn Val Ala Arg Val Val Val Trp Glu Cys Leu Asn
          20           25           30
Glu His Ser Arg Trp Arg Pro Tyr Thr Ala Thr Val Cys His His Ile
          35           40           45
Glu Asn Val Leu Lys Glu Asp Ala Arg Gly Ser Val Val Leu Gly Gln
          50           55           60
Val Asp Ala Gln Leu Val Pro Tyr Ile Ile Asp Leu Gln Ser Met His
          65           70           75           80

```

Gln	Phe	Arg	Gln	Asp	Thr	Gly	Thr	Met	Arg	Pro	Val	Arg	Arg	Asn	Phe	
				85					90							
Tyr	Asp	Pro	Ser	Ser	Ala	Pro	Gly	Lys	Gly	Ile	Val	Trp	Glu	Trp	Glu	
			100					105								
Asn	Asp	Gly	Gly	Ala	Trp	Thr	Ala	Tyr	Asp	Met	Asp	Ile	Cys	Ile	Thr	
		115					120									
Ile	Gln	Asn	Ala	Tyr	Glu	Lys	Gln	His	Pro	Trp	Leu	Asp	Leu	Ser	Ser	
			130					135								
Leu	Gly	Phe	Cys	Tyr	Leu	Ile	Tyr	Phe	Asn	Ser	Met	Ser	Gln	Met	Xaa	
		145					150									
Arg	Gln	Thr	Arg	Arg	Arg	Arg	Arg	Leu	Arg	Arg	Arg	Leu	Asp	Leu	Ala	
				165					170							
Tyr	Pro	Leu	Thr	Val	Gly	Ser	Ile	Pro	Lys	Ser	Gln	Ser	Trp	Pro	Val	
			180					185								
Gly	Xaa	Ser	Ser	Gly	Gln	Pro	Cys	Ser	Xaa	Gln	Gln	Cys	Leu	Leu	Val	
		195					200									
Asn	Ser	Thr	Arg	Ala	Val	Ser	Asn	Val	Ile	Leu	Xaa	Ser	Gln	Arg	Arg	
		210					215									
Lys	Val	Xaa	Pro	Ala	Pro	Pro	Leu	Ser	Xaa	Pro	Xaa	Xaa	Pro	Gly	Gly	
		225					230									
Pro	Pro	Gly	Ala	Leu	Gly	Val	Arg	Pro	Ser	Val	Thr	Phe	Thr	Gly	Xaa	
			245					250								
Xaa	Leu	Xaa	Glu	Val	Xaa	Phe	Xaa	Gly	Pro	Val	Glu	Pro	Xaa	Xaa	Ser	
			260					265								
Pro	Gly	Xaa	Pro	Pro	Arg	Ser	Pro	Gly	Ala	Pro	Gly	Gly	Ala	Arg	Thr	
		275					280									
Pro	Gly	Gln	Asn	Asn	Leu	Asn	Arg	Xaa	Gly	Pro	Gln	Arg	Thr	Thr	Xaa	
		290					295									
Val	Ser	Ala	Arg	Ala	Ser	Ile	Pro	Pro	Gly	Val	Pro	Ala	Leu	Pro	Val	
		305					310									
Lys	Asn	Leu	Asn	Gly	Thr	Gly	Pro	Val	His	Pro	Ala	Leu	Ala	Gly	Met	
			325					330								
Thr	Gly	Ile	Leu	Leu	Cys	Ala	Ala	Gly	Leu	Pro	Val	Cys	Leu	Thr	Arg	
			340					345								
Ala	Pro	Lys	Pro	Ile	Leu	His	Pro	Pro	Pro	Val	Ser	Lys	Ser	Asp	Val	
		355					360									
Lys	Pro	Val	Pro	Gly	Val	Pro	Gly	Val	Cys	Arg	Lys	Thr	Lys	Lys	Lys	
		370					375									
His	Leu	Lys	Lys	Ser	Lys	Asn	Pro	Glu	Asp	Val	Val	Arg	Arg	Tyr	Met	
		385					390									
Gln	Lys	Val	Lys	Asn	Pro	Pro	Asp	Glu	Asp	Cys	Thr	Ile	Cys	Met	Glu	
			405					410								
Arg	Leu	Val	Thr	Ala	Ser	Gly	Tyr	Glu	Gly	Val	Leu	Arg	His	Lys	Gly	
			420					425								
Val	Arg	Pro	Glu	Leu	Val	Gly	Arg	Leu	Gly	Arg	Cys	Gly	His	Met	Tyr	
		435					440									
His	Leu	Leu	Cys	Leu	Val	Ala	Met	Tyr	Ser	Asn	Gly	Asn	Lys	Asp	Gly	

```

      450              455              460
Ser Leu Gln Cys Pro Thr Cys Lys Ala Ile Tyr Gly Glu Lys Thr Gly
465              470              475              480
Thr Gln Pro Pro Gly Lys Met Glu Phe His Leu Ile Pro His Ser Leu
      485              490              495
Pro Gly Phe Pro Asp Thr Gln Thr Ile Arg Ile Val Tyr Asp Ile Pro
      500              505              510
Thr Gly Ile Gln Gly Pro Glu His Pro Asn Pro Gly Lys Lys Phe Thr
      515              520              525
Ala Arg Gly Phe Pro Arg His Cys Tyr Leu Pro Asn Asn Glu Lys Gly
      530              535              540
Arg Lys Val Leu Arg Leu Leu Ile Thr Ala Trp Glu Arg Arg Leu Ile
      545              550              555              560
Phe Thr Ile Gly Thr Ser Asn Thr Thr Gly Glu Ser Asp Thr Val Val
      565              570              575
Trp Asn Glu Ile His His Lys Thr Glu Phe Gly Ser Asn Leu Thr Gly
      580              585              590
His Gly Tyr Pro Asp Ala Ser Tyr Leu Asp Asn Val Leu Ala Glu Leu
      595              600              605
Thr Xaa Gln Gly Val Ser Glu Ala Ala Gly Lys Ala
      610              615              620

```

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 303 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: unknown

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

```

Met Ala Ser Ser Ala Gly Ser Ala Ala Ser Gly Ser Val Val Pro Gly
1      5      10      15
Gly Gly Gly Ser Ala Ala Ser Ser Cys Ala Thr Met Ala Leu Ser Thr
20     25     30
Ala Gly Ser Gly Gly Pro Pro Val Asn His Ala His Ala Val Cys Val
35     40     45
Trp Glu Phe Glu Ser Arg Gly Lys Trp Leu Pro Tyr Ser Pro Ala Val
50     55     60
Ser Gln His Leu Glu Arg Ala His Ala Lys Lys Leu Thr Arg Val Met
65     70     75     80
Leu Ser Asp Ala Asp Pro Ser Leu Glu Gln Tyr Tyr Val Asn Val Arg
85     90     95
Thr Met Thr Gln Glu Ser Glu Ala Glu Thr Arg Ser Gly Leu Leu Thr
100    105    110
Ile Gly Val Arg Arg Met Leu Tyr Ala Pro Ser Ser Pro Ala Gly Lys
115    120    125

```

```

Gly Thr Lys Trp Glu Trp Ser Gly Gly Ser Ala Asp Ser Asn Asn Asp
 130                      135                      140
Trp Arg Pro Tyr Asn Met His Val Gln Cys Ile Ile Glu Asp Ala Trp
145                      150                      155                      160
Ala Arg Gly Glu Gln Thr Leu Asp Leu Cys Asn Thr His Ile Gly Leu
                      165                      170                      175
Pro Tyr Thr Ile Asn Phe Cys Asn Leu Thr His Val Arg Gln Pro Ser
                      180                      185                      190
Gly Pro Met Arg Ser Ile Arg Arg Thr Gln Gln Ala Pro Tyr Pro Leu
                      195                      200                      205
Val Lys Leu Thr Pro Gln Gln Ala Asn Gln Leu Lys Ser Asn Ser Ala
210                      215                      220
Ser Val Ser Ser Gln Tyr Asn Thr Leu Pro Lys Leu Gly Asp Thr Lys
225                      230                      235                      240
Ser Leu His Arg Val Pro Met Thr Arg Gln Gln His Pro Leu Pro Thr
                      245                      250                      255
Ser His Gln Val Gln Gln Gln Gln His Gln Leu Gln His Gln Gln Gln
                      260                      265                      270
Gln Gln Gln Gln His His His Gln His Gln Gln Gln Gln His Gln Gln
                      275                      280                      285
Gln Gln Gln His Gln Met Gln His His Gln Ile His His Gln Thr
290                      295                      300

```

## (2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 181 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```

Arg Lys Pro Pro Lys Lys His Ser Glu Ile Ser Thr Thr Asn Leu Arg
 1                      5                      10                      15
Gln Ile Leu Asn Asn Leu Asn Ile Phe Ser Ser Ser Thr Lys His Gln
                      20                      25                      30
Ser Asn Met Ser Thr Ala Ala Ser Ala Ser Ser Ser Ser Ser Ala
35                      40                      45
Ser Leu His His Ala Asn His Leu Ser His Ala His Phe Ser His Ala
50                      55                      60
Lys Asn Met Leu Thr Ala Ser Met Asn Ser His His Ser Arg Cys Ser
65                      70                      75                      80
Glu Gly Ser Leu Gln Ser Gln Arg Ser Ser Arg Met Gly Ser His Arg
                      85                      90                      95
Ser Arg Ser Arg Thr Arg Thr Ser Asp Thr Asp Thr Asn Ser Val Lys
                      100                      105                      110
Ser His Arg Arg Arg Pro Ser Val Asp Thr Val Ser Thr Tyr Leu Ser
115                      120                      125

```

```

His Glu Ser Lys Glu Ser Leu Arg Ser Arg Asn Phe Ala Ile Ser Val
130          135          140
Asn Asp Leu Leu Asp Cys Ser Leu Gly Ser Asp Glu Val Phe Val Pro
145          150          155          160
Ser Val Pro Pro Ser Ser Leu Gly Glu Arg Ala Pro Val Pro Pro Pro
165          170          175
Leu Pro Leu His Pro
180

```

## (2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 224 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```

Ser Ile Ala Gly Ser Ile Val Gly Val Asp Pro Ala Ser Asp Met Ile
1           5           10           15
Ser Arg Phe Val Lys Val Val Glu Pro Pro Leu Trp Pro Asn Ala Gln
20          25          30
Pro Cys Pro Met Cys Met Glu Glu Leu Val His Ser Ala Gln Asn Pro
35          40          45
Ala Ile Ser Leu Ser Arg Cys Gln His Leu Met His Leu Gln Cys Leu
50          55          60
Asn Gly Met Ile Ile Ala Gln Gln Asn Glu Met Asn Lys Asn Leu Phe
65          70          75          80
Ile Glu Cys Pro Val Cys Gly Ile Val Tyr Gly Glu Lys Val Gly Asn
85          90          95
Gln Pro Ile Gly Ser Met Ser Trp Ser Ile Ile Ser Lys Asn Leu Pro
100         105         110
Gly His Glu Gly Gln Asn Thr Ile Gln Ile Val Tyr Asp Ile Ala Ser
115         120         125
Gly Leu Gln Thr Glu Glu His Pro His Pro Gly Arg Ala Phe Phe Ala
130         135         140
Val Gly Phe Pro Arg Ile Cys Tyr Leu Pro Asp Cys Pro Leu Gly Arg
145         150         155         160
Lys Val Leu Arg Phe Leu Lys Ile Ala Phe Asp Arg Arg Leu Leu Phe
165         170         175
Ser Ile Gly Arg Ser Val Thr Thr Gly Arg Glu Asp Val Val Ile Trp
180         185         190
Asn Ser Val Asp His Lys Thr Gln Phe Asn Met Phe Pro Asp Pro Thr
195         200         205
Tyr Leu Gln Arg Thr Met Gln Gln Leu Val His Leu Gly Val Thr Asp
210         215         220

```

## (2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 204 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```

Met Ala Ser Ser Ala Gly Ser Ala Ala Ser Gly Ser Val Val Pro Gly
 1           5           10           15
Gly Gly Gly Ser Ala Ala Ser Ser Cys Ala Thr Met Ala Leu Ser Thr
 20           25           30
Ala Gly Ser Gly Gly Pro Pro Val Asn His Ala His Ala Val Cys Val
 35           40           45
Trp Glu Phe Glu Ser Arg Gly Lys Trp Leu Pro Tyr Ser Pro Ala Val
 50           55           60
Ser Gln His Leu Glu Arg Ala His Ala Lys Lys Leu Thr Arg Val Met
 65           70           75           80
Leu Ser Asp Ala Asp Pro Ser Leu Glu Gln Tyr Tyr Val Asn Val Arg
 85           90           95
Thr Met Thr Gln Glu Ser Glu Ala Glu Thr Arg Ser Gly Leu Leu Thr
 100          105          110
Ile Gly Val Arg Arg Met Leu Tyr Ala Pro Ser Ser Pro Ala Gly Lys
 115          120          125
Gly Thr Lys Trp Glu Trp Ser Gly Gly Ser Ala Asp Ser Asn Asn Asp
 130          135          140
Trp Arg Pro Tyr Asn Met His Val Gln Cys Ile Ile Glu Asp Ala Trp
 145          150          155          160
Ala Arg Gly Glu Gln Thr Leu Asp Leu Cys Asn Thr His Ile Gly Leu
 165          170          175
Pro Tyr Thr Ile Asn Phe Cys Asn Leu Thr His Val Arg Gln Pro Ser
 180          185          190
Gly Pro Met Arg Ser Ile Arg Arg Thr Gln Gln Ala
 195          200

```

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 19 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```

Val Xaa Pro Ala Pro Pro Leu Ser Xaa Pro Xaa Xaa Pro Gly Gly Pro
 1           5           10           15
Pro Gly Ala

```



## (2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Xaa Ser Pro Gly Xaa Pro Pro Arg Ser Pro Gly Ala Pro Gly Gly  
1 5 10 15

## (2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ser Ile Pro Pro Gly Val Pro Ala Leu Pro Val Lys  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 13 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Arg Ala Pro Lys Pro Ile Leu His Pro Pro Pro Val Ser  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 10 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Val Lys Pro Val Pro Gly Val Pro Gly Val  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 15 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Arg Ala Pro Val Pro Pro Leu Pro Leu His Pro Arg Gln Gln  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Arg Ala Pro Thr Met Pro Pro Pro Leu Pro Pro Val Pro Pro Gln Pro  
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 14 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Arg Ala Val Pro Pro Pro Leu Pro Pro Arg Arg Lys Glu Arg  
 1 5 10

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 61 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Cys Thr Ile Cys Met Glu Arg Leu Val Thr Ala Ser Gly Tyr Glu Gly  
 1 5 10 15

Val Leu Arg His Lys Gly Val Arg Pro Glu Leu Val Gly Arg Leu Gly  
 20 25 30

Arg	Cys	Gly	His	Met	Tyr	His	Leu	Leu	Cys	Leu	Val	Ala	Met	Tyr	Ser
							40					45			
Asn	Gly	Asn	Lys	Asp	Gly	Ser	Leu	Gln	Cys	Pro	Thr	Cys			
	50					55					60				

## (2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CACCATCTGC ATGGAGCGAC TGGT

24

## (2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

TGTGGCCACA TGTACCACCT GCTG

24

## (2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 24 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

TACGGGGAGA AGACGGGTAC GCAG

24

## (2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 23 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:29:

AAGATGGAGT TCCACCTCAT CCC

23

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 6 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Cys Met Glu Arg Leu Val  
1 5

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 6 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Tyr Gly Glu Lys Thr Gly  
1 5

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Thr Ile Arg Ile Val Tyr Asp Ile  
1 5

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 9 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Gly Phe Pro Arg His Cys Tyr Leu Pro

1 5

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Arg Arg Leu Ile Phe Thr Ile Gly  
1 5

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 7 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Met Cys Met Glu Glu Leu Val  
1 5

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Tyr Gly Glu Lys Val Gly  
1 5

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Thr Ile Gln Ile Val Tyr Asp Ile  
1 5

## (2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 9 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Gly Phe Pro Arg Ile Cys Tyr Leu Pro  
1 5


## (2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Arg Arg Leu Leu Phe Ser Ile Gly  
1 5

International Application No: PCT/

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>69</u> , lines <u>1-20</u> of the description	
<b>A. IDENTIFICATION OF DEPOSIT *</b> Further deposits are identified on an additional sheet	
Name of depositary institution <b>American Type Culture Collection</b>	
Address of depositary institution (including postal code and country) <b>12301 Parklawn Drive Rockville, MD 20852 US</b>	
Date of deposit <b>November 17, 1995</b> Accession Number <b>97341</b>	
<b>B. ADDITIONAL INDICATIONS</b> (leave blank if not applicable). This information is continued on a separate attached sheet	
<b>C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE *</b> (if the substances are not all designated States)	
<b>D. SEPARATE FURNISHING OF INDICATIONS *</b> (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (Specify the general nature of the indications e.g., "Accession Number of Deposit")	
<b>E.</b> <input checked="" type="checkbox"/> This sheet was received with the International application when filed (to be checked by the receiving Office) <div style="text-align: right;"> (Authorized Officer)</div> <input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau was _____ (Authorized Officer)	

Form PCT/RO/134 (January 1981)

**WHAT IS CLAIMED IS:**

1. A purified vertebrate Deltex protein.
- 5 2. The protein of claim 1 which is a mammalian protein.
3. The protein of claim 1 which is a human protein.
- 10 4. The protein of claim 1 having the amino acid sequence depicted in Figure 2A-C (SEQ ID NO:12).
- 15 5. A purified protein comprising a fragment of a vertebrate Deltex protein, said fragment consisting of at least 10 continuous amino acids of the vertebrate Deltex protein.
- 20 6. A purified protein comprising a fragment of a vertebrate Deltex protein, said fragment consisting of at least 20 continuous amino acids of the vertebrate Deltex protein.
- 25 7. A purified fragment of a vertebrate Deltex protein consisting of at least 10 continuous amino acids of a vertebrate Deltex protein, which displays one or more functional activities associated with a full-length vertebrate Deltex protein.
- 30 8. The fragment of claim 7 which consists of at least 20 continuous amino acids of the Deltex protein.
9. The protein of claim 5 in which the protein is able to be bound by an antibody to a Deltex protein.
- 35 10. A purified protein comprising a fragment of a vertebrate Deltex protein, which fragment binds to a Notch protein or to a molecule comprising the cdc10/SW16/ankyrin repeats of a Notch protein.



11. A purified protein comprising a fragment of a first vertebrate Deltex protein, which fragment binds to a second Deltex protein or to a molecule comprising a fragment of a second Deltex protein.

5

12. A purified protein comprising a fragment of a vertebrate Deltex protein, which fragment comprises a SH3-binding domain of the vertebrate Deltex protein.

10

13. A chimeric protein comprising a functionally active fragment of a vertebrate Deltex protein joined via a peptide bond to an amino acid sequence of a protein other than a vertebrate Deltex protein.

15

14. The protein of claim 13 in which the fragment binds to a Notch protein or to a molecule comprising the cdc10/SW16/ankyrin repeats of a Notch protein.

20

15. The protein of claim 13 in which the fragment comprises an SH3-binding domain.

25

16. The protein of claim 13 in which the fragment comprises a zinc finger domain.

30

17. A purified derivative of the protein of claim 1, which is characterized by the ability to be bound by antibody to the protein of claim 1, which derivative has one or more insertions, deletions, or substitutions relative to the protein.

35

18. A purified peptide having an amino acid sequence in the range of 10-35 amino acids, said sequence being a portion of a vertebrate Deltex protein sequence.

19. A purified derivative of the protein of claim 1, which is able to display one or more functional activities of the protein of claim 1.

20. A molecule comprising the sequence of a human Deltex protein.
- 5 21. An antibody which binds to a vertebrate Deltex protein, and which does not bind to a *Drosophila* Deltex protein.
22. The antibody of claim 21 which binds to a human Deltex protein.
- 10 23. The antibody of claim 21 which is monoclonal.
24. A fragment or derivative of the antibody of claim 23 containing the binding domain of the antibody.
- 15 25. A purified nucleic acid encoding a vertebrate Deltex protein.
26. The nucleic acid of claim 25 which lacks introns.
- 20 27. The nucleic acid of claim 25 which encodes a protein having the amino acid sequence depicted in Figure 2A-C (SEQ ID NO:12).
- 25 28. The nucleic acid of claim 25 which comprises the coding region of the nucleotide sequence depicted in Figure 2A-C (part of SEQ ID NO:11).
- 30 29. A purified nucleic acid complementary to the nucleic acid of claim 25.
- 30 30. The nucleic acid of claim 25 which encodes a human Deltex protein.
- 35

31. A purified first nucleic acid which is hybridizable to a second nucleic acid under conditions of low stringency, said second nucleic acid comprising the nucleotide sequence depicted in Figure 2A-C (SEQ ID NO:11), said first nucleic acid comprising at least 110 continuous nucleotides of SEQ ID NO:11.

32. A purified first nucleic acid which is hybridizable to a second nucleic acid under conditions of high stringency, said second nucleic acid comprising the nucleotide sequence depicted in Figure 2A-C (SEQ ID NO:11), said first nucleic acid comprising at least 110 continuous nucleotides of SEQ ID NO:11.

33. A purified first nucleic acid which is hybridizable to a second nucleic acid under conditions of low stringency, said second nucleic acid encoding a protein comprising the amino acid sequence depicted in Figure 2A-C (SEQ ID NO:12), said first nucleic acid encoding a protein comprising the first 50 amino acids of SEQ ID NO:12.

34. A purified first nucleic acid which is hybridizable to a second nucleic acid under conditions of high stringency, said second nucleic acid encoding a protein comprising the amino acid sequence depicted in Figure 2A-C (SEQ ID NO:12), said first nucleic acid encoding a protein comprising the first 50 amino acids of SEQ ID NO:12.

35. A purified first nucleic acid which is hybridizable to a second nucleic acid under conditions of high stringency, said second nucleic acid comprising nucleotide numbers 500-1044, 1045-1821, or 1822-2380 of SEQ ID NO:11.

36. A purified first nucleic acid which is hybridizable to a second nucleic acid under conditions of low stringency, said second nucleic acid comprising nucleic acids 500-1044, 1045-1821, or 1822-2370 of SEQ ID NO:11.

37. A purified nucleic acid comprising a nucleotide sequence encoding a protein comprising the first 25 amino acids of SEQ ID NO:12.

38. A purified nucleic acid comprising a nucleotide sequence encoding a protein comprising the first 50 amino acids of SEQ ID NO:12.

5 39. A purified nucleic acid comprising a nucleotide sequence encoding a protein comprising the first 100 amino acids of SEQ ID NO:12.

40. A purified nucleic acid comprising a nucleotide sequence encoding a protein comprising the first 150 amino acids of SEQ ID NO:12.

10

41. A purified nucleic acid comprising a nucleotide sequence encoding a protein comprising the first 230 amino acids of SEQ ID NO:12.

15 42. A purified nucleic acid comprising 110 continuous nucleotides of SEQ ID NO:11.

43. A purified nucleic acid encoding the protein of claim 5.

20 44. A purified nucleic acid encoding the protein of claim 10.

45. A purified nucleic acid encoding the protein of claim 11.

25 46. A purified nucleic acid encoding the protein of claim 12.

47. A nucleic acid encoding the chimeric protein of claim 13.

30 48. The nucleic acid of claim 25 as contained in plasmid pBS hdx as deposited with the ATCC and assigned accession number 97341.

49. A nucleic acid vector comprising the nucleic acid of claim 25.

35 50. A nucleic acid vector comprising the nucleic acid of claim 26.

51. A recombinant cell containing the nucleic acid vector of  
claim 49.

5 52. A recombinant cell containing the nucleic acid vector of  
claim 50.

53. A method for producing a vertebrate Deltex protein  
comprising growing the recombinant cell of claim 51, such that the vertebrate  
10 Deltex protein is expressed by the cell; and recovering the expressed vertebrate  
Deltex protein.

54. A method for producing a protein comprising growing a cell  
15 containing a recombinant nucleic acid comprising the nucleic acid of claim 33, such  
that the protein is expressed by the cell; and recovering the expressed protein.

55. A pharmaceutical composition comprising a therapeutically  
effective amount of a vertebrate Deltex protein; and a pharmaceutically acceptable  
20 carrier.

56. The composition of claim 55 in which the vertebrate Deltex  
protein is a human Deltex protein.

25 57. A pharmaceutical composition comprising a therapeutically  
effective amount of the protein of claim 7; and a pharmaceutically acceptable  
carrier.

30 58. A pharmaceutical composition comprising a therapeutically  
effective amount of the protein of claim 10; and a pharmaceutically acceptable  
carrier.

35 59. A pharmaceutical composition comprising a therapeutically  
effective amount of the protein of claim 11; and a pharmaceutically acceptable  
carrier.

60. A pharmaceutical composition comprising a therapeutically effective amount of the protein of claim 12; and a pharmaceutically acceptable carrier.

5

61. A pharmaceutical composition comprising a therapeutically effective amount of the protein of claim 13; and a pharmaceutically acceptable carrier.

10

62. A pharmaceutical composition comprising a therapeutically effective amount of a derivative of a vertebrate Deltex protein, which derivative is characterized by the ability to bind to a Notch protein or to a molecule comprising the cdc10/SW16/ankyrin repeats of a Notch protein.

15

63. A pharmaceutical composition comprising a therapeutically effective amount of a nucleic acid encoding a vertebrate Deltex protein; and a pharmaceutically acceptable carrier.

20

64. The pharmaceutical composition of claim 63 in which the Deltex protein is a human Deltex protein.

25

65. A pharmaceutical composition comprising a therapeutically effective amount of an antibody which binds to a vertebrate Deltex protein but not to a *Drosophila* Deltex protein, or a fragment or derivative of the antibody containing the binding domain thereof; and a pharmaceutically acceptable carrier.

30

66. A method of treating or preventing a disease or disorder in a subject comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of a molecule which antagonizes the function of a vertebrate Deltex protein.

35

67. The method according to claim 66 in which the disease or disorder is a malignancy characterized by increased Notch activity or increased

expression of a Notch protein or of a Notch derivative capable of being bound by an anti-Notch antibody, relative to said Notch activity or expression in an analogous non-malignant sample.

5

68. The method according to claim 66 in which the disease or disorder is cervical cancer.

10

69. The method according to claim 66 in which the disease or disorder is breast cancer.

15

70. The method according to claim 66 in which the disease or disorder is colon cancer.

71. The method according to claim 66 in which the malignancy is selected from the group consisting of melanoma, seminoma, and lung cancer.

20

72. The method according to claim 67 in which the subject is a human.

25

73. The method according to claim 66 in which the molecule is an antibody to vertebrate Deltex or a derivative of said antibody containing the binding domain thereof, which antibody does not bind to *Drosophila* Deltex.

30

74. The method according to claim 66 in which the molecule is a protein comprising a portion of a vertebrate Deltex protein capable of binding to a Notch protein or to a second molecule comprising the cdc10/SW16/ankyrin repeats of a Notch protein.

35

75. The method according to claim 66 in which the molecule is a protein comprising the SH3 binding domain of a vertebrate Deltex protein.

76. The method according to claim 66 in which the molecule is a protein comprising the zinc finger domain of a vertebrate Deltex protein.

5 77. The method according to claim 66 in which the molecule is an oligonucleotide which (a) consists of at least six nucleotides; (b) comprises a sequence complementary to at least a portion of an RNA transcript of a vertebrate *deltex* gene; and (c) is hybridizable to the RNA transcript.

10 78. A method of treating or preventing a disease or disorder in a subject in need of such treatment or prevention comprising administering to the subject a therapeutically effective amount of a molecule which promotes the function of a vertebrate Deltex protein.

15 79. A method of treating or preventing a malignancy in a subject comprising administering to a subject in need of such treatment or prevention an effective amount of a vertebrate Deltex protein.

20 80. The method according to claim 79 in which the Deltex protein is a human Deltex protein.

25 81. A method of treating or preventing a malignancy in a subject comprising administering to a subject in need of such treatment or prevention an effective amount of the nucleic acid of claim 25.

30 82. A method of treating or preventing a malignancy in a subject comprising administering to a subject in need of such treatment or prevention an effective amount of the antibody of claim 21.

35 83. A method for treating a patient with a tumor, of a tumor type characterized by expression of a *Notch* or vertebrate *deltex* gene, comprising administering to the patient an effective amount of an oligonucleotide, which oligonucleotide (a) consists of at least six nucleotides; (b) comprises a sequence



complementary to at least a portion of an RNA transcript of the vertebrate *deltex* gene; and (c) is hybridizable to the RNA transcript.

5                   84. An isolated oligonucleotide consisting of at least six nucleotides, and comprising a sequence complementary to at least a portion of an RNA transcript of a vertebrate *deltex* gene, which oligonucleotide is hybridizable to the RNA transcript.

10                   85. A pharmaceutical composition comprising the oligonucleotide of claim 84; and a pharmaceutically acceptable carrier.

15                   86. A method of inhibiting the expression of a nucleic acid sequence encoding a vertebrate Deltex protein in a cell comprising providing the cell with an effective amount of the oligonucleotide of claim 84.

20                   87. A method of diagnosing a disease or disorder characterized by an aberrant level of Notch-vertebrate Deltex protein binding activity in a patient, comprising measuring the ability of a Notch protein in a sample derived from the patient to bind to a vertebrate Deltex protein, in which an increase or decrease in the ability of the Notch protein to bind to the vertebrate Deltex protein, relative to the ability found in an analogous sample from a normal individual, indicates the presence of the disease or disorder in the patient.

25                   88. A method of identifying a molecule that inhibits or reduces the binding of a vertebrate Deltex protein to a Notch protein, comprising:  
30                   (a) contacting (i) a Notch protein or fragment thereof that mediates binding to a Deltex protein, and (ii) a vertebrate Deltex protein or fragment thereof that mediates binding to a Notch protein, such that binding between the Notch protein or fragment and the Deltex protein or fragment can occur, in the presence of one or more molecules which are desired to be tested for the ability to inhibit or reduce binding between  
35

the Notch protein or fragment and the Deltex protein or fragment; and

- (b) identifying the one or more molecules that inhibit or reduce the binding of the Deltex protein or fragment to the Notch protein or fragment.

5

89. The method of claim 88 in which the Deltex protein is a human Deltex protein.

10

90. A method of inactivating Notch function in a cell comprising introducing into the cell a molecule, said molecule comprising (a) a Deltex protein or portion thereof that mediates binding to a Notch protein; and (b) a protease or proteolytically active portion thereof.

15

91. A method for the expansion of a precursor cell comprising contacting the cell with an amount of a vertebrate Deltex portion or functionally active portion thereof effective to inhibit differentiation of the cell, and exposing the cell to cell growth conditions such that the cell proliferates.

20

25

30

35

1/26

10	20	30	40	50	60
* * *	* * *	* * *	* * *	* * *	* * *
AAATGCTAGA	AAAACCGTTT	TTACCATCAA	ACGTGAATTC	TTAAGCTGCG	CCTAAACGAA
70	80	90	100	110	120
* * *	* * *	* * *	* * *	* * *	* * *
ACCGAGTGAC	TAAAGAACCA	GAACGAAAC	TTCGGGAAA	TGGAAGCCAG	GGAAAATCAG
130	140	150	160	170	180
* * *	* * *	* * *	* * *	* * *	* * *
GGATAACTAA	CGCTGGCAGC	GGGTCCACCA	TTTTTAATTT	CTTGTATTAT	TTTGTGCCCCA
190	200	210	220	230	240
* * *	* * *	* * *	* * *	* * *	* * *
TCTTCGCGAG	CGAGCGAGAT	AGCGCGACAG	CAACAGCAAG	AGAGAGCGAG	AGAGAGAGTG
250	260	270	280	290	300
* * *	* * *	* * *	* * *	* * *	* * *
AGTGAGTGAG	AGCTAGTGAA	GAGAGCGCAG	GAGGAGTTGG	ATATGGAAAT	GGGCATGGAT
310	320	330	340	350	360
* * *	* * *	* * *	* * *	* * *	* * *
ATGGCAATGG	GCTCACTCCA	CGGATAACGG	ATCAACTGCA	AGCAATGGCC	AGCAGCGCCG

M A S S A>

FIG. 1A

SUBSTITUTE SHEET (RULE 26)

370	380	390	400	410	420
* * *	* * *	* * *	* * *	* * *	* * *
GAAGTGGGC	ATCCGGATCC	GTGTTCCCG	GTGGCGGAGG	TAGCGCCGCC	TCCAGTTGTG
G S A A	S G S V	V P P G	G G G G	S A A S	S S C>
430	440	450	460	470	480
* * *	* * *	* * *	* * *	* * *	* * *
CCACCATGGC	CCTGTCCACC	GCCGGATCCG	GTGGGCCGCC	CGTGAACCAC	GCCCACGCCG
A T M A	L S T A	G S S G	G P P P	V N H A	H A>
490	500	510	520	530	540
* * *	* * *	* * *	* * *	* * *	* * *
TCTGCGTGTG	GGAGTTCGAG	TCGCGCGGCA	AGTGGCTGCC	CTATTGCGCG	GCGGTGTGCG
V C V W	E F E S	R G K W	L P L P	Y S P A	V S>
550	560	570	580	590	600
* * *	* * *	* * *	* * *	* * *	* * *
AGCACTTGA	ACGCGCCCCAC	GCCAAGAAAC	TGACGCGCGT	CATGCTGAGC	GATCGGGATC
Q H L E	R A H A	K K L T	R V M L	S D A D>	
610	620	630	640	650	660
* * *	* * *	* * *	* * *	* * *	* * *
CCAGCCTGGA	GCAGTACTAC	GTCAACGTGC	GCACAATGAC	CCAGGAATCG	GAGCGGAAA
P S L E	Q Y Y Q	V N V R	T M T Q	E S E A	E>

FIG. 1B

3/26

670	680	690	700	710	720
* * *	* * *	* * *	* * *	* * *	* * *
CGCGCTCCGG	CCTGCTGACC	ATCGGTGTTT	GCGCAGTGT	ATACGCACCC	AGCTCGCCGG
T R S G	L L T	I G V	R R M L	Y A P	S S P>
730	740	750	760	770	780
* * *	* * *	* * *	* * *	* * *	* * *
CGGGCAAGGG	CACCAAGTGG	GAGTGGTCGG	GCGGCAGTGC	CGATAGCAAC	AACGACTGGC
A G K G	T K W	E W S	G G S A	D S N	N D W>
790	800	810	820	830	840
* * *	* * *	* * *	* * *	* * *	* * *
GGCCCTACAA	CATGCACGTC	CAGTGCATCA	TCGAGGACGC	CTGGGCGAGG	GGCGAACAAA
R P Y N	M H V	Q C I	I E D A	W A R	G E Q>
850	860	870	880	890	900
* * *	* * *	* * *	* * *	* * *	* * *
CCTTGGACCT	GTGCAACACC	CACATCGGCC	TGCCGTACAC	CATTAAATTT	TGCAATCTCA
T L D L	C N T	H I G	L P Y T	I N F	C N L>
910	920	930	940	950	960
* * *	* * *	* * *	* * *	* * *	* * *
CCCACGTGCG	CCAACCCAGC	GGACCCCATGC	GCAGCATTCG	GGGTACCCAA	CAGGCGCCGT
T H V R	Q P S	G P M	R S I R	R T Q	Q A P>

FIG. 1C

SUBSTITUTE SHEET (RULE 26)

4/26

970	980	990	1000	1010	1020
* * *	* * *	* * *	* * *	* * *	* * *
ATCCCTTGGT	GAAACTAACG	CCACAACAGG	CCAACCAACT	CAAGTCGAAT	TCCGCCAGCG
Y P L V	K L T	P Q Q	A N Q L	K S N	S A S>
1030	1040	1050	1060	1070	1080
* * *	* * *	* * *	* * *	* * *	* * *
TGAGCAGCCA	GTACAACACT	CTACCCAAAC	TGGGCGACAC	CAAGAGCCCTG	CACAGAGTGC
V S S Q	Y N T	L P K	L G D T	K S L	H R V>
1090	1100	1110	1120	1130	1140
* * *	* * *	* * *	* * *	* * *	* * *
CCATGACCCAG	GCAACAGCAC	CCATTGCCCA	CCAGCCATCA	AGTGCAGCAG	CAGCAGCATC
P M T R	Q Q H	P L P	T S H Q	V Q Q	Q Q H>
1150	1160	1170	1180	1190	1200
* * *	* * *	* * *	* * *	* * *	* * *
AGCTCCAGCA	TCAACAGCAG	CAGCAGCAGC	AACATCATCA	CCAGCATCAG	CAACAACAGC
Q L Q H	Q Q Q	Q Q Q	Q H H H	Q H Q	Q Q Q>
1210	1220	1230	1240	1250	1260
* * *	* * *	* * *	* * *	* * *	* * *
ATCAGCAACA	GCAGCAACAT	CAGATGCAGC	ACCATCAGAT	CCATCATCAG	ACGGCGCCCA
H Q Q Q	Q Q H	Q M Q	H H Q I	H H Q	T A P>

FIG. 1D

SUBSTITUTE SHEET (RULE 26)

5/26

1270	1280	1290	1300	1310	1320
* *	* *	* *	* *	* *	* *
GGAAGCCGCC	CAAGAAGCAC	AGCGAGATCT	CCACCACCAA	TCTACGCCAG	ATACTCAACA
R K P P	K K H	S E I	S T T N	L R Q	I L N>
1330	1340	1350	1360	1370	1380
* *	* *	* *	* *	* *	* *
ACCTAAACAT	CTTCAGCAGC	AGCACTAAGC	ACCAATCGAA	CATGTCGACG	GCGGCCAGTG
N L N I	F S S	S T K	H Q S N	M S T	A A S>
1390	1400	1410	1420	1430	1440
* *	* *	* *	* *	* *	* *
CCAGTTCATC	CTCCTCATCG	GCCTCGCTGC	ACCATGCCAA	CCATCTGTGC	CATGCGCACT
A S S S	S S S	A S L	H H A N	H L S	H A H>
1450	1460	1470	1480	1490	1500
* *	* *	* *	* *	* *	* *
TTTCGCACGC	CAAGAACATG	CTGACTGCCT	CGATGAACAG	TCATCATAGT	CGCTGCTCGG
F S H A	K N M	L T A	S M N S	H H S	R C S>
1510	1520	1530	1540	1550	1560
* *	* *	* *	* *	* *	* *
AGGGATCGCT	GCAGTCGCAA	AGGAGCAGCC	GGATGGGCTC	GCATCGCTCG	AGATCGCGAA
E G S L	Q S Q	R S S	R M G S	H R S	R S R>

FIG.1E

SUBSTITUTE SHEET (RULE 26)

6/26

1570	1580	1590	1600	1610	1620
* * *	* * *	* * *	* * *	* * *	* * *
CGCGGACCTC	GGACACGGAC	ACGAACAGTG	TGAAATCGCA	TCGGCGGAGA	CCCAGTGTGG
T R T S	D T D	T N S	V K S H	R R R	P S V>
1630	1640	1650	1660	1670	1680
* * *	* * *	* * *	* * *	* * *	* * *
ACACCGTGTC	CACCTACCTC	AGCCACGAGA	GCAAGGAGAG	CCTGCGCAGC	AGGAACTTTG
D T V S	T Y L	S H E	S K E S	L R S	R N F>
1690	1700	1710	1720	1730	1740
* * *	* * *	* * *	* * *	* * *	* * *
CCATTTCGGT	CAATGATCTG	CTGGACTGCT	CGCTTGGCAG	CGATGAAGTT	TTTGTGCCCT
A I S V	N D L	L D C	S L G S	D E V	F V P>
1750	1760	1770	1780	1790	1800
* * *	* * *	* * *	* * *	* * *	* * *
CCGTGCCCGCC	ATCGTCGCTG	GGCGAAAGGG	CGCCGGTGCC	GCCGCCATTA	CCACTGCATC
S V P P	S S L	G E R	A P V P	P P L	P L H>
1810	1820	1830	1840	1850	1860
* * *	* * *	* * *	* * *	* * *	* * *
CGCGACAGCA	ACAGCAGCAG	CAACAACAGC	AGCAACAGCT	GCAGATGCAA	CAGCAGCAAC
P R Q Q	Q Q Q	Q Q Q	Q Q Q	L Q M	Q Q Q>

FIG. 1F



7/26

1870	1880	1890	1900	1910	1920
* * *	* * *	* * *	* * *	* * *	* * *
AGCGCAGCA	GCAGCAGCAG	CAATCAATCG	CCGGTTCGAT	TGTGGGCGGTG	GACCCGGCCA
Q A Q Q	Q Q Q Q	Q S I A	G S I V	G V D P	A >
1930	1940	1950	1960	1970	1980
* * *	* * *	* * *	* * *	* * *	* * *
GCGATATGAT	ATCGCGTTTT	GTCAAGGTGG	TGGAGCCACC	GCTGTGGCCC	AATGCCCCAGC
S D M I	S R F V	K V V E	P P L W	P N A Q	
1990	2000	2010	2020	2030	2040
* * *	* * *	* * *	* * *	* * *	* * *
CCTGTCCCAT	GTGCATGGAG	GAGCTGGTGC	ACTCCGCCCA	GAATCCGGCC	ATTTCCGCTGA
P C P M	C M - E	E L V H	S A Q N	P A I S	L >
2050	2060	2070	2080	2090	2100
* * *	* * *	* * *	* * *	* * *	* * *
GTCGCTGCCA	GCATCTCATG	CATTGTCAGT	GCCTCAATGG	GATGATAATT	GCCCAGCAAA
S R C Q	H L M H	L Q C L	N G M I	I A Q Q	
2110	2120	2130	2140	2150	2160
* * *	* * *	* * *	* * *	* * *	* * *
ACGAAATGAA	CAAGAACCTT	TTCATCGAGT	GCCCTGTATG	CGGCATCGTT	TACGGCGAGA
N E M N	K N L F	I E C P	V C G I	V Y G E	

FIG. 1G

SUBSTITUTE SHEET (RULE 26)

8/26

2170	2180	2190	2200	2210	2220
* * *	* * *	* * *	* * *	* * *	* * *
AGGTCGGCAA	TCAGCCCAT	GGCAGCATGT	CGTGGAGCAT	AATTAGCAAG	AATCTGCCAG
K V G N	Q P I G S M	S W S I	I S K N	L P >	
2230	2240	2250	2260	2270	2280
* * *	* * *	* * *	* * *	* * *	* * *
GACACGAGGG	TCAGAACACC	ATACAGATTG	TTTACGACAT	TGCATCGGGA	CTGCAGACGG
G H E G	Q N T I Q I	V Y D I	A S G L	Q T >	
2290	2300	2310	2320	2330	2340
* * *	* * *	* * *	* * *	* * *	* * *
AGGAGCATCC	GCATCCAGGT	CGTGCCCTTCT	TCGCCGTGGG	ATTCCCCGGG	ATCTGCTACT
E E H P	H P G R A F	F A V G	F P R I	C Y >	
2350	2360	2370	2380	2390	2400
* * *	* * *	* * *	* * *	* * *	* * *
TGCCGGACTG	CCCGCTGGGG	CGAAAGGTTT	TGCGCTTCCT	CAAGATTGCA	TTCGATCGTC
L P D C	P L G R K V	L R F L	K I A F	D R >	
2410	2420	2430	2440	2450	2460
* * *	* * *	* * *	* * *	* * *	* * *
GGCTGCTTTT	CTCGATCGGA	CGATCGGTGA	CCACCGGACG	CGAGGATGTG	GTGATCTGGA
R L L F	S I G R S V	T T G R	E D V	I W >	

FIG. 1H

SUBSTITUTE SHEET (RULE 26)

9/26

2470	*	*	2480	*	*	2490	*	*	2500	*	*	2510	*	*	2520	*
ACAGTGTGGA	TCACAAGACG	CAGTTCAATA	TGTTTCCGGA	TCCCACCTAT	TTGCAGCGAA											
N S V D	H K T	Q F N	M F P	D P T	Y L Q	R>										
2530	*	*	2540	*	*	2550	*	*	2560	*	*	2570	*	*	2580	*
CCATGCAACA	GCTGGTGCAC	CTGGGCGTGA	CGGATTAAGG	ATTAGTTCCC	TGTCCCCAAG											
T M Q Q	L V H	L G V	T D	*>												
2590	*	*	2600	*	*	2610	*	*	2620	*	*	2630	*	*	2640	*
TAGAACTACC	AACCAACCAA	TCAACCACCC	ACCCACCGAA	GTCCCCCTCGA	TCATTCTCTT											
2650	*	*	2660	*	*	2670	*	*	2680	*	*	2690	*	*	2700	*
CCATTGCTCG	TTAAGTTACT	TTCTACATAA	TCTCAGTGTG	TGTGCAATCC	TCGTTTACTA											
2710	*	*	2720	*	*	2730	*	*	2740	*	*	2750	*	*	2760	*
TGATATATTT	TTTTTATAGA	TATATTGTAA	TAGCGTTTGA	GCTGCTCGAA	CCCTAAACA											
2770	*	*	2780	*	*	2790	*	*	2800	*	*	2810	*	*	2820	*
ACAGCAAACC	ACAATTGCAA	TTGTAGCTTC	CTTTCGCTC	TTCCAATTGG	TATTGTGACG											

FIG. 1I

SUBSTITUTE SHEET (RULE 26)

10/26

2830            2840            2850            2860            2870            2880  
\*            \*            \*            \*            \*            \*  
CACATACGCA ATAAGTTGGC GTACATCATA TGTATTAGCT AGTTAGTTAG TTAGTTAGTT  
2890            2900            2910            2920            2930            2940  
\*            \*            \*            \*            \*            \*  
AGTTGTAGCT GTAGTTCCCA AGAGAATCTT GACCCAAGAC ACCTACTAGT ATTAGGCATT  
2950            2960            2970            2980            2990            3000  
\*            \*            \*            \*            \*            \*  
ATCCTGATTC TTGATTCCCTG ATTCGATTCA AGCCAAGCCA AGCCACGCCA TTCGAGTGCA  
3010            3020            3030            3040            3050            3060  
\*            \*            \*            \*            \*            \*  
AGCTGTGCCA AAATCGTAGC GCTCCCGTTT ATAGGATATG TATATTGTTG ATATAGCTAG  
3070            3080            3090            3100            3110            3120  
\*            \*            \*            \*            \*            \*  
CTATAACCAT TGCCCATCTC TCCATCTCTC TCGGTTTCGA ATTTGTCTCT TTCAATCAGAT  
3130            3140            3150            3160            3170            3180  
\*            \*            \*            \*            \*            \*  
CCATGTGAAT TTCTTTTATA TCGGATTTAT ATAGGATTAA AATAGTATTT TGAGAGAGGA

FIG. 1J

SUBSTITUTE SHEET (RULE 26)

11/26

3190	3200	3210	3220	3230	3240
* * *	* * *	* * *	* * *	* * *	* * *
AATGGAGATG	GGTAAATTGG	ATAGACTTGT	CTCACTTGTC	TGGCCATT	AATCTCTTTC
3250	3260	3270	3280	3290	3300
* * *	* * *	* * *	* * *	* * *	* * *
ATTACAGCGAA	TTTGATGTGA	TTTTAATTGG	AATTATTTCAT	TATTAACGG	AGCATTTAGG
3310	3320	3330	3340	3350	3360
* * *	* * *	* * *	* * *	* * *	* * *
AAGCATAGTT	GTAACGCAGC	CAGATATTCC	ATTACGCATA	TACATATACA	TATACATATA
3370	3380	3390	3400	3410	3420
* * *	* * *	* * *	* * *	* * *	* * *
CATACATACA	TAAACATATT	TTAACATAGC	CCCATAGCCA	TACGACATAA	CAATAATTTT
3430	3440	3450	3460	3470	3480
* * *	* * *	* * *	* * *	* * *	* * *
TTTTATCGAA	TCCCTTGCAT	ACATTTGATG	AATTGTTGCT	TTCATATTGA	TATCATCGAG
3490	3500	3510	3520	3530	3540
* * *	* * *	* * *	* * *	* * *	* * *
CATCGAACGA	ACTATCGTAT	ACATCGCCAA	TATATAGCAT	ATATAGCATA	TAGTATGTAG

FIG. 1K

SUBSTITUTE SHEET (RULE 26)

3550	3560	3570	3580	3590	3600
* AGATCGTACG	* GACAGCTAGC	* GGCTACTGAC	* CGCGCCACCA	* TATTGGATAT	* GATATGATAT
3610	3620	3630	3640	3650	3660
* GATTTTACTA	* AGTTGTATTT	* AGCACTGATT	* AGTTATATAA	* GTTCATTTGA	* CGAATATTCC
3670	3680	3690	3700	3710	3720
* ACAACAAATT	* CCACACCATT	* TATGTATGCA	* TATTACGCAT	* ATATAATACA	* GTACATTATT
3730	3740	3750	3760	3770	
* ATATAGTTCA	* AATAAAGTAA	* CTTCATTTCAT	* GTTCAAAAAA	* AAAAAA AAAA	A

FIG. 1L

BNSDOCID: <WO\_\_\_9718822A1\_IA>

13/26

10 30 50  
GCGAGAAGCCCCACTGAAGCCGGCGCAGGGTCTGGACGCAGTTGGAGTGCAAGGGC

70 90 110  
TGGCTGAGAGCCGCAGGAGCAGCAGGCTGTGGCCCCAGGCCCTCTGGGTGACAGGCCCTGT

130 150 170  
CTGGCGGGGAACAGGGACCAAGAGACAAACACAGAAGAGGCTGGACCTCGAACAGGGGCGG

190 210 230  
CTGCCCTCACTCCCTACCTGAGCCAGCCGAGGGGCCAAGGACTTTAGAGCTTTTCCTCC

250 270 290  
GGCATAAGAGAGACACTTGCTTTCCAGGGCAGCACCCCTTTATCGGAGAAAGGCTCTACAGG

310 330 350  
GAAGGGGTCTTTGCAGCCCTGGATGGCCATCCACATTCCTTTAACGGAGGTCCTAGGCC

370 390 410  
TCAGAGAGAACCCAGAGTTAGAAAGGAGGCCAGACGGTCCTTGCTGTCCCCCTGGGGAGA

430 450 470  
GAGGAAGTTGCCGCCTGCTGCCAGGCCCAGGAGGAGCTGGGCCTGCAATAGTGGGGGACC

490 510 530  
TGGCCCCCTGAGGCAGTGGGGGCCATGTACGGCCAGGCCACGGTGGGCTGATGCCTGTGA  
M S R P G H G L M P V N

FIG. 2A

SUBSTITUTE SHEET (RULE 26)

14/26

550 570 590  
ATGGTCTGGGCTTCCACCGCAGAACGTGGCCCGGGTGGTGGTGGAGTGTCTGAATG  
G L G F P P Q N V A R V V V V W E C L N E

610 630 650  
AGCACAGCCGCTGGGGCCCTACAGGCCACCGTGTGCCACCACATGTGAGAACGTGCTGA  
H S R W R P Y T A T V C H H I E N V L K

670 690 710  
AGGAGGACGCTCGCGGTTCCGTGGTCTGGGGCAGGTGGACGCCCAGCTTGTGCCCTACA  
E D A R G S V V L G Q V D A Q L V P Y I

730 750 770  
TCATCGACCTGCAGTCCATGCACCAGTTTCGCCAGGACACAGGCACCATGCGGCCCGTGC  
I D L Q S M H Q F R Q Q D T G T M R P V R

790 810 830  
GGCGCAACTTCTACGACCCGTCGTGGCGCCCGGCAAGGGCATCGTGTGGAGTGGGAGA  
R N F Y D P S S A P G K G I V W E W E N

850 870 890  
ACGACGGCGGCATGGACGGCCTACGATATGGACATCTGCATCACCATCCAGAACGCCT  
D G G A W T A Y D M D I C I T I Q N A Y

910 930 950  
ACGAGAAGCAGCACCCGTGGCTCGACCTCTCATCGCTAGGCTTCTGCTACCTCATCTACT  
E K Q H P W L D L S S L G F C Y L I Y F

FIG. 2B

SUBSTITUTE SHEET (RULE 26)



15/26

970 990 1010  
TCAACAGCATGTGCGAGATGARCCGCCAGACGGCGCGCGCGCGCGTCTGCGCGCGCGCC  
N S M S Q M X R Q T R R R R R L R R L

1030 1050 1070  
TGGACCTGCGCTACCCGCTACCGTGGGCTCCATCCCTAAGTCGCAGTCGTGCGCGCGTGG  
D L A Y P L T V G S I P K S Q S W P V G

1090 1110 1130  
GTGBCAGCTCGGGHCAAGCCCTGCTCTGMCAGCAGTGCCTGYTTGGTCAACAGCAGCGCGG  
X S S G Q P C S X Q Q C L L V N S T R A

1150 1170 1190  
CCGTCTCCAACGTCATCCTGGYCTGCGAGCGTGTGTAAGTGMCCCCCGCGCGCGCTGT  
V S N V I L X S Q R R K V X P A P P L S

1210 1230 1250  
CGYCGCGYCGMCACCTGGAGGGCCTCCAGGCGCGCTTGGCGTGGCGCCAGYGTACCT  
X P X X P G G P P G A L G V R P S V T F

1270 1290 1310  
TCACAGGCGNGCTCTGNGAAGTGNNTTCNACGGTCCCGTCGAGCCCGMGYCGTCTC  
T G X X L X E V X F X G P V E P X X S P

1330 1350 1370  
CCGGGGYCCCCCAGGAGCCCGGGCGCCCCCGGGGAGCGCGCACCCCGGGGAGACA  
G X P P R S P G A P G G A R T P G Q N N

FIG. 2C

SUBSTITUTE SHEET (RULE 26)

16/26

1390 1410 1430  
ACCTCAACCGGBCCGGCCCCAGCGCACCAACAGHGTGAGCGCGCGCCTCCATCCCGC  
L N R X G P Q R T T X V S A R A S I P P

1450 1470 1490  
CGGGGTCCCGCACTCCCGGTGAAGAACTTGAATGGTACTGGCGCGGTCCATCCGGCCC  
G V P A L P V K N L N G T G P V H P A L

1510 1530 1550  
TGGCAGGGATACCGGGATACTGCTGTGCGCGCGCGGTGCCCTGTGCTGACGCGGG  
A G M T G I L L C A A G L P V C L T R A

1570 1590 1610  
CCCCAAGCCCATCTGCACCCGCGCCGTGAGCAAGAGCGACGTGAAGCCCGTGCCCTG  
P K P I L H P P P V S K S D V K P V P G

1630 1650 1670  
GCGTGCCCGGGTGTGCCGCAAGACCAAGAAGAACCTTAAAGAGTAAGATCCCG  
V P G V C R K T K K K H L K K S K N P E

1690 1710 1730 hdx-1  
AGGATGTGGTTCCGAAGATACATGCAGAAAGGTGAATAAACCCACCTGATGAGGACTGCACCA  
D V V R R Y M Q K V K N P P D E D E T I

1750 1770 1790  
TCTGCATGGAGCGGACTGGTCAACAGCATCAGGCTACGAGGGCGTGTCTCGGCACAAAGGGCG  
E M E R L V T A S G Y E G V L R H K G V

FIG. 2D

SUBSTITUTE SHEET (RULE 26)

17/26

1810 1830 hdx-2 1850  
TGCGGCCTGAGCTCGTGGGCGCCCTGGCGCGCTGTGGCCACATGTACCACCTGCTGTCC  
R P E L V G R L G R Q G H M Y H L L Q L

1870 1890 1910  
TCGTGGCCATGTACTCCAATGGCAACAAGGATGGCAGCCTGCAGTGCCCCACCTGCAAGG  
V A M Y S N G N K D G S L Q Q P T Q K A

1930 hdx-3 1950 hdx-4 1970  
CCATCTACGGGAGAAAGACGGGTACGCAGCCGCCCTGGGAAGATGGAGTTCCACCTCATCC  
I Y G E K T G T Q P P G K M E F H L I P

1990 2010 2030 \$  
CCCACTCGCTGCCCGGCTTCCCTGATACCCAGACCATCCGCATCGTCTATGACATCCCA  
H S L P G F P D T Q T I R I V Y D I P T

2050 2070 2090  
CAGGCATCCAGGCGCCCTGAGCACCCCAACCCCGGGAAGATTCAACCGCAAGAGATTCC  
G I Q G P E H P N P G K K F T A R G F P

2110 2130 2150  
CTCGCCACTGCTATCTACCCAACAACGAGAAAGCGCGGAGGTGCTGCGGCTGCTCATCA  
R H C Y L P N N E K G R K V L R L L I T

2170 2190 2210  
CGGCCTGGGAGAGAAGACTCATCTTCACTATCGGCACGTCCAACACCGGCGAGTCGG  
A W E R R L I F T I G T S N T T G E S D

FIG. 2E

SUBSTITUTE SHEET (RULE 26)

18/26

2230 2250 2270  
ACACCGTGGTGGACGAGATCCACCAAGACCGAGTTGGATCCAACTCACGGGAC  
T V V W N E I H H K T E F G S N L T G H

2290 2310 2330  
ACGGCTACCCGGACGCTAGCTACCTAGACAAACGTGCTGGCTGAGCTCACAGSCCAGGGCG  
G Y P D A S Y L D N V L A E L T X Q G V

2350 2370 2390  
TATCCGAGGCTGCAGGCAAGGCTTGAGGSCCAAGGCTGCCCACTTCCCTCCTGTTGG  
S E A A G K A END

2410 2430 2450  
CCCTGGTCCGGCAAATGCCCTCCTTCGCCAGGTGTGTCTCTGGTAGCCCCAGGTTACGGGCTG

2470 2490 2510  
GGGAGGAGCCTGCCGGAAGGGGCCGAGCCATTACAGGGGACTGNCCTGGNGGAAGTTGGATG

2530  
AGGAGAGNTGGATTTNAGGTTGGCCCC

FIG. 2F

SUBSTITUTE SHEET (RULE 26)

1	M	A	S	S	A	G	S	A	S	G	S	V	P	G	G	G	S	A	A	S	S	C	A	T	M	A	L	S	T	A	G	S	G	G	P	P	V	FLY DELTEX		
1	M	S	R	-	-	-	-	-	-	-	-	-	P	G	H	G	G	-	-	-	-	-	-	-	L	M	P	V	N	G	L	G	F	P	P	Q	HUMAN DELTEX			
41	N	H	A	H	A	V	C	V	W	E	-	F	E	S	R	G	K	W	L	P	Y	S	P	A	V	S	Q	H	L	E	R	A	-	H	A	K	K	L	T	R
21	N	V	A	R	V	V	-	V	W	E	C	L	N	E	H	S	R	W	R	P	Y	T	A	T	V	C	H	H	I	E	N	V	L	K	E	D	A	R	G	S
79	V	M	L	S	D	A	D	P	S	L	E	Q	Y	Y	V	N	V	R	T	M	T	Q	E	S	E	A	E	T	R	S	G	L	L	T	I	G	V	R	R	M
60	V	V	L	G	Q	V	D	A	Q	L	V	P	Y	I	I	D	L	Q	S	M	H	Q	F	R	Q	D	-	-	T	G	T	M	R	-	P	V	R	R	N	
119	L	Y	A	P	S	S	P	A	G	K	G	T	K	W	E	W	S	G	G	S	A	D	S	N	N	D	W	R	P	Y	N	M	H	V	Q	C	I	-	I	E
96	F	Y	D	P	S	S	A	P	G	K	G	I	V	W	E	W	E	N	D	G	A	-	-	-	W	T	A	Y	D	M	D	I	-	C	I	T	I	Q		
158	D	A	W	A	R	G	E	Q	T	L	D	L	C	N	T	H	I	G	L	P	Y	T	I	N	F	C	N	L	T	H	V	R	Q	P	S	G	P	M	R	S
131	N	A	Y	E	K	Q	H	P	W	L	D	L	S	S	-	-	L	G	F	C	Y	L	I	Y	F	N	S	M	S	Q	M	X	R	Q	T	R	R	R	R	
198	I	R	R	T	Q	Q	A	P	Y	P	L	V	-	-	K	L	T	P	Q	Q	A	N	Q	L	K	S	N	S	A	S	V	S	S	Q	Y	N	T	L	P	K
169	L	R	R	R	L	D	L	A	Y	P	L	T	V	G	S	I	P	K	S	Q	S	W	P	V	G	X	S	S	G	Q	P	C	S	X	Q	Q	C	L	L	-
236	L	G	D	T	K	S	L	H	R	V	P	M	T	R	Q	Q	H	P	L	P	T	S	H	Q	V	Q	Q	Q	H	Q	L	Q	H	Q	Q	Q	Q	Q	Q	Q
208	V	N	S	T	R	A	V	S	N	V	I	L	X	S	Q	R	R	K	V	X	P	A	P	P	L	S	X	P	X	-	-	-	-	-	-	-	-	-	-	
276	Q	H	H	H	Q	H	Q	Q	Q	H	Q	Q	Q	Q	H	Q	M	Q	H	H	Q	I	H	H	Q	T	A	P	R	K	P	P	K	K	H	S	E	I		
238	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		

FIG.3A

SUBSTITUTE SHEET (RULE 26)

316	S	T	T	N	L	R	Q	I	L	N	N	L	N	I	F	S	S	T	K	H	Q	S	N	M	S	T	A	A	S	A	S	S	S	S	A	S	L	FLY DELTEX						
249	P	S	V	T	F	T	G	X	X	L	X	E	V	X	F	X	G	P	V	E	P	X	X	S	P	G	X	P	P	R	S	P	G	A	P	G	G	A	R	HUMAN DELTEX				
356	H	H	A	N	H	L	S	H	A	H	F	S	H	A	K	N	M	L	T	A	S	M	N	S	H	H	S	R	C	S	E	G	S	L	Q	S	Q	R	S	S	FLY DELTEX			
289	P	G	Q	N	L	N	R	X	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	G	P	Q	R	T	T	HUMAN DELTEX			
396	R	M	G	S	H	R	S	R	T	R	T	S	D	T	D	T	N	S	V	K	S	H	R	R	R	P	S	V	D	T	V	S	T	Y	L	S	H	E	-	-	-	FLY DELTEX		
304	X	V	S	A	R	A	S	I	P	P	G	V	P	A	L	P	V	K	N	L	N	G	T	G	P	V	H	P	A	L	A	G	M	T	G	I	L	-	-	-	-	HUMAN DELTEX		
436	S	K	E	S	L	R	S	R	N	F	A	I	S	V	N	D	L	L	D	C	S	L	G	S	D	E	V	F	V	P	S	V	P	P	S	S	L	G	E	R	-	FLY DELTEX		
341	-	-	-	-	-	-	-	-	-	-	-	L	C	A	G	L	P	V	C	-	L	T	R	A	P	K	P	I	L	H	P	P	V	S	K	S	D	V	-	-	-	-	HUMAN DELTEX	
476	A	P	V	P	P	P	L	P	L	H	P	R	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	Q	S	I	-	-	-	FLY DELTEX	
369	K	P	V	P	G	V	P	G	V	C	R	K	T	K	K	H	L	K	K	S	K	N	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	HUMAN DELTEX
516	A	G	S	I	V	G	V	D	P	A	S	D	M	I	S	R	F	V	K	V	V	E	P	P	L	W	P	N	A	Q	P	C	P	M	C	M	E	E	L	V	-	FLY DELTEX		
392	-	-	-	-	-	-	-	-	-	-	P	E	D	V	V	R	R	Y	M	Q	K	V	K	N	-	-	P	P	D	E	D	C	T	I	C	M	E	R	L	V	-	-	-	HUMAN DELTEX
556	-	-	-	-	-	-	-	-	-	-	H	S	A	Q	N	P	A	I	-	-	S	L	S	R	C	Q	H	L	M	H	L	Q	C	L	N	G	M	I	I	A	-	-	-	FLY DELTEX
420	T	A	S	G	Y	E	G	V	L	R	H	K	G	V	R	P	E	L	V	G	R	L	G	R	C	G	H	M	Y	H	L	L	C	L	V	A	M	Y	-	-	-	-	-	HUMAN DELTEX
584	Q	Q	N	E	M	N	K	N	L	F	I	E	C	P	V	C	G	I	V	Y	G	E	K	V	G	N	Q	P	I	G	S	M	S	W	S	I	T	S	K	N	-	FLY DELTEX		
458	-	-	S	N	G	N	K	D	G	S	L	Q	C	P	T	C	K	A	I	Y	G	E	K	T	G	T	X	P	P	G	K	M	E	F	H	L	I	P	H	S	-	-	-	HUMAN DELTEX

FIG.3B

SUBSTITUTE SHEET (RULE 26)

624	L	P	G	H	E	G	Q	N	T	I	Q	I	V	Y	D	I	A	S	G	L	Q	T	E	E	H	P	H	P	G	R	A	F	F	A	V	G	F	P	R	I	FLY DELTEX	
496	L	P	G	F	P	D	T	Q	T	I	R	I	V	Y	D	I	P	T	G	I	Q	G	P	E	H	P	N	P	G	K	K	F	F	T	A	R	G	F	P	R	H	HUMAN DELTEX
664	C	Y	L	P	D	C	P	L	G	R	K	V	L	R	F	L	K	I	A	F	D	R	R	L	L	F	S	I	G	R	S	V	T	T	G	R	E	D	V	V	FLY DELTEX	
536	C	Y	L	P	N	E	K	G	R	K	V	L	R	L	L	I	T	A	W	E	R	R	L	I	F	T	I	G	T	S	N	T	T	G	E	S	D	T	V	HUMAN DELTEX		
704	I	W	N	S	V	D	H	K	T	Q	F	-	-	-	-	-	-	N	M	F	P	D	P	T	Y	L	Q	R	T	M	Q	Q	L	V	H	L	G	V	T	D	FLY DELTEX	
576	V	W	N	E	I	H	H	K	T	E	F	G	S	N	L	T	G	H	C	Y	P	D	A	S	Y	L	D	N	V	L	A	E	L	T	X	Q	G	V	S	E	HUMAN DELTEX	
737																																									FLY DELTEX	
616	A	A	G	K	A																																					HUMAN DELTEX

FIG.3C

10	*	*	20	*	*	30	*	*	40	*	*	50	*	*	60	*
MASSAGSAAS GSVVPGGGGS AASSCATMAL STAGSGGPPV NHAHAVCVWE FESRGKWL PY																
A																
D																
70	*	*	80	*	*	90	*	*	100	*	*	110	*	*	120	*
SPAVSQHLER AHAKKLTRVM LSDADPSLEQ YVNVRTMTQ ESEAETRSL LTIGVRRML Y																
A																
D																
130	*	*	140	*	*	150	*	*	160	*	*	170	*	*	180	*
APSSPAGKGT KWEWSGGSD SNNDWRPYNM HVQCIEDAW ARGEQTL DLC NTHIGL PYTI																
A																
D																

FIG. 4A

SUBSTITUTE SHEET (RULE 26)



FIG. 4B

BNSDOCID: &lt;WO\_\_\_\_9718822A1\_IA&gt;

**FIG. 4C**

730  
\* \* \*  
TYLQRTMQQL VHLGVTD  
C >

FIG. 4D

**SUBSTITUTE SHEET (RULE 26)**

26/26




FIG.5




FIG.6

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/18675

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
Electronic data bases.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, GENBANK, MEDLINE, EMBASE, BIOSIS.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	XU, Tian et al. deltex, a Locus Interacting with the Neurogenic Genes, Notch, Delta and mastermind in Drosophila melanogaster. Genetics. November 1990, Vol. 126, pages 665-677, see entire document.	1-91
Y	BLANK, Volker et al. NF- $\kappa$ B and related proteins: Rel/dorsal homologies meet ankyrin-like repeats. Trends in Biochemical Sciences. April 1992, Vol 17, pages 135-140, see entire document.	1-91
Y	ARTAVANIS-TSAKONAS, Spyros et al. Choosing a cell fate: a view from the Notch locus. Trends in Genetics. November/December 1991, Vol. 7, No. 11/12, pages 403-408, see entire document.	1-91

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search      Date of mailing of the international search report

12 MARCH 1997

17 APR 1997

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

ERNEST JONES

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/18675

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 92/19734 A1 (YALE UNIVERSITY) 12 November 1992, see entire document.	1-91
Y	WO 95/19779 A1 (YALE UNIVERSITY) , 27 July 1995, see entire document.	1-91

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/18675

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)\*

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/18675

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 35/12; C07H 17/00; C07K 1/00, 14/00, 16/00; C12N 1/00, 5/00, 15/00; C12Q 1/00, 1/68; G01N 33/53

## A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/130.1; 435/6, 7.1, 69.1, 172.1, 172.3, 243, 320.1, 325; 514/2, 44; 530/350, 387.1, 388.1; 536/23.1, 23.2, 23.4, 23.5, 24.1, 24.3

## B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

424/130.1; 435/6, 7.1, 69.1, 172.1, 172.3, 243, 320.1, 325; 514/2, 44; 530/350, 387.1, 388.1; 536/23.1, 23.2, 23.4, 23.5, 24.1, 24.3

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

- I. Claims 1-12, 17-20, and 87-91 drawn to purified Deltex proteins.
- II. Claims 13-16, drawn to chimeric proteins comprising a portion of Deltex proteins.
- III. Claims 21-24, drawn to antibodies to Deltex proteins.
- IV. Claims 25-46, 48-54, drawn to nucleic acids encoding Deltex proteins and associated vectors and host cells.
- V. Claim 47, drawn to nucleic acids encoding chimeric proteins.
- VI. Claims 55-62, 66-72, 74-76, 78-80, drawn to pharmaceutical compositions comprising Deltex proteins and methods of treating a disease using said compositions (Note that claims 66-72, and 78 will be examined only to the extent that they read on the use of Deltex proteins as therapeutic agents.)
- VII. Claims 63-64, 66-72, 78, and 81, drawn to pharmaceutical compositions comprising Deltex protein encoding nucleic acids and methods of treating a disease using said compositions. (Note that claims 66-72, and 78 will be examined only to the extent that they read on the use of Deltex protein encoding nucleic acids as therapeutic agents.)
- VIII. Claims 65, 66-73, 78 and 82, drawn to pharmaceutical compositions comprising antibodies to Deltex proteins and methods of treating a disease using said compositions. (Note that claims 66-72, and 78 will be examined only to the extent that they read on the use of antibodies to Deltex protein as therapeutic agents.)
- IX. Claims 66-72, 77-78, 83-86, drawn to drawn to pharmaceutical compositions comprising Deltex antisense nucleic acids and methods of treating a disease using said compositions. (Note that claims 66-72, and 78 will be examined only to the extent that they read on the use of Deltex antisense nucleic acids as therapeutic agents.)

The compositions of the inventions of groups I - III do not share any special technical feature because they are drawn to divergent chemical compositions with differing properties. For example the invention of groups I and II are drawn to proteins and that of group III to nucleic acids. Aside from their divergent chemical natures, these groups of compositions require separate analysis. For example, consideration of nucleic acids requires analysis of gene coding regions and expression vectors and considerations of proteins require analysis of protein isolation purification and function. The antibodies of the invention of group III are distinct from the proteins of group I because antibody compositions require analysis of means of producing specific protein binding reagents and uses thereof and such analysis is not required for consideration of structural proteins per se. Similarly, the inventions of groups IV-VI do not share a special technical feature because they are based upon the use of materially different compositions; proteins, nucleic acids and antibodies, respectively.

The proteins of the invention of group I do not share a special technical feature with the pharmaceutical compositions of the invention of group IV because said proteins may be used for the in vitro production of antibodies which does not involve use in the in vivo environment. Therefore, analysis of the proteins of group I does not require consideration of means of administration and assays for determination of efficacy as required for the analysis of the invention of group



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/18675

IV. Similarly, the antibodies of the invention of group II do not share a special technical feature with the pharmaceutical compositions of the invention of group VI because the latter invention requires analysis of the in vivo introduction of antibodies and because the antibodies of the invention of group II may be used in vivo.

The proteins of the invention of group I do not share a special technical feature with any of the methods of groups V-VII because said methods do not utilize said proteins and therefore consideration of said proteins per se is not required for analysis of any of said groups of methods.

The proteins of the invention of group I do not share a special technical feature with the method of the invention of group VII because said method requires consideration of disease states and correlations between protein binding and said states and such considerations and analysis is not required for examination of proteins per se.

The antibodies of the invention of group III do not share a special technical feature with any of the methods of groups IV, V, VII, and VIII because said methods do not utilize said antibodies and therefore, consideration of said antibodies per se is not required for analysis of any of said groups and methods.

The nucleic acids of the invention of group V do not share a special technical feature with the pharmaceutical compositions of the invention of groups IV, and VI because said compositions require consideration of in vivo use (see above) which is not required for analysis of nucleic acids per se and because said nucleic acids may be used in vitro. For example, said nucleic acids may be used to produce proteins.

The nucleic acids of the invention of group IV do not share a special technical feature with the method of group VIII because said method does not utilize said nucleic acids and therefore consideration of said nucleic acids per se is not required for the analysis of said method.

The nucleic acids of the invention of group IV do not share a special technical feature with the methods and compositions of the invention of group IX because the latter invention involves the use of antisense nucleotides which do not encode proteins, which regulate gene expression and which are designed for in vivo use. In contrast, the nucleic acids of the invention of group IV encode proteins (non-regulatory) and may be used for in vitro production of proteins. Therefore, analysis of the nucleic acids of the invention of group IV does not require the in vivo or regulatory considerations required for analysis of the invention of group VII. Similarly, the inventions of group V and IX do not share a special technical feature because the former invention utilizes nucleic acids encoding proteins and the latter invention utilizes antisense nucleic acids that regulate gene expression.

The invention of group VI does not share a special technical feature with the methods of the invention of group IX because the latter methods utilize antisense nucleic acid therapeutics whereas the former utilize proteins. Consideration of the use of antisense nucleic acids requires analysis of selection of appropriate sequences and means of regulating gene expression and such analysis is not required for consideration of methods based upon protein therapeutic agents.

The invention of any of groups IV-VII does not share a special technical feature with the methods of group VIII because the former inventions utilize pharmaceutical compositions for in vivo treatment whereas the latter invention uses proteins for in vitro diagnostic. Therefore, the method of group VIII does not require considerations of in vivo methodologies.

The invention of group VI does not share a special technical feature with the invention of group VII because the former invention utilizes proteins and the latter invention utilizes nucleic acids. Therefore, the analysis of each invention requires considerations distinct to each distinct class of pharmaceutical.

Therefore, the separate inventions as listed above are not so linked by any single special technical feature so as to form a single inventive concept within the meaning of PCT Rule 13.2. It is noted that the Deltex proteins are used in all of the inventions of groups I-IV and VI-VIII, however, these proteins were known in the prior art and therefore do not represent a contribution over the prior art as defined by PCT Rule 13.2.

